

### **Private and Confidential**

Professor Soniya Nityanand Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow Uttar Pradesh 226014 India E-mail: <a href="mailto:grants@wellcomedbt.org">grants@wellcomedbt.org</a>
Tel: Hyd: +91 40 4018 9445

New Del: +91 011 4100 8403

Our Ref: IA/I/16/1/502374

14/03/2017

Fellowship Durotin 01-04-2017 -31-04-2022

Dear Professor Nityanand,

The Wellcome Trust/DBT India Alliance has agreed to award **Dr Chandra Chaturvedi** an **Intermediate Feliowship** for 60 months for his study entitled, "**Deciphering Role of Epigenetic Mechanisms in Normal and Malignant Hematopoiesis**", under your sponsorship.

An award of up to ₹ 3,60,55,580.00 has been provided to the Sanjay Gandhi Postgraduate Institute of Medical Sciences (hereinafter referred to as 'Host Institution') for this purpose.

The grant has been given a start date of <u>01/04/2017</u> and is intended to provide support as follows:

**RING-FENCED FUNDS:** 

	Total (₹)
Post 1 – INTERMEDIATE FELLOW	
Personal support for Dr Chaturvedi	69,12, <b>00</b> 0.00
CONTRIBUTION TOWARDS INSTITUTIONAL OVERHEADS	32,77,780.00
OVERSEAS ALLOWANCE	
Subsistence for 6 months (\$3000/month at a conversion rate of \$1=₹70)	12,60, <b>00</b> 0.00
Travel	1,50,000.00
Sub Total (A)	1,15,99,780.00

TRANSFERABLE FUNDS:

	Total (₹)
STAFF SALARIES	
Post 2 (PhD Student)	20,90,400.00
Post 3 (PhD Student)	20,90,400.00

Regd. Office: Department of Biotechnology, C.G.O. Complex, Block II, Lodhi Road, New Delhi, India 110 003 Admn. Office: Hyderabad: Plot No. 19, H.No. 8-2-684/3/K/19, 1st Floor, Kaushik Society, Road No.12, Banjara Hills, Hyderabad, India- 500 034 T: +91 040 4018 9445/6/7 F +91 040 4018 9449

Delhi: Flat No 1110, DLF Tower B, Jasola District Centre, Behind Apollo Hospital, New Delhi – 110025 T: 011-41008403 www.wellcomedia.org

The Wellcome Trust/DBT India Alliance is a charitable trust registered in India.

Bayen

FLEXIBLE FUNDING ALLOWANCE	7,50,000.00
TRAVEL TO MEETINGS	
Dr Chaturvedi	7,50,000.00
Post 2	5,00,000.00
Post 3	5,00,000.00
MATERIALS & CONSUMABLES	96,75,000.00
EQUIPMENT (List Attached)	47,00,000.00
MISCELLANEOUS	34,00,000.00
Sub Total (B)	2,44,55,800.00
GRAND TOTAL (A+B)	₹ 3,60,55,580.00

The following details along with the enclosed **Award Conditions**, outline the framework in which the Fellowship will operate.

- 1 Terms
- 2 Costs
  - 2.1 Ring-Fenced Funds
  - 2.2 Transferable Funds
- 3 Acceptance
- 4 Payment
- 5 Joining
- 6 Reports
  - 6.1 Annual
  - 6.2 End-of-Fellowship
- 7 Fellows' Title
- 8 Publications from Fellowship
- 9 Mid-term Review Process
- 10 Mentorship Requirement
- 11 IP arising from the Fellowship
- 12 Award Extension
- 13 Other Fellowships and Grants
- 14 Variation and Termination of Fellowship
- 15 Statement on Equality and Diversity
- 16 Managing reputational risks
- 17 Fellows' Meetings
- 18 Application Reviews
- 19 Contact
- 1 Terms of the awards
- 1.1 Terms for the activation of the Award:

Salen

2
0
S
5
0
PROVISIO
쏐
REVISED
2
e a
ď

### AL GRANT PAYMENT PROFILE

Feeting   Feet	ver wearenne			NO COST EXTENSION	ENSION		70222	Work Outside Host Inst (OA)	ct Inct (OA)		IA Fallow	Dorganal Cumper	Details
Changle Chantred   Type of Grant INTEMEDIATE   Basic   Changle State   Changle Chantred   SGPIME   Changle State   Changle Chantred   SGPIME   Changle State   Changle State							27707	DI SOISION NO.	at High Car		MOIID WI	rersonal auppor	Deignis
S CHANGE UP INVALIDATED         HOLE (1992) (1992)         S CHANGE UP INVALIDATED         HOLE (1992) (1992)         <	Applicant's Name:	Dr Chandra Chatur	rvedi	Type of Grant:	INTERMEDIATE		Basic	6 Months pm @	\$3,000	Year (FY)	Estimated Fixe	D Perconal Suppo	inning of EV
	Host Institute Name:	SGPIMS, UP					02	Exchange Rate	No. of Months		IA Salary Cap	Institute Salary	Top-up / IA PS
Autoposition   Control of the Cont	IA Reference No:	1A/i/16/1/502374	Î	ost Institute Ref. No: 5	SGPGIMS, LUCKNOW		_		ACCOUNT OF THE PARTY OF THE PAR	2017-18	115200	0	1,15,200
A				Award Letter Date:	14-03-2017	04-07-2022				2018-19	115200	0	1,15,200
	Grant Award Amt. 1			Grant Start Date:	01-04-2017	01-04-2022				2019-20	115200	198756	0
Fig. 50   Fig.				Grant End Date:	31-03-2022	31-03-2023		70		2020-21	115200	205686	0
State   Stat	Bank A/c Details:	Note:		Equipment Cost (E)		inst. Sal Actg Period		70	9	2021-22	115200	205686	0
Prof. of Conclusion   Prof. of Conclusion	SBI/SB#10095237491			47,00,000		Apr - Mar				2022-23	115200	205686	0
No of Months   No o		Details:		y in -Charge	email:s	[pgiresearch@gmail	l.com	(+) O Travel	1,50,000	2023-24	115200	205686	
Perintelists   AWANAD AMT.   2017-12   2017-25   2017-		No. of Months	60	12	12	12	12	12	0	0			
Particle   Particle	Part	cuian neigo	AWARD AMT.	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	RETENTION (R)	- Adjustment	NET AWARD
Period Reduction In Top-   Reduction In Top-	Ring-fenced Funds (R-f)												
	Revised Fellow S	alary (FS)	69,12,000	13,82,400	13,82,400	٥	0	0	0	0		-41,47,200	27,64,800
NetRelate of [15]   19   69.12.000   13.2.4.4.00   13.2.4.00   1	Adj. of Unspent/DISALLQ	WED / Reduction in Top-u	CALLY COMMENTS	0	0	-5,06,880	The state of the s		0	0		-5,06,880	-5,06,880
	Net Net	O15		(0.45%)	13,82,400	5,06,880	0	0 m 1 m 2 Lat S	0	O THE SHAPE OF THE STREET	STREET, STREET	46,54,080	22.57,920
National Mathematical Mathema	Overseas All. (Work of	itside Host Inst.) (OA)	14,10,000		0				0	0		-14,10,000	0
Net Release of (OA)   Photose of (OA)   Photos	Adj. of Unspent / Reduct	ion in (OA)	100000000000000000000000000000000000000	0	0	0	0	0	0	0	***************************************	0	0
Net R F F Ind (C) = (a+b)   83,22,000   13,82,400   5,06,800   0   0   0   0   0   0   0   0   0	Net.	Refease of (OA) (b	SALL PROPERTY.	0	The Property of the Party of th	0	0	0	0.4	O STATE OF THE PARTY OF THE PAR	是明明也是	14,10,000	O THE PERSON
Designation of the Relation		Net R-f Fund (C) = (a+b)		13,82,400	13,82,400	-5,06,880	0	0	0	o		-60,64,080	22,57,920
8,32,200         1,38,240         1,38,240         -5,068         0         0         0         0         -6,06,408           24,45,580         8,65,116         3,95,116         6,37,463         3,95,116         5,39,234         0         0         0         0         0         -6,06,408           4,15,59         8,65,116         3,55,116         -6,77,463         -1,52,304         -3,56,120         5,24,246         0         7,38,206         -7,14,087           4,44,55,800         86,51,160         39,51,160         39,51,160         39,51,160         39,51,160         39,51,160         59,15,541         0         7,38,206         6,07,437         0           4,455,800         86,51,160         39,51,160         39,51,160         59,15,641         0         7,38,206         6,07,437         0           4,44,55,800         86,51,160         39,51,160         39,51,160         59,15,641         0         7,38,206         6,07,437         89,15,541           4,44,55,800         86,51,160         39,51,160         59,15,641         39,51,600         59,15,541         6,07,437         6,07,437         6,07,437           4,44,55,800         86,51,60         39,51,60         39,51,60         57,97,230         0		H. Cont. @10%											
24,45,580         8,65,116         3,95,116         6,774,63         3,95,116         5,73,720         5,39,724         5,91,544         5,91,554           41,15,99,780         23,45,580         10,03,518         -6,77,463         -5,74,683         -5,74,683         -7,74,087         -7,72,914           41,15,99,780         23,85,776         1,58,746         -6,77,463         -5,24,246         0         7,38,206         -7,22,914           41,15,99,780         23,85,766         16,87,405         -6,38,570         -1,52,304         3,62,000         5,24,246         0         7,38,206         -6,73,301           4,44,55,800         86,51,160         39,51,160         39,51,160         39,51,160         39,51,160         59,15,41         0         7,38,206         0           1,10,25,580         86,51,160         39,51,160         39,51,160         39,51,160         59,15,541         0         0         7,38,206         0         0         1,13,41,41         0         1,13,41,41         0         1,13,41,41         0         1,13,41,41         0         1,13,41,41         0         1,14,41,41         0         1,14,41,41         0         1,14,41         0         1,14,41,41         0         0         1,14,41         0	OH on	R-f Fund (c)	8,32,200	1,38,240	1,38,240	-50,688	0	0	0	0		-6,06,408	2,25,792
1,15,90,726   1,10,20,236   1,20,200   1,15,304   1,15,304   1,15,304   1,15,304   1,10,20,236   1,10,20,20,236   1,10,20,20,236   1,10,20,20,236   1,10,20,20,236   1,10,20,20,236   1,10,20,20,236   1,10,20,20,236   1,10,20,20,20,20,20,20,20,20,20,20,20,20,20	OH ou	T-Fund (g)	24,45,580	8,65,116	3,95,116		6,77,463	3,95,116	5,79,723	0		5,91,554	30,37,134
Column   C	Adjustment of Inter-	est Earned on IA Funds			-3,28,351	-1,44,859	-1,52,304	33,096	-55,477	o		-7,14,087	-7,14,087
1,15,99,780   23,85,756   15,87,405   -1,31,890   3,52,020   5,24,246   0   7,38,206   -7,28,941	Overheads Retained		1				-6,77,463				6,77,463		
(4         1,15,39,780         23,85,756         15,87,405         -6,38,570         -1,52,304         3,62,020         5,24,246         0         7,38,206         -67,93,021           2,44,55,800         86,51,160         39,51,160         39,51,160         39,51,160         39,51,160         39,51,160         59,15,541         0         7,38,206         -67,93,021           2,44,55,800         86,51,160         39,51,160         4,89,16         59,15,541         0         0         59,15,541           1, 2,44,55,800         86,51,160         39,51,160         53,51,160         39,51,160         59,15,541         0         0         59,15,541           1, 2,44,55,800         86,51,160         39,51,160         53,51,160         57,97,230         0         6,07,427         0           1, 3,65,580         1, 10,35,518         55,38,562         67,74,634         39,51,160         57,97,230         0         6,07,427         59,15,541		nstitutional O.H. Cont. (G)	The state of the state of	10,03,356	2,05,005	1,31,690	-1,52,304	3,62,020	5,24,246	O'S THE RESERVE OF THE PARTY OF	7,38,206	-7,28,941	25,48,839
2,44,55,800         86,51,160         39,51,160         39,51,160         39,51,160         39,51,160         39,51,160         39,51,160         39,51,160         39,51,160         59,15,541         0	Total - Ring-fenced F	unds (RF) (t	1,15,99,780	23,85,756	15,87,405	-6,38,570	-1,52,304	3,62,020	5,24,246	0	7,38,206	-67,93,021	48,06,759
Color   Colo	Transferable Funds (TF		2,44,55,800	86,51,160	39,51,160	39,51,160	39,51,160	39,51,160	0	0		0	2,44,55,800
Color   Colo	Adj: Other Adjustments	(-)/+										0	0
2,44,55,800         86,51,160         6,38,570         72,63,750         39,51,160         59,15,541         0         0         59,15,541           (1         2,244,55,800         86,51,160         39,51,150         6,73,120         6,73,120         0         6,07,427         5,91,554           3,60,55,80         1,10,36,15         55,38,565         0         6,22,230         43,13,180         63,21,476         0         13,46,633         43,77,480	Adj. of Ecess/Un Spent 1	F Funds +/(-)	0	The second contract of	The state of the s	-33,12,590	33,12,590	The table of table o	59,15,541	10000000000000000000000000000000000000		59,15,541	59,15,541
	Net Transferable	Funds	2,44,55,800	86,51,160	39,51,160	6,38,570	72,63,750	39,51,160	59,15,541	o	0	59,15,541	3,03,71,341
(1         2.44.55.800         86.51.160         39.51.150         67.97.230         0         6.07.427         58.15.541           3.60.55.580         1,10.35.516         55.38.565         0         6.22.330         43.13.160         63.21.476         0         13.45.633         48.77.480	Less: Retention Amt. @7	1% on TF (R)	The state of the s			CHS/Man - Transfer	4,89,116		-1,18,311		6,07,427	0	0
3.60,55,580 1,10,38,515 55,38,565 0 56,22,330 *** 43,13,180 63,21,478 0 13,45,633 43,77,480	THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TW	100	· Charles Care	54473471	39,51,150	6,38,570	57,74,634	39,51,160	57,97,230	O THE REAL PROPERTY.	の変がれた	59,15,541	3,03,71,341
	Grand Total (GT) (	一年の日本の日本の日本の日の日	3,60,55,580		55,38,565	0	66.22,330	43,13,180	63,21,476	0	St 1822	8,77,480	3,51,78,100
	ADD: SUPPLEMENTARY F	UNDS:											
	TOTAL - SUPPLEMENTAR	Y FUNDS (SF) (R)	というない とういうない はんかい	からない 大田 田田 田田 日日			-						

CHICAGO TO THE TOTAL WATER TO THE TOTAL TO	indiate.	700'03'0	1,44,037	L'Stylen	33,096	114/55	OF STREET, SALES STREET, SALES	The state of the s	EL STRUCTURE L	Total Grant Arm.	355,35
ADI: REVISION / (PERMANENT REDUCTION - (PR))											
Revision / (PR) in Fellow Salary (FS)	(46,54,080)						(46,54,080)				
Revision / (PR) in Overseas Allowance (OA)	(14,10,000)						(14,10,000)			Poly	
Revision / (PR) in Transferrable Funds (TF)	59,15,541						59,15,541				
Institutional O.H. @ 10% on above (FS+OA+TF)	(1,28,941)		(3,28,351)	(1,44,859)	(1,52,304)	(33,096)	(70,331)			100	
TOTAL - REVISION / (PR) (R)	(8,77,480)		(3,28,351)	(1,44,859)	(1,52,304)	(33,096)	(2,18,870)			REVISED AWARD &	3,51,78,10
SPENT DETAILS	TOTAL SPENT	1	2	ю	4	2	9	7		TOTAL UNSPENT	TOTAL RECEIPT (
Fellow Salary (FS)	22,57,920	13,82,400	8,75,520								22,57.92
Overseas All. (Work outside Host Inst.) (OA)											
Transferable Funds (TF)	2,01,12,101	19,59,352	49,02,301	50,32,411	38,76,345	43,41,692				38,54,583	2,39,66,68
Institutional O.H. @ 10% on above (FS+OA+TF)	22,37,002	3,34,175	5,77,782	5,03,241	3,87,635	4,34,169	•			(9,50,615)	12,86,38
TOTAL AMOUNT &	2,46,07,023	36,75,927	£9,55,603	55,35,652	42,63,980	47,75,861	STATE STATE STATE	三年 日本	***************************************	29,03,968	2,75,10,9
Unspeni Amount (1)	29,03,968	73,60,989	(8,17,038)	(\$5,35,652)	23,58,350	(4,62,681)	行るのは後における	大学になるない 海流の	<b>はいのはままりにはいわれ</b>	29,03,968	36,18,03
Committed Amount Provision ₹ (CP)	•		13,47,326	(5,86,409)	67,35,615	(74,96,532)					
Unspent after Commitment Prov K	29,03,968	73,50,989	(21,64,364)	(49,49,243)	(43,77,265)	70,33,851	大学   大学   大学   大学   大学   大学   大学   大学	京 大学 大学	が と 日本の	29,03,968	36,18,0
UNSPENT //EXCESS) SPENT - (FS)	5,06,880	THE CHARLEST CONTRA	088'90'\$	The state of the s	THE PERSON NAMED IN	大学の日本の日本の	はは機能性にもいい	1. でんだいないないない	本のないないできる	5,57,568	
UNSPENT / (EXCESS) SPENT - (OA)			THE PARTY AND VALUE OF	0);	The second secon	Charles the Control	中国 日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日	STATE OF THE PARTY OF	のなるとは、	THE PROPERTY OF THE PARTY OF TH	47.97,0
UNSPENT / JEXCESS) SPENT - (TR)	38,54,583	808 16 99	(22,38,467)	(38,07,432)	(38.37.326)	71,05,000	· 新州 · 中川	ないのはないほど	ないないのではないという	42,40,041	

companie local payment	1,10,36,916	1,65,75,481	1,65,75,481   1,65,75,481	2,31,97,811	2,75,10,991	3,38,32,467	3,38,32,467	2,31,97,811 2,75,10,991 3,38,32,467 3,38,32,467 3,51,78,100	3.51.78.100
Current Liability (CL) (Unspent Adjusted Payable)	-		36,43,849	(36,43,849)					
Expenditure (GT+R+CL) 3,51,78,100	1,10,36,918	55,38,565	36,43,849	41.93,972	Share 43,13,180	64,51,618	200000000000000000000000000000000000000	THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TRANSPORT OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS N	
Deferred Liability (Oi)	2,50,18,664	1,91,51,749	1,53,63,040	1,10,16,764	66,70,488	の地震を行うない	はからだんなはない	A CONTRACTOR OF THE PARTY OF TH	
Please Note:									
1. Payment of yearly installment will be made subject to submission of (a)	ssion of (a) Ledger Co	ov/ R&P/ I&E/ Statemen	it of A/c of Fellows P.	rolect, (b)Latest Pay	Slip AND monthly S	Salary statement for	the previous year. fe	c) Valid Phical Annual / C.	a) Ledger Copy/RBP/18E/Statement of A/c of Fellows Project. (b)Latest Pay Sin AND monthly Salary statement for the mevious wear. (c) Valid Philas Annoval / Certificate from Sconson His and 1
(d) Signed Grant Spend Report for the previous year (e) Fellows Research Report, (f) Latest Audited Financial Statements AND Annual Report of the Institution (o) WOH Visit & Scent later from several reports on the previous year (e) Fellows Research Report, (f) Latest Audited Financial Statements AND Annual Report of the Institution (o) WOH Visit & Scent later from several reports or the previous year (e) Fellows Research Report, (f) Latest Audited Financial Statements AND Annual Report of the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from several reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH Visit & Scent later from Several Reports or the Institution (o) WOH VISIT & Scent later from Several Reports or the Institution (o) WOH VISIT & Scent later from Several	ort, (f) Latest Audited &	Unaudited Financial Sta	rements AND Annu	al Report of the Ins	fibrition (e) WOH Vis	it & Spent letter from	n external snonsor	(h) Amount Committed Infor	rmation for next EV (if any)
2. UNSPENT TF & OA amounts will be adjusted from 3rd installment, it will be released upon submission of Spend Report and Future recuirements.	stallment, it will be	released upon sub	mission of Spend	Report and Fut	ure requirement				(August) a second control of the con

### No. BT/RLF/Re-entry/13/2014 Government of India Ministry of Science & Technology Department of Biotechnology

Block No. 2, 6-8th Floors CGO Complex, Lodi Road, New Delhi - 110 003.

Dated: 20th April, 2017.

ORDER

Sunction of the President is hereby accorded under Rule 18 of the Delegation of Financial Power Rules, 1978, for the implementation of the Project proposal entitled "Autophagy regulation of microglia/ macrophage phenotype and catecholaminergic neuronal function fellowed by Japanese encephalitis virus infection." by Dr. Alok Kumar, Department of Neurology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow- 226014 at a total cost of Rs. 88.00 lakhs (Rupees Eighty eight Lakhs only) as a part of his Ramalingaswami Fellowship 2014-15 w.e.f. 21st January, 2017 on the terms and conditions detailed as per under:-

2.0 The Project

Project Title: 2.1

"Autophagy regulation of microglia/ macrophage phenotype and catecholaminergic neuronal function fellowed by Japanese encephalitis virus infection".

Investigator 2.2

Name of the Awardee:

Dr. Alok Kumar

Department of Neurology

Sanjay Gandhi Post Graduate Institute of Medical

Sciences. (SGPGMS) Lucknow- 226014

Objectives

Test the hypothesis that Autophagy dysregulated in activated microglia/ macrophages and dopaminergic neuron followed by JE infection.

Test the hypothesis that impaired Autophagy flux stimulates deleterious innate immune response and oxidative stress signaling that leads to exaggerate dopaminergie's neuronal dysfunction followed by JE infection.

Test the hypothesis that restoration of Autophagy flux will attenuate pro-infammatory 3. responses and promote anti-inflammatory pathways of activated microglia/macrophage and improve dopaminergic neuronal survival and function followed by JE infection.

2.3 Time Schedule

The duration of the fellowship is 5 years w.e.f. 21st January, 2017

### 2.4 Fellowship Amount

2.4 1 Culonstrip	*	Fe'		(Rs.	in Lakhs)	
And the second s	1st Yr.	2 <sup>nd</sup> Yr.	3rd Yr.	4th Yr.	5th Yr.	Total
Fellowship@ Rs.85,000/ p.m	10.20	10.20	10.20	10.20	10.20	51.00
(consolidated) Research/Contingency grant	10.00	7.50	5.00	5.00	5.00	32.50
HRA @ Rs. 7,560 p.m. consolidated	0.90	0.90	0.90	0.90	0.90	4.50
Total	21.10	18.60	16.10	16.10	16.10	88.00

2.5 The contingency/research grant may be utilized for the purchase of consumables, minor equipment, international and domestic travel, engaging manpower and other contingent expenditure to be incurred in connection with the implementation of the project.

3. a) If the host institute is providing free accommodation, no House Rent Allowance (HRA) is

admissible and same needs to be refunded to the department. b) If the host institute is deducting HRA and license fee for the accommodation provided, then the same may be recovered from the HRA being paid to the fellow. However, reimbursement shall be limited to the HRA being paid by DBT. Excess recovery, if any, has to be made by the host institute

As regards the medical benefits, host institute may consider giving medical benefits from directly from the fellow. their own resources at level of Scientist 'D' as applicable to their regular faculty

In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest at the rate of ten per cent per annum thereon shall be recovered.

Budget Head 6.

The expenditure involved i Demand No. 85	s debitab	Department of Biotechnology Other Scientific Research (2017-2018)
3425 3425.60 3425.60.200 3425.60.200.29	: : :	Other (Sub Major Head) Assistance to other Scientific Bodies (Minor Head) Biotechnology Research and Development. Human Resource Development, Research Resources
3425.60.200.29.17 3425.60.200.29.17.31	:	and Facilities Assistance for Research and Development Grants-in-aid General

The Accounts of the grantee institution shall be open to inspection by the sanctioning 7.

The Director, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow- 226014 is requested to furnish to this Department 'Utilization Certificate' and an audited 'Statement of 8. Expenditure' at the end of the year.

This issues under the powers delegated to this Department and with the concurrence of IFD vide their SAN No. 102/IFD/SAN/57/2017-187 dated:19-4-2017. 9.

This sanction order has been noted at Serial No. 5 in the Register of Grants. 10.

Director/Scientist 'F'

To.

The Pay & Accounts Officer Department of Biotechnology New Delhi -110003

Copy forwarded for information/ necessary action to:

- The Principal Director of Audit (Scientific Departments), AGCR Building, IP Estate, New 1. Delhi - 110 002.
- Cash Section, DBT (2 copies) 2.
- Dr. Alok Kumar, Department of Neurology, Sanjay Gandhi Post Graduate Institute of IFD, DBT 3. 4. Medical Sciences, Lucknow- 226014
- The Director, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow-226014 5.

Sanction Folder б.

(Meenakshi Munshi) Director/Scientist 'F'



### **Private and Confidential**

Professor Eesh Bhatia
Head of Department
Department of Endocrinology
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lucknow 226014
India

Dear Professor Bhatia

E-mail: <a href="mailto:grants@wellcomedbt.org">grants@wellcomedbt.org</a>
Tel: Hyd :+91 40 4018 9445
New Del: +91 011 4100 8403
Our Ref: IA/I/16/2/502691

13/10/2017

Fellowship Dunahim 13/10/2017-12/10/2022

The Wellcome Trust/DBT India Alliance has agreed to award **Dr Rohit Anthony Sinha** an Intermediate Fellowship for 60 months for his study entitled, "Determining the role of pancreatic alpha-cell autophagy in intra-cellular glucagon turnover and its modulation as an **anti-diabetic** therapy.", under your sponsorship.

An award of up to ₹ 3,39,34,890.00 has been provided to the Sanjay Gandhi Postgraduate Institute of Medical Sciences (hereinafter referred to as 'Host Institution') for this purpose.

The grant has been given a start date of <u>01/11/2017</u> and is intended to provide support as follows:

### **RING-FENCED FUNDS:**

	Total (₹)
Post 1 – INTERMEDIATE FELLOW	
Full personal support for Dr Sinha	69,12,000.00
CONTRIBUTION TOWARDS INSTITUTIONAL OVERHEADS	30,84,990.00
Sub Total (A)	99,96,990.00

TRANSFERABLE FUNDS:

14	Total (₹)
STAFF SALARIES	
Post 2 Research Fellow ( JRF / SRF for 60 months)	18,86,400.00
Post 3 Research Associate (Postdoctoral for 60 months)	27,07,200.00
FLEXIBLE FUNDING ALLOWANCE	7,50,000.00
TRAVEL TO MEETINGS	
Dr Sinha	7,50,000.00
Post 3 (Postdoctoral)	5,00,000.00
MATERIALS & CONSUMABLES	52,25,000.00

Regd. Office: Department of Biotechnology, C.G.O. Complex, Block II, Lodhi Road, New Delhi, India 110 003
Admn. Office: Hyderahad: Plot No. 19, H.No. 8-2-684/3/K/19, 1st Floor, Kaushik Society, Road No.12, Banjara Hills, Hyderahad, India- 500 034 T: +91 040 4018 9445/6/7 F +91 040 4018 9449

The Wellcome Trust/DBT India Alliance is a charitable trust registered in India.

Jampa .

EQUIPMENT PURCHASE (see list attached)	
- de la	98,52,000.0
ANIMALS & FOOD	
Mouse, C57BI/6N (Male)	
Purchase: 166 mice @ ₹ 100 each	16,600.00
Maintenance (for Aim1): 68 mice for 10 weeks @ ₹ 50 each/week	34,000.00
Maintenance (for Aim3): 68 mice for 15 weeks @ ₹ 50 each/week	51,000.00
Maintenance (for Aim1): 30 mice for 8 weeks @ ₹ 50 each/week	12,000.00
Mouse, C57BI/6 Akita mice (male)	
Purchase: 34 mice @ ₹ 15,000 each	5,10,000.00
Maintenance (for Aim2): 34 mice for 8 weeks @ ₹ 50 each/week	13,600.00
Animal Experimental Procedure Cost	
Intra-peritoneal injections	5,100.00
Animal Associated Costs	
Staff Training	10,000.00
Animal Diet including Control and High fat Diet (Animal environment, training and enrichment)	1,00,000.00
MISCELLANEOUS	15,15,000.00
Sub Total (B)	
	2,39,37,900.00
GRAND TOTAL (A+B)	₹ 3,39,34,890.00

The following details along with the enclosed **Award Conditions**, outline the framework in which the Fellowship will operate.

- 1 Terms
- 2 Costs
  - 2.1 Ring-Fenced Funds
  - 2.2 Transferable Funds
- 3 Acceptance
- 4 Payment
- 5 Joining
- 6 Reports
  - 6.1 Annual
  - 6.2 End-of-Fellowship
- 7 Fellows' Title
- 8 Publications from Fellowship
- 9 Mid-term Review Process
- 10 Mentorship Requirement

Bapon

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

然の技術をいいる時間があれた。

	IA Fellow Personal Support Defails	Estimated FIXED Personal Support (FSI* D.M.	18 Caland Can inetitute Salary Top-up / IA PS	C	0	115200 0 115,200	0		5 0	500	115200 0 115,200		INSURANZE SENTENCE OF SENTENCE	0 6,912,000	0	(2017年9日 日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日	0		のできるなどのである。 といればいるのでははないというというないので			0 691,200	47,876 0 2,393,790	0 . 0	100名とおりにはいるのでは、日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日	0	0 23,937,900		0 0	0 0 0	478.758 0	
		Year (FY) & Errin		2000	2017-18	2019-20	The second of	20202	2021-22	2022-23	2023-24	<b>始</b>	報告の13426名の間   RETEN			THE REAL PROPERTY AND PERSONS IN COLUMN TWO IS NOT THE OWNER.	THE PERSON NAMED IN COLUMN	Jee C	の 一	THE RESIDENCE OF THE PARTY OF T	0		0	0	No. of the local particular and the local part				STA.			11.1
	1718 Work Outside Host. Inst. (OA)		+	Kate No. of Months							(x) P	7	17.00年前(南西)(16.225.23周周	900 900	me'and me'ass'r	CANADA STREET,	では という は は は は は は ない は ない は ない は ない は ない は		Company of the Party of the Par		1,382,400 806,400	00000	322 PYL CV8 CCC		SAPERATOR STATE ST	SATISFIE	1,104,402			325 273 1 000 1 543 355		A PARTY AND A PART
	1718 Work Outs	Basic		Exchange Kate		47/4	V/N				(+) O Travel (x)	12 . 12	第4年20202-24月前日   東京42-0202-24   東京		1,382,400	1	COLT 38 CAUSE IN COLUMN SECTION SECTIO	0 4	0		1,382,400 1,3		138,240		CHINEME			7,817,180	25		4,617,18U 4,0	
. =					•		-		Inst. Sal'Actg Period	Apr - Mar		12	HAT 07 65 22 8132		1,382,400	_1	のかける。 では、 ののでは、 ので		0		1,382,400		138,240		Control of the second of the s			2,817,150		1	2,817,180	
AL GRANT PAYMENT PROFILE	50	Type of Grant: INTERMEDIATE	•	•	Host institute Ref. No: SGPGIMS, Lucknow	н	- 1	ito: 31/10/2022	Equipment Cost (E)   Removable Exp.(R) Inst. Sal Actg Period	00			A 12 TO 2017 18 15 18 18 18 18 2019 18 18 18 18 18 18 18 18 18 18 18 18 18		1,382,40		THE PROPERTY OF THE PARTY OF	0	0	の意識をはるない。	1,382,400		500 138,240			Sept Sept 1		325 2,817,180	_		325 2,817,180	
AL GRANT PA	-83	Type of Gran	11		Host institute Ref. N	Award Letter Date:	Grant Start Date:	Grant End Dafe:	CH: Equipment Cost (	9,852,000		v	44 Mar 2017 18 10		200 226,000			0	0	「10」	000 276,000			790 1,102,583	-	90 September 106		900 11,025,825	_		900 11,025,825	
PROVISION/	and a	nho					<u>.</u>		Note: "(FS) Fixed till 'MARCH!	Only, for current PY		\$	S.SAWA		6,912,000	Je			The second secon	地域の意味性を開	6,912,000		691,200	2,393,790		ななる。		23,937,900	-		23,937,900	
Wellcometrum : * 5 111 2	(IA) INDIA ALLIANCE	Applicant's Name: Dr. Rohit Antony Sinho		••	IA Reference No : 14/1/16/2/502691		Grant Award Amt, 4 35,934,690		Not			No. of Months	一年の大大大学の日本の大学の工作の工作のでは、一大学の大学の大学の大学の大学の大学の大学の大学の大学の大学の大学の大学の大学の大	Ring-fenced Funds (R-f)	Revised Fellow Salary (FS)	Adj. of Unspent/DISALLOWED / Reduction in Top-up o	TO THE PROPERTY OF THE PARTY OF	Overseas All. (Work outside Host Inst.) (OA)	Adj. of Unspent / Reduction in (OA)	TO THE WASHINGTON TO SELECT THE PROPERTY OF THE PARTY OF	Net R-f Fund (C) = (a+b)	Add: institutional O.H. Cont. @10%	OH on R-f Fund (c)	OH on T-Fund (g)	Adjustment of Interest Earned on IA Funds	Salaria (Salaria and Salaria) Bitting Bitting (D.H. Contacted)	Total - Ring-fenced Funds (RF) (e) = (c+d)	Transferable Funds (TF)	Adj: Other Adjustments +/(-)	Adj. of Ecess/Un Spent TF Funds +/[-]	Net Transferable Funds	100

CONTRACTOR OF SUPPLIES NO. 1831934,890 

Anti- DEVISION / IBSTRANSINT REDUCTION - (PR)

ADD: SUPPLEMENTARY FUNDS:

Grand Total (GT)

ADJ: REVISION / PERMANENI REDUCTION - (PR)						10000	Children of the party of the last of the last	40		17
このとのないないないないとないというないというないというないないと	自然は最高ないから とありま	のはいないというなどのであると	いとではないというないが、			(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	が記れている	A STATE OF	Sec. 500 1.	
Revision A(PR) In Hellow Mello, (PS) William Control of the Contro	で、大きのないのと、 からは、 はんで	を正式に対かれているのとのであれてい	STATE OF THE STATE	Tree Contract of the Contract			おり かいつかいだいか	Carried Annual Control		大学のない
Bautilian / [DR] in Overseast Allowance (OA)	間を選択的権力を表示とい	いっかしているというなから	が、状态に必ずければ	Salah Property and Commercial	STATE OF THE PARTY		The state of the s	1		C. D
The state of the s		Short of the state	STATE OF THE PROPERTY OF THE PARTY.	一次の一個の一个の様はあるのである	11日であるのでは、12人では、	<b>的复数形式的</b>	い とは は 大きの	1		1
Nevision / (PK)-Includentable included (Includentable includentable incl			1,000			-	" a hindhaldelledie	記 ない 文字	が、かればある。	V. 18.00 S. D.
Institutional O.H. @ 10% on above (FS+OA+TF)	本のでは、100mm (新元 11 mm) である。 のでは、100mm (新元 11 mm) である。 のでは、100mm (新元 11 mm) である。 のでは、100mm (新元 11 mm) (于于于于于于于于于于于于于于于于于于于于于于于于于于于于于于于于于于				17.		- Santa	遺 記さい	EVISED AWARD C	PEGIZE CAN
TOTAL-REVISION/(PRI) (T) TOTAL-REVISION/(PRI) (T)	★報告報報を入る数 事項の名を行った数	世界が表現しま	一方式を はいちのない	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2000		1	ľ	TOTAL LINCOGNIT	TOTAL RECEIPT
SPENT DETAILS	TOTAL SPENT 1	2	m	4	S	9	-		1	
Fellow Salary (FS)						1			1	
Overseas All, (Work outside Host Inst.) (OA)	•					1			-	
Transferable Funds (TF)							-		-	
Institutional O.H. @ 10% on above (FS+OA+TF)	•		•			· Contraction of the last of t	THE REAL PROPERTY.	THE CHARLES WHEN THE	WAS LABOUR DESIGNATION OF THE PARTY OF THE P	TACHER SECURIC
さいとう は、	子のない こうしゅいかい	はない (女子がないない)	を を を を を を を を を を を を を を を を を を を	がはないのではあって	2000年の日本の	は 日本		The second secon		
Unspenie Amount (1) and the Wall of the Control of	PARTICIPATION OF MARINES AND	Create College of the State of	の一般を表現される。	10世代の大学に	一名門の別の表は	STATE OF STA	MARKET STREET, USA	Serve St. Parelle St. Barre	Control of the Contro	NAME OF TAXABLE PARTY.
									· Control of the cont	Children September
Under Description of Contract	<b>新疆市场中国的企业的</b>	<b>新新教育的教育的</b>	四分数数据的	<b>東京の名前の名前</b>	発育医療の機能	が高いのである。	<b>光波 成果 即 1000</b>	工芸術をおい		
UNSPENDICKEESSISPENIESIESI	STORY OF PARTICIPATION AS	<b>50.000年 10.000000000000000000000000000000</b>	を		の 日本の かんかん 日本の 一本の					
たったいのからの しかによるない はっていることのことのことはいいというないとしてもなべい	中国的政治的政治的政治。	<b>化工作工作工作工作工作工作工作工作工作工作工作工作工作工作工作工作工作工作工作</b>	TO DESCRIPTION OF A	では ないのか からか	A STATE OF S				1000年の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の	
UNSPENTAL EXCESSI SPENT TELETON TO THE PROPERTY OF THE PROPERT	新教育の (100mm) (大変などできる) 1.00mm	の対象を対象を対象を	ないないないないできない	元のでは、一般の	のなかないと いっちょう	SECTION SECTIO	からない。はないはないできない。	THE STANDARD IN		
							*		The state of the s	

The second secon						The state and	1 746 000 00	32 AND 356 1	068 750 25	ng trains
Cumulative Total Payment		12,762,008	17,381,546	22,001,084	26,620,622	30,713,526	33,4UB,45b	30,713,526 33,408,456 35,4408,430 ;	200120000	
Current Lability (CL) (Unspent Adiosted Payable)	-		•					Contract of the last of the la	STATE OF THE PERSON NAMED IN COLUMN	
Expending (G198 HCL) Well in Section 1989 (All 1989) In Section 1980 (All 1989) In Section 1980 (All 1	TOTAL PROPERTY OF STREET	SP 402 752 008	(47.47.47.619.53.6) (2.86.47.6.553.34a)	74 (11 911 906)	**************************************	6 4 4 4 4 4 5 1 8 4 5 1 8 4 5	454545947305 45454545454			
The same the same and the same			THE WILLIAM STREET, ST				1000	TOTAL CONTRACTOR	A to the same of the	Company Company



Bajpai vsm









MINISTRY OF SCIENCE & TECHNOLOGY

भारत सरकार
विज्ञान और प्रौद्योगिकी मंत्रालय
बायोटेक्नोलॉजी विभाग
ब्लाक-2,7 वां तल, सी० जी० ओ० कम्पलेक्स
लोदी रोड, नई दिल्ली-110003
GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY
Block-2, 7th Floor C.G.O. Complex
Lodi Road, New Delhi-110003

Dr. (Mrs.) Meenakshi-Munshi Adviser/ Scientist 'G' Ph. 011-24361035 Email: <u>rlsfellowship@dbt.nic.in</u>

D.O. NO. BT/HRD/35/02/2006

Dated: 16th March, 2020.

Dear Dr. Srivastava,

I am pleased to inform that you have been selected for Ramalingaswami Re-entry Fellowship of the Department of Biotechnology for the year 2019-2020. This is one of our most prestigious fellowships and I congratulate you on being selected.

You will receive a fellowship amount of Rs.1,00,000/- per month, House Rent Allowance (HRA) @ Rs. 18,500/- p.m., Research/Contingency grant of Rs. 10.00 lakhs for the 1<sup>st</sup> & 2<sup>nd</sup> year, Rs. 7.50 lakhs for 3<sup>rd</sup> & 4<sup>th</sup> year and Rs. 5.00 lakhs for 5<sup>th</sup> year and institutional overhead @ Rs. 50,000/year.

The terms and conditions for availing the fellowship are enclosed. Kindly send your acceptance along with the terms & conditions duly forwarded by the host institute to Dr. Kakali Dey Dasgupta, Scientist 'E' (Tel. Phone No. 011-24361035, Email: <a href="mailto:rlsfellowship@dbt.nic.in">rlsfellowship@dbt.nic.in</a>). Once you join the host institute, you may submit a copy of your joining report duly forwarded by the host institute, before formal sanction order is issued. You are expected to join your host institute within <a href="mailto:Nine Months">Nine Months</a> from the date of issue of this letter.

With best wishes,

Yours Sincerely

(Meenakshi Munshi)

Encl: As above

Dr. Anshika Srivastava Postdoctoral Fellow, University of Michigan, Ann Arbor, MI, USA

Email Id: asrivastavapgi@gmail.com

Balon

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

### No. BT/RLF/Re-entry/48/2019 Government of India Ministry of Science & Technology Department of Biotechnology

Block No. 2, 6-8th Floors CGO Complex, Lodi Road, New Delhi - 110 003

Dated: 11th August, 2020.

ORDER

Sanction of the President is hereby accorded under Rule 18 of the Delegation of Financial Power Rules, 1978, for the implementation of the Project proposal entitled "Functional characterization of rare founder alleles causing neurodevelopmental disorders for biomarker identification and community genetics surveillance" awarded to Dr. Anshika Srivastava, Assistant Professor, Department of Medical Genetics, SGPGIMS, Raebareli Road, Haibat Mau Mawaiya, Lucknow - 224014, U.P. at a total cost of Rs. 42.50 lakhs (Rupees Forty-two Lakhs fifty thousand only) as a part of her Ramalingaswami Fellowship 2018-19 w.e.f. 1st July, 2020 on the terms and conditions detailed as per under:-

2.0 The Project

2.1 Project Title: "Functional characterization of rare founder alleles causing neurodevelopmental disorders for biomarker identification and

community genetics surveillance".

2.2 Investigator

Name of the Awardee:

Dr. Anshika Srivastava. Assistant Professor.

Department of Medical Genetics, SGPGIMS, Raebareli Road,

Haibat Mau Mawaiya, Lucknow – 224014, U.P

**Objectives** 

Identify genetic mechanism of ISCA1 and LAMTOR4 pathogenic alleles with disproportionate impact on Indian population.

Determine the function of ISCA1 and LAMTOR4 in neural differentiation of iPSCs to

brain organoids.

Identify the genome-wide ISCA1 and LAMTOR4 mediated transcriptional regulation required for neural differentiation of iPSCs to neural progenitor cells (NPCs).

2.3 Time Schedule

The duration of the fellowship is 5 years w.e.f. 1st July, 2020.

2.4 Fellowship Amount

Head	1st Yr.	2 <sup>nd</sup> Yr.	3rd Yr.	4th Yr.	5th Yr.	(Rs. in Lak
Research/Contingency grant	10.00	10.00	7.50	7.50	5.00	40.00
Overheads Rs. 0.50 lakhs/ per year	0.50	0.50	0.50	0.50	0.50	2.50
Total 2.5 The	10.50	10.50	8.00	8.00	5.50	42.50

- 2.5 The contingency/research grant may be utilized for the purchase of consumables, minor equipment, international and domestic travel, engaging manpower and other contingent expenditure to be incurred in connection with the implementation of the project.
- 2.6 The continuation of the project/ fellowship will be subject to the appraisal of the relevant scheme for continuation beyond 31 March, 2021.

- 3. a) If the host institute is providing free accommodation, no House Rent Allowance (HRA) is admissible and same needs to be refunded to the department.
- b) If the host institute is deducting HRA and license fee for the accommodation provided, then the same may be recovered from the HRA being paid to the fellow. However, reimbursement shall be limited to the HRA being paid by DBT. Excess recovery, if any, has to be made by the host institute directly from the fellow.
- As regards the medical benefits, host institute may consider giving medical benefits from their own resources at level of Scientist 'D' as applicable to their regular faculty
- In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest at the rate of ten per cent per annum thereon shall be recovered.

Budget Head

The expenditure involved is debitable to

Demand No. 88 Department of Biotechnology

3425 Other Scientific Research (2020-2021) 3425.60

Other (Sub Major Head) 3425.60.200

Assistance to other Scientific Bodies (Minor Head) 3425.60.200.29 Biotechnology Research and Development

3425.60.200.29.17 Assistance for Research and Development 3425.60.200.29.17.31

Grants-in-aid General

The Accounts of the grantee institution shall be open to inspection by the sanctioning

The Director, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Haibat Mau Mawaiya, Lucknow - 224014 is requested to furnish to this Department 'Utilization Certificate' and an audited 'Statement of Expenditure' at the end of the year. 9

This issues under the powers delegated to this Department and with the concurrence of IFD vide their SAN No. 102/IFD/SAN/ 626 /2020-21 dated: 10/08/2020.

i0 This sanction order has been noted at Serial No. 54 \_\_in the Register of Grants.

> (Meenakshi Munshi) Adviser/Scientist Gasa delibrat of / Scientist G'

भूगोटेकोस्तंची निवान/Deptt. of Biolechnology

Chaire that shell, statem / No Science & Toch.

भारत सारकार, भई दिल्ली / Gove of India, N. Delhi

The Pay & Accounts Officer Department of Biotechnology New Delhi -110003

Opy forwarded for information/ necessary action to:

The Principal Director of Audit (Scientific Departments), AGCR Building, IP Estate,

Cash Section, DBT (2 copies)

IFD, DBT

Dr. Anshika Srivastava, Assistant Professor, Department of Medical Genetics, SGPGIMS, Raebareli Road, Haibat Mau Mawaiya, Lucknow - 224014, U.P.

The Director, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS),

Raebareli Road, Haibat Mau Mawaiya, Lucknow - 224014 Sanction Folder

Lt Col Varun Bajpai VSM **Executive Registrar** SGPGIMS, Lucknow

Adviser/Scientist 'G'

ATT MIX WALL WHAT / 19/0 Science & Tech. याच्या प्रत्याप्तर, यहं दिएसी / Govt. of loads, Nr. Delbi No. BT/RLF/Re-entry/48/2019 Government of India Ministry of Science & Technology Department of Biotechnology

> Block No. 2, 6-8<sup>th</sup> Floors CGO Complex, Lodi Road, New Delhi – 110 003.

Dated: 11th August, 2020.

### ORDER

In continuation of this Department's sanction order of even number dated: 11<sup>th</sup> August, 2020 sanction of the President is hereby accorded under Rule 18 of the Delegation of Financial Power Rules, 1978, for the release of an amount of **Rs. 10.50 lakhs (Rupees Ten Lakhs fifty thousand only)** to **The Director**, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Haibat Mau Mawaiya, Lucknow – 224014 being the first installment of Ramalingaswami Re-entry Fellowship (2019-20) awarded to Dr. Anshika Srivastava, Assistant Professor, Department of Medical Genetics, SGPGIMS, Raebareli Road, Haibat Mau Mawaiya, Lucknow – 224014, U.P. for the implementation of the project proposal entitled "Functional characterization of rare founder alleles causing neurodevelopmental disorders for biomarker identification and community genetics surveillance." as per the details given below:-

### Fellowship Amount

(Rs. in Lakhs)

S.No.	Head	Released Amount*
1	Contingency/Research Grant	10.00
2.	Overhead	0.50
	Total	10.50

\* The release is made under recurring heads

2. The other terms and conditions of the grant shall remain unaltered.

3. The Accounts of the grantee institution shall be open to inspection by the sanctioning authority/ audit.

4. It is certified that this being the first release no UC/SE pertaining to grants released under this programme is pending with the institute.

5. a) If the host institute is providing free accommodation, no House Rent Allowance (HRA) is admissible and same needs to be refunded to the department.

b) If the host institute is deducting HRA and license fee for the accommodation provided, then the same may be recovered from the HRA being paid to the fellow. However, reimbursement shall be limited to the HRA being paid by DBT. Excess recovery, if any, has to be made by the host institute directly from the fellow.

 As regards the medical benefits, host institute may consider giving medical benefits from their own resources at level of Scientist 'D' as applicable to their regular faculty.

7. The amount of Rs. 10.50 lakhs (Rupees Ten Lakhs fifty thousand only) will be directly credited by PAO in the account as detailed below:-

The Director, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Haibat Mau Mawaiya, Lucknow – 224014, U.P. through RTGS as per the following details

Name of Bank : State Bank of India

Branch Address : SGPGIMS Branch, Raebareli Road, Lucknow

A/c. No. : 10095237491 IFSC Code : SBIN0007789

Sapon

Lt Cof Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

- 8. The Director, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS). Raebareli Road, Haibat Mau Mawaiya, Lucknow - 224014, U.P will submit audited Utilisation Certificate and Statement of Expenditure in respect of the mentioned amount.
- As per Rule 236 (1) of GFR, 2017, the Accounts of all grantee institution or 9. Organisation shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG (DPC) Act 1971 and internal audit by the Principal Accounts Officer of the Ministry or Department, whenever the Institution or Organisation is called upon to do so.

10. In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest at the rate of ten per cent per annum thereon shall be recovered.

The Institute/Agency will keep the whole of the grant in a Bank Account earning 11. interest, and the interest so earned should be reported to DBT in the utilization certificate and statement of expenditure. The Interest so earned will be treated as created to the Institute/Agency and shall be adjusted towards further instalment of the grant and or at the time of Final Settlement of Accounts.

12. **Budget Head** 

The expenditure involved is debitable to

Demand No. 88 Department of Biotechnology

3425 Other Scientific Research (2020-2021)

3425,60 Other (Sub Major Head)

3425.60.200 Assistance to other Scientific Bodies (Minor Head)

3425.60.200.29 Biotechnology Research and Development, 3425.60.200.29.17 Assistance for Research and Development 3425.60.200.29.17.31

Grants-in-aid General

This issue under the powers delegated to this Department and with the concurrence of 13. IFD vides their SAN No. 102/IFD/SAN/ 627/2020-21 dated: 10/08/2020.

This sanction has been noted at serial no. 54 in the Register of Grants.

Adviser/Scientist 'G'

दिएक क्षेत्र में में में महालग 🗥 🕆 The Pay & Accounts Officer

Department of Biotechnology New Delhi -110003

Copy forwarded for information/ necessary action to:

- The Principal Director of Audit (Scientific Departments), AGCR Building, IP Estate, New Delhi - 110 002.
- 2. Cash Section, DBT (2 copies)
- 3. IFD, DBT

To.

- 4. Dr. Anshika Srivastava, Assistant Professor, Department of Medical Genetics, SGPGIMS, Raebareli Road, Haibat Mau Mawaiya, Lucknow - 224014, U.P.
- 5. The Director, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Haibat Mau Mawaiya, Lucknow - 224014

6. Sanction Folder

> (Meenakshi Munshi) Adviser/Scientist 'G

the Robert of fire



डॉ. रेणु स्वरूप DR. RENU SWARUP WHE WINDS

(GETA SIT STEPLES GETAG)

AND STEPLES GETAG

WITH 2, 781 EM, ALE SILE SEPRESE

WILL TIK HE ENW 110001X

BECRETARY

GOVERNMENT OF INCIA

MINISTRY OF SCIENCE & TECHSOLOGY

DEPARTMENT OF BIOTECHNOLOGY

Block-2,71th Floor, C.O.O. Complex

Lodhi Road, New Delhi-110003

D.O. No. BT/010/IYBA/2018/Main File

07.11.2019

Dan Dr Ansliken Survey

I am pleased to inform you that you have been selected for the "Har Gobind Khorana-Innovative Young Biotechnologist Award for the year 2019". This is a presugrous Award of Department of Biotechnology, Govt. of India to identify and nurture outstanding young scientists with innovative ideas for pursuing research in frontier areas of Biotechnology. I extend my heartiest congratulations to you for selection to this Award.

You may send your acceptance to Dr. Kakali Dey Dasgupta, Scientist 'E'. Department of Biotechnology, Govt. of India.

With best wishes,

Yours sincerely.

F-11 m

(Renu Swarup)

Dr. Anshika Srivastava

Assistant Professor

Department of Medical Genetics

SGPGIMS, Racbareli Rd

Haibat Mau Mawaiya, Lucknow- 226014

Utaa Pradesh

Enadl: asrivastavappi algmail.com

Scanned with CamScanner

### No. BT/12/IYBA/2019/13

### GOVERNMENT OF INDIA MINISTRY OF SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY

Block 2, 6-8th Floors CGO Complex, Lodhi Road, New Delhi- 110 003

Dated:-02.03.2020

### ORDER

Sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rules, 1978, for the implementation of the project entitled "Probing the dynamic balance of histone H2AUb1 regulatory axis in hypertrophic cardiomyopathy and early heart development" under Har-Gebind Khorana-Innovative Young Biotechnologist Award -2019 (IYBA -2019) for a period of 3 Year 0 Month at a total cost of Rs. 60.61600 Lakh (Rupees Sixty Lakh Sixty One Thousand Six Hundred Only) on the terms and conditions detailed here under:-

- 2. The Project:
- 2.1 Title: "Probing the dynamic balance of histone H2AUb1 regulatory axis in hypertrophic cardiomyopathy and early heart development"
- 2.2 Details of the Awardee:

Dr. Anshika Srivastava, Assistant Professor, Department of Medical Genetics, SGPGIMS, Raebareli Rd, Haibat Mau Mawaiya, Lucknow—226014, Uttar Pradesh

### 2.3 Objectives:

- Determine the pathogenic mechanism of ASXL3-dependent histone H2A deubiquitination in cardiogenesis
- 2. Determine the pathogenic mechanism of TRIM37-dependent histone H2A ubiquitination in cardiogenesis.
- 3. Determine shared genetic mechanism and pathways in hypertrophic cardiomyopathy caused due to mutations in H2AUb1 regulatory axis members

### 2.4 Time Schedule:

The duration of the project is 3 Year 0 Month from the date of this sanction order.

Sapon

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

### 2.5 Project Cost:

The total cost of the project is Rs. 60.61600 Lakh (Rupees Sixty Lakh Sixty One Thousand Six Hundred Only) as per details given below:

778°A	W	*	
ars.	10	1 14	L'h

S.No.	Head		Buc	lget	
		Year I	Year II	Year III	Total
the same of	Equipment/Software	10.00	0.00	0.00	10.00
2.	Manpower- One Project Associate-II (Rs. 35000+ 16% HRA for all three years)	4.872	4.872	4.872	14.616
3.	Consumables/Contingencies/Travel (Travel expenditure is to be restricted up to Rs. 50000/-per year)	10.00	10.00	10.00	30.00
4.	Overhead Charges	1.00	1.00	1.00	3.00
5.	Cash Award	1.00	1.00	1.00	3.00
6.	Total	26.872	16.872	16.872	60.616

### 2.6 Equipment:

The details of the equipment sanctioned for the implementation of the project at Annexure-I

### 2.7 Manpower:

The details of the manpower sanctioned for the implementation of the project at Annexure-II

### 3. Head of Account:

The Non-Recurring expenditure involved is debitable to:

Demand No. 87	Department of Biotechnology	
3425	Other Scientific Research 2019-20	
3425.60	Others (Sub Major Head)	
3425.60.200	Assistance to other Scientific Bodies (Minor Head)	
3425.60.200.29	Biotechnology Research and Development,	
3425.60.200.29.17	Assistance for Research and Development	
3425.60.200.29.17.35	Grants-in-Creation of Cupital Assets	

The Recurring expenditure involved is debitable to:

Demand No. 87	Department of Biotechnology	
3425	Other Scientific Research 2019-20	
3425.60	Others (Sub Major Head)	
3425.60.200	Assistance to other Scientific Bedies (Minor Head)	
3425.60.200.29	Biotechnology Research and Development	
3425.60.200.29.17	Assistance for Research and Development	
3425.60.200.29.17.31	Grants-in-aid General	

Salons

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

4. Term & Condition

In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest at the rate to ten percent per annum thereon shall be recovered.

Non-Recurring Grants shall be utilized with 18 months of their release.

- 4.1 The other terms and conditions governing this sanction are attached at Annexure- I.
- 4.2 A Memorandum of Agreement (MoA) will be signed between the Department of Biotechnology and the grantee institution on Non-Judicial stamp paper Rs. 100/- in the DBT format and the second release/installment will be made only after signing of MoA by the grantee institutions and its acceptance by DBT. In case of NGO or Private Institution, MOA signed is mandatory first release. A format of the MoA is enclosed in Annexure-III
- 4.3 The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilisation Certificate and Statement of Expenditure. The Interest so earned will be treated as created to the institute/Agency and shall be adjusted towards further installment of the grant and or at the time of Final Settlement of Accounts.
- 5. No international Travel will be undertaken from the sanctioned project grant unless specified otherwise.
- 6. The Director, Sanjay Gandhi Postgraduate Institute of Medical Sciences (S.G.P.G.I.M.S.) would be responsible for submission of Statements of Expenditure (SoE), utilization certificates (UC), Assets Certificates, Manpower staffing & expenditure details in prescribed DBT formats to DBT in respect of grants released in this project from time to time.
- 7. Awardee of DBT sponsored IYBA Award 2019 can consider appointment of JRF from Category-II merit list of DBT-BET exam so that candidates can be paid fellowships at par with NET/GATE/BET qualified candidates as per DST OM No. A.SR/S9/Z-09/2012 dated on 21 Oct 2014. However, there is no compulsion on Awardee's to select candidates for JRF in their projects from Category-II of DBT-BET.
- 8. As As per Rule 236 (1) of GFR 2017, the accounts of all Grantee Institutions or Organizations shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG (DPC) Act 1971 and internal audit by the Principal Accounts Office of the Ministry or Department, whenever the Institution or Organization is called upon to do so.
- 9. This issues under the power delegated to this Department and with the concurrence of IFD vide their San No.102/I.F.D./SAN/3921/2019-20, dated:-28.02.2020

10.	This sanction order has been noted at serial no.	4)	in the Register of Grants
	The state of the s		THE SHAW KANDESPERS OF CONTRACTOR

(Dr. Kakali Dey Dasgupta)

Or Kakan Day Dasgupta.

Califies \$ / Science \$

Order of Science \$

Outline \$ / Science \$

Outline \$

Outline \$ / Science \$

Outline \$ /

many sand

Salon







MINISTRY OF SCIENCE & TECHNOLOG

Dr. (Mrs.) Meenakshi Munshi Adviser/Scientist 'G' Ph. 011-24361035 Email: <u>rlsfellowship@dbt.nic.in</u>

D.O. NO. BT/HRD/35/02/2006

Dear Dr. Patel,

भारत सरकार कि विज्ञान और प्रौद्योगिकी मंत्रालय
वायोटेक्नोलॉजी विभाग
ब्लाक—2,7 वां तल, सी० जी० ओ० कम्पलेक्स
लोदी रोड, नई दिल्ली—110003
GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY
Block-2, 7th Floor C.G.O. Complex
Lodi Road, New Delhi-110003

Dated: 30th March, 2021.

I am pleased to inform you that you have been selected for 'Ramalingaswami Reentry Fellowship' of the Department of Biotechnology, Govt. of India for the year 2020-2021. This is one of our most prestigious fellowships and I congratulate you on being selected for the same.

During the tenure of your fellowship, you will receive a fellowship amount of Rs.1,00,000/- per month. House Rent Allowance (HRA) @ Rs.18,500/- P.M., Research/Contingency grant of Rs.10,00,000/- for 1<sup>st</sup> & 2<sup>nd</sup> year. Rs. 7,50,000/- for 3<sup>rd</sup> & 4<sup>th</sup> year and Rs. 5,00,000/- for 5<sup>th</sup> year. In addition, an institutional overhead @ Rs. 50,000/- per year will also be provided.

The terms and conditions for availing the fellowship are enclosed. Kindly send your acceptance along with the terms & conditions duly forwarded by the head of the host institute to DBT-HRD PMU, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Haryana -121001 Faridabad (Tel. Phone No. +91-129-2848775, 2848539, Email: <a href="mailto:rrf.dbt/arcb.res.in">rrf.dbt/arcb.res.in</a>). Once you join the host institute, you may submit a copy of your joining report as 'Ramalingaswami Re-entry Fellow' duly forwarded by the Host Institute (HI) along with the bank account details of your HI as per the attached format to enable us to issue a formal sanction order. Please note that you have to join your host institute within Nine Months from the date of issue of this letter.

With best wishes,

Yours Sincerely

(Meenakshi Munshi)

Dr. Girijesh Kumar Patel Research Associate, Texas Tech University Health Science Center, Department of Cell Biology and Biochemistry, 3601 4th Street, Lubbock, TX-79430-6540, USA. patelgirijesh@gmail.com, girijesh.patel@ttuhsc.edu

Sapo

Lt Col Varun Bajpai VSM

Executive Registrar

SGPGIMS, Lucknow

Website: http://www.dbtindia.nic.in http://www.btisnet.gov.in दूरभाव / Telephone : 24363012, 24362329 फेंक्स / Fax : 011-24362884 Eoffice File No. RAD-22017/13/2021-MED-DBT (Computer No. 13981)

### No. BT/PR45460/MED/12/952/2022

GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY

Block 2, 6-8th Floors CGO Complex, Lodhi Road, New Delhi- 110 003 Dated:30.03.2022

### ORDER

Sanction of the President is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rules ,1978 , for the implementation of the project entitled "Mission Program on Pediatric Rare Genetic Disorders" for a period of 5 Year 0 Month at a total cost of Rs.881556516 (Rupees Eighty Eight Crores Fifteen Lakhs Fifty Six Thousand Five Hundred and Sixteen Only) on the terms and conditions detailed here under:-

### ! The Project :

2.1 Title :

Mission Program on Pediatric Rare Genetic Disorders

2.2 Details of the Project Coordinator and Investigators:

**Project Cordinator** 

Dr. K. Thangaraj

Director,

Centre for DNA Fingerprinting and Diagnostics (CDFD)

Inner Ring Road, Uppal, Hyderabad - 500 039

Name of Institution	Principal Investigators Name, Designation, Contact details and Email ID	Co-Principal Investigators Name, Designation, Contact details and Email ID	Co- Investigators Name, Designation, Cont t details and Email
	Dr. K Thangaraj Director, Centre for DNA Fingerprinting and Diagnostics (CDFD) Inner Ring Road, Uppal, Hyderabad – 500 039	Murali Dharan Bashyam Scientist VII, Centre for DNA Fingerprinting and Diagnostics (CDFD) Inner Ring Road, Uppal, Hyderabad – 500 039	
Centre for DNA Fingerprinting and Diagnostics, Hyderabad	Dr. Ashwin Dalal Scientist VII, Centre for DNA Fingerprinting and Diagnostics (CDFD) Inner Ring Road, Uppal, Hyderabad -	Dr. Akash Ranjan Scientist VII, Centre for DNA Fingerprinting and Diagnostics (CDFD) Inner Ring Road, Uppal, Hyderabad – 500 039	
	500 039	Dr. Rashna Bhandari Scientist VI, Centre for DNA	Sil

Generated through eProMIS

XX

Page No. [1 / 23]

Nath liwary

पायादेक्नास्त्र विकास of Biotechnology विज्ञान और प्राप्त, नेपाल्य Mo Science & Tech. पायत संपर्का Lt Cof Varun Bajpai VSM

Executive Registrar SGPGIMS, Lucknow

, T., .			Sciences (AIIMS), Bhubaneswar – 751019
1		Managara da Ma	
	SHOW.		
Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala	(RGCB), Thiruvanthapuram, Kerala - 695 014	Dr. R. V Omkumar Scientist G, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvanthapuram, Kerala - 695 014	
Nizam's Institute of Medical Sciences, Hyderabad	Dr. Prajnya Ranganath Additional Professor Department of Medical Genetics, Fourth Floor, Specialty Block, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India.Pin:500082	Dr.Sireesha Yareeda Additional Professor, Department of Neurology, Millennium Blo k, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India.Pin:500082	
All India Institute of Medical Sciences, New Delhi	Dr. Neerja Gupta Associate Professor Department of Paediatrics All India Institute of Medical Sciences Ansari nagar, New Delhi- 110029	Madhumita Roy Chowdhury Senior Scientist, Department of Paediatrics, Division of Genetics, AIIMS, New Delhi - 110029	
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow	Dr. Amita Moirangthem Assistant Professor, Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014	Name: Dr Kirti Naranje Additional Professor, Department of Neonatology Address Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow- 226014, Uttar Pradesh, India	10

डॉ. ऑकार नाथ तिवारी Dr. Onkar Nath Tiwari वैज्ञानिक हैं / Scientist 'E'

वायोटेक्नोलॉर्जा विनाम / Deptt. of Biotechnology

विज्ञान और प्रोधा, मञ्जूलय/ Plage No: १३९/०२3]

nerated through eProMIS

J. J.

Soul of India N Date

	of Science, Banaras Hindu University, Varanasi- 221 005, Uttar Pradesh	Hindu University, Varanasi, Uttar Pradesh - 221 005	
University of Jammu, Jammu and Kashmir	Dr.Parvinder Kumar Sr. Asst Professor University of Jammu, Baba Saheb Ambedkar Road, Jammu Tawi, Jammu, Jammu & Kashmir, - 180006	Dr. Sanjeev K Digra Prof. In pediatrics SMGS Hospital, GMC Jammu-180001	
NIMHANS, Bengaluru	Dr. Chetan GK Professor Dept. of Human Genetics, National Institute of Mental Health and Neuro Sciences, Bangalore – 560 029	DR GAUTHAM ARUNACHAL UDUPI Assistant Professor, Department Of Human Genetics, NIMHANS, Hosur Road, Bengaluru, Karnataka, 560029	
Christian Medical College, Vellore	Dr. Shaji RV Professor Department of Haematology, Centre for Stem Cell Research, Christian Medical College Vellore- 632004, Tamilnadu,	Dr. Biju George Professor Department of Haematology, Christian Medical College, Vellcre, Tamil nadu India - 632004  Eunice Sindhuvi Professor Department of Haematology, Christian Medical College, Vellore- 632004, Tamil Nadu, India.	

ड अन्तर पाय विवासी D. On-er Neth Tiweri वर्जा-ए ई / Scientist 'E' बायोटेक्नोलीली विभाग / Deptt. of Biolechnology

बायोटेंच्नोलींची Iदनाग/Deptt of Biolechnology विज्ञान और प्रांद्यों, मंग्रालय/IWo Science & Tech भारत सरकार नई किन्नी /Gov. of India N Dev

inerated through eProMIS

Di

VX

Page No. [5 / 23]

### I India Institute of Medical Sciences (AIIMS), New Delhi

- 1. Recruitment of patients with Pediatric rare genetic diseases
- Awareness programmes -Workshops/Training programmes, Webinars, Community genetics awareness- Open day programmes, lectures in schools/colleges

### Baba Ghulam Shah Badshah University

- 1. Recruitment of patients with Pediatric rare genetic diseases
- Awareness programmes -Workshops/Training programmes, Webinars, Community genetics awareness- Open day programmes, lectures in schools/colleges

### Banaras Hindu University

- 1. Recruitment of patients with Pediatric rare genetic diseases
- Awareness programmes -Workshops/Training programmes, Webinars, Community genetics awareness- Open day programmes, lectures in schools/colleges

### Central University of Punjab, Bathinda

- Recruitment of patients with Pediatric rare genetic diseases
- Awareness programmes -Workshops/Training programmes, Webinars, Community genetics awareness- Open day programmes, lectures in schools/colleges

### Centre For DNA Fingerprinting and Diagnostics

- Genomic analysis for diagnosis of rare genetic disorders
- 2. Data ase development and analysis
- 3. Functional validation of novel variants/novel genes
- 4. Development of affordable diagnostics/screening strategies for rare genetic diseases
- 5. Awareness programmes -Workshops/Training programmes, Wahinars, Community genetics vareness- Open day programmes, lectures in school colleges

### Centre For Human Genetics

- 1. Recruitment of patients with Pediatric rare genetic diseases
- 2. Awareness programmes -Workshops/Training programmes, Webinars, Community genetics awareness- Open day programmes, lectures in schools/colleges

### Christian Medical College, Vellore

- Recruitment of patients with Pediatric rare genetic diseases
- 2. Lentiviral vector mediated gene editing for treatment of rare genetic diseases
- 3. Awareness programmes -Workshops/Training programmes, Webinars, Community genetics awareness- Open day programmes, lectures in schools/colleges

### ICMR-National Institute for Research in Tribal Health

- 1. Recruitment of patients with Pediatric rare genetic diseases
- 2. Awareness programmes -Workshops/Training programmes, Webinars, Community genetics awareness- Open day programmes, lectures in schools/colleges

### INSTITUTE OF LIFE SCIENCES, Bhubaneswar

- 1. Recruitment of patients with Pediatric rare genetic diseases
- 2. Functional validation of novel variants/novel genes
- 3. Awareness programmes Workshops/Training programmes, Webinars, Community

nerated through eProMIS

XX

Page No. [२०/६२३]श तियारी
Dr. Onkar Nath Tiwari
Guttin Strentist 'E'
बराहिक के जिल्ला / Dept. of Biotechnology
विभाग और प्रांची महास्वय / Livo Science & Tech

### 2.4 7 ne Schedule:

The duration of the project is 5 Year 0 Month from the date of this sanction order.

### 2.5 Project Cost:

The total cost of the project is Rs. 881556516/-(Rupees Eighty Eight Crores Fifteen Lakhs Fifty Six Thousand Five Hundred and Sixteen Only) as per details given below:

Institute	Year I	Year II	Year III	Year IV	Year V	Tota Cost(Rs.)
1. All India Institute of Medical Sciences (AIIMS), New Delhi	2186240	2186240	2186240	2186240	2186240	10931200
2. Baba Ghulam Shah Badshah University	2046080	2046080	2046080	2046080	2046080	10230400
3. Banaras Hindu University	2116160	2116160	2116160	2116160	2116160	10580800
4. Central University of Punjab, Bathinda	2046080	2046080	2046080	2046080	2046080	10230400
5. Centre For DNA Fingerprintin g and Diagnostics	294740800	126064800	125672680	125172680	19285956	690936916
6. Centre For Human Genetics	2186240	2186240	2186240	2186240	2186240	10931200
7. Christian Medical College, Vellore	15112800	3612800	4012800	4212800	4062800	31014000
8. ICMR- National Institute for Research in Tribal Health	2116160	2116160	2116160	2116160	2116160	10580800
9. INSTITUTE OF LIFE SCIENCES, Bhubaneswar	3800800	4300800	4300800	4300800	4300800	21004000
10. National Institute for Mental Health and Neuroscience	2186240	2186240	2186240	2186240	2186240	10931200
1. National	2186240	2186240	2186240	2186240	2186240	10931200

erated through eProMIS

ड आकार नाथ तिवारी Dr. Onkar Nath Thvari बेडाजिड ई / Scientist 'E'

विद्यादेक्नांलांजी विभाग / Deptt. of Biotechnology विद्यान और प्रीधी, मंत्रालय / M/o Science & Tech भारत सरकार नई जिल्ली / Govt of the a N Ge Page No. [9 / 23]

(13)

### FILE NO. CRG/2021/006013

### SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(A statutory body of the Department of Science & Technology, Government of India)

ogy, Government of India)
Science and Engineering Research Board
3rd & 4th Floor, Block II
Technology Bhavan, New Mehrauli Road
New Delhi - 110016

Dated: 22 March, 2022

### ORDER

Subject: Financial Sanction of the research project titled Role of Emerging SARS-CoV-2 variants in reshaping of serological responses of COVID-19 recovered patients and in vaccinated individuals: Study in North Indian Population under the guidance of Dr. SANTOSH KUMAR VERMA, Molecular Medicine and Biotechnology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli road lucknow india, Lucknow, Uttar pradesh-226014 and by Prof. Debi P Sarkar, Professor, Biochemistry, University Of Delhi and by Dr. Rahul Katharia, Associate Professor, Transfusion Medicine, Sanjay Gandhi Postgraduate Institute Of Medical Sciences and by Prof. Anupam Verma, Professor, Transfusion Medicine, Sanjay Gandhi Postgraduate Institute Of Medical Sciences and by Dr. Swasti Tiwari, Professor And Head, Molecular Medicine And Biotechnology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences - Release of 1st grant.

Sanction of **Science and Engineering Research Board (SERB)** is hereby accorded to the above mentioned project at a total cost of **Rs. 6681312/-** (**Rs. Sixty Six Lakh Eighty One Thousand Three Hundred and Twelve Only)** with break-up of **Rs. 1000000/-under Capital (Non-recurring) head and Rs. 5681312/- under General (Recurring)** head for a duration of 36 months. The items of expenditure for which the total allocation of **Rs. 6681312/-** has been approved are given below:

The following budget may be considered for Sanjay Gandhi Postgraduate Institute Of Medical Sciences, Raebareli Road Lucknow India

S. No	Head	Total (in Rs.)
A	Non-recurring	
1	Equipment -> -20 deepfreezer -> Orbital shaker -> Protein blotting assembly -> Protein electrophoresis unit with power pack	1000000
A'	Total (Non-Recurring)	1000000
В	Recurring Items	
1	Recurring - I : (Manpower) Recurring - II : (Consumables, Travel, Contingencies) Recurring - III : Scientific Social Responsibility	1753920 3300000 20000
2	Recurring - IV : (Overhead Charges)	607392
B'	Total (Recurring)	5681312
С	Total cost of the project (A' + B')	6681312

- 2. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at website (www.serb.gov.in).
- 3. Overhead expenses are meant for the host Institute towards the cost for providing infrastructural facilities and general administrative support etc. including benefits to the staff employed in the project.
- 4. While providing operational flexibility among various subheads under head Recurring-II, it should be ensured that not more than Rs. 1.5 lakh each should be spent for travel and contingency.
- 5. Budget sanctioned under Scientific Social Responsibility (SSR) is meant only for activites enlisted under SSR norms and under no circumstances it can be reappropriated.
- 6. As per rule 211 of GFR, the accounts of project shall be open to inspection by sanctioning authority/audit whenever the institute is called upon to do so.
- 7. The sanctioned equipment would be procured as per GFR and its disposal of the same would be done with prior approval of SERB.
- 8.The institute will furnish to the SERB, separate Utilization certificate(UCs) financial year wise to the SERB for Reduction (Grants-in-aid General) & Non-Recurring (Grants for creation of capital assets) and an audited statement of account pertaining to the grant immediately after the end of each financial year.
- 9. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.

10. The manpower sanctioned in the project, if any is co-terminus with the duration of the project and SERS will have no billity to meet the fellowship and salary of supporting staff if any, beyond the duration of the project

11. The institute may refund any unspent balance to SERB by means of a Demand Draft favoring "FUND FOR SCIENCE AND ENGINEERING RESEARCH" payable at New Delhi.

12. The project File no. CRG/2021/006013 should be mentioned in all communications arising from the above project. The organization/institute/university should ensure that the technical support/financial assistance provided to them by SERB should invariably be highlighted/ acknowledged in their media releases as well as in bold letters in the opening paragraphs of their Annual Report.

13. In addition, the investigator/host institute must also acknowledge the support provided to them in all publications, patents and any other output emanating out of the project/program funded by SERB.

14. Sanction order for release of funds under a) Non-recurring and b) Recurring will be issued separately depending on the availability of funds. The project become operational from the day the first release of grant received by the implementing Institute.

(Dr. Thangaradjou T) Scientist F msls@serb.gov.in

To, Under Secretary SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C.R.Building, IIIrd Floor I.P. Estate, Delhi-110002
2.	Sanction Folder, SERB , New Delhi.
3.	File Copy
4.	Dr. SANTOSH KUMAR VERMA Molecular Me pine and Biotechnology Sanjay Gandh ostgraduate Institute of Medical Sciences, Raebareli road luckno adia, Lucknow, Uttar pradesh-226014 Email: verma2sar(* sh@gmail.com Mobile: 916394134072
	Prof. Debi P Sarker Biochemistry University Of Delhi  Dr. Rahul Katharia Transfusion Medicine Sanjay Gandhi Postgraduate Institute Of Medical Sciences
	Dr. Prabhaker Mishra Biostatistics And Health Informatics Sanjay Gandhi Postgraduate Institute Of Medical Sciences
	Prof. Anupam Verma Transfusion Medicine Sanjay Gandhi Postgraduate Institute Of Medical Sciences
	Dr. Swasti Tiwari  Molecular Medicine And Biotechnology  Sanjay Gandhi Postgraduate Institute Of Medical Sciences  (Start date of the project may be intimated by name to the undersigned. For guidance, terms & Conditions etc. Please visit <a href="https://www.serb.gov.in">www.serb.gov.in</a> .)
5.	DIRECTOR, Sanjay Gandhi Postgraduate Institute Of Medical Sciences, Raebareli Road Lucknow India
-	(Receipt of Grant may be intimated by name to the undersigned)

(Dr. Thangaradjou T) Scientist F msls@serb.gov.in

msls@serb.gov.ii

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS,Lucknow

### Dr Arindan Organizing Sec Observer, Gujarat Medical Council Dr Anish Joshi Dr Rajesh Chandra Mishra Workshops: 6" & 7" April 2022 | Conference: 8" to 10" April 2022 Gujarat Medical Council has granted Four Credit Points Chairman Salentific Committee Mehatina Mandir Convention Centre, Gandhinagar Workshop at CRITICARE 2022 held on 7" April 2022 read clarebanulin Certificate of Narticipation CRITICARE 2022 has participated as a Faculty in Observer, Gujarat Medical Council Mohan Gurjar Research & Statistical Methodology Dr. Tushar Patel This is to certify that Co-Chairman & Chairman Abstract Committee Dr Dhruva Chaudhry President, Gujarat Medical Council Dr Nifin Vora Dr Deepak Govil Organizing Chairman Madeus Good



### **Certificate of Appreciation**



### UTTAR PRADESH MASIHI ASSOCIATION

values

Dr. Vinita Elizabeth Mani

For you have served the Rord through the faithful exercises of your gifts.

Ephesians 2 : 10

For we are God's workmanship created in Christ Jesus to do good work which

God prepared in advance for us to do "

ANTONY

Dated: 19.04.2022.

R.K. CHATTREE Secretary





### Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow 226 014

FAX: 91-522-2668017, 2668129 Email: registrar@sgpgi.ac.in

Ref: PGI/ER/ACAD/CF-29/ 286 /2022

File RSD No.: 10584/13

Phones: 91 (522) 2494009 2494011

Dated: /9/0//12022

### OFFICE ORDER

Dr. Khaliqur Rahman, Additional Professor, Department of Hematology has been permitted to attend 23rd INDO-US Flow Cytometry Workshops- 2022 to be held from 08.02.2022 to 11.02.2022 without financial support from the Institute on the following terms and

- Permission to attend 23<sup>rd</sup> INDO-US Flow Cytometry Workshops- 2022 to be held from 08.02.2022 to 11.02.2022 at University of Rajasthan, Jaipur,
- 2. 03 days Duty Leave with departure date on 09.02.2022 (afternoon) and arrival on
- 3. TETC will book and provide economy class flight tickets and boarding and lodging for the
- 4. Dr. Khaliqur Rahman will submit his participation certificate and a report on the above
- 5. HOD will ensure the availability of 50% faculty members on duty during the entire period 6. There will be no financial burden on


This issues with the approval of the Director.

Dr. Afzal Azim Executive Registrar

Copy to:

- Dr. Khaliqur Rahman, Additional Professor, Department of Hematology. Concerned HOD.
- iii. Finance Officer.
- iv. Concerned File.

Dr. Afzal Azim Executive Registrar



Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow 226 014

Phones: 91 (522) 2494009 2494011

2.

FAX: 91-522-2668017, 2668129 Email: registrar@sgpgi.ac.in

Ref: PGI/ER/ACAD/CF-40/ /062

File RSD No.: 6537/14

### OFFICE ORDER

Dr. Amit Rastogi, Associate Professor, Department of Anaesthesiology has been permitted to attend the '25th National Conference of the Indian Association of Cardiovascular & Thoraic Anesthesiologists' scheduled to be held from 25.03.2022 to 27.03.2022 at Courtyard by Mariott, Tamil Nadu, Madurai, India with financial support from the Institute on the following terms and conditions:-

Permission to attend the '25th National Conference of the Indian Association of Cardiovascular & Thoraic Anaesthesiologists' scheduled to be held from 25.03.2022 to 27.03.2022 at Courtyard by Mariott, Tamil Nadu, Madurai, India. 1.

TA/DA as per rules.

04 days Duty Leave i.e. from 25.03.2022 to 28.03.2022. 2.

Registration fee of Rs. 12980/- on production of original receipt.

He will submit his participation certificate and a report on the conference within 15 3. 4. 5.

HOD will ensure availability of 50% faculty members on duty during the entire 6.

This will be his 1st National Conference with financial support from the Institute in 7. the FY 2021-2022.

This issues with the approval of the Director.

Dr. Afzal Azim **Executive Registrar** 

Copy to:


- 1. Dr. Amit Rastogi, Associate Professor, Department of Anaesthesiology.
- 2. Concerned HOD.
- 3. Finance Officer, SGPGI.
- 4. Concerned File.

Dr. Afzal Azim **Executive Registrar** 

Lt Col Varun Bajpai VSM

**Executive Registrar** SGPGIMS, Lucknow





FAX :91-512-1668017

संजय गाँधी स्नातकोत्तर आयुर्विज्ञान संस्थान, लखनऊ

SANJAY GANDHI POST GRADUATE INSTITUTE OF MEDICAL SCIENCES,

Raebareli RoadLucknow -226014 (India) Ref No. PGI/ER/ACAD/CF 29/ 893 /2022 RSD No.10584/13

26 41 February, 2022

### Office Order

Dr. Khaliqur Rahman, Additional Professor, Department of Hematology has been permitted to attend "62" Annual Scientific Meeting of the British Society of Hematology-2022 at Manchester Central Convention, Manchester, U.K. scheduled to be held from 03<sup>rd</sup> to 05<sup>th</sup> April, 2022 with financial support from the Institute under the following terms & conditions:-

- 1. Permission to attend "62<sup>nd</sup> Annual Scientific Meeting of the British Society of Hematology-2022 scheduled to be held from 03<sup>rd</sup> to 05<sup>th</sup> April, 2022 at Manchester Central Convention, Manchester, U.K.
- 2. Registration Fee 175 GBP on the production of original receipt.
- 3. TA/DA as per rules for the conference period only.
- 4. He will be paid Visa Fee & Medical Insurance as per rules of the Institute.
- 5. Duty leave from 01.04.2022(afternoon) to 07.04.2022(afternoon).
- 6. He will su' mit participation certificate and a report within a period of 15 days of return from above said Conference.
- 7. HOD will ensure the the availability of 50% faculty members on duty during the entire period of absence of a faculty members.
- 8. Head, concerned department will ensure that departmental work will not suffer due to absence of Ur. Khaligur Rahman.
- 9. This Institute funded International Conference will be considered against two year slot

This issues with the approval of the Director.

(Dr. Afzai Azirn) Executive Registrar

Copy forwarded for information & necessary action to:

- Dr. Khaliqur Rahman, Additional Professor, Department of Hematology.
- 2. HOD, Department of Hematology.
- 3. Finance Officer.

4/ Concerned File.

(Dr. Afzal Azim) Executive Registrar

of ful



# 23rd National Conference of IAP Intensive Care Chapter

## CERTIFICATE OF PARTICIPATION

This is to certify that

## Dr. Banani Poddar

has actively participated in the conference held at

SMS Medical College Auditorium, Jaipur from 29th April - 1st May, 2022

### as FACULTY

Rajasthan Medical Council has granted 06 (SIX) Credit Hours (Ref. No.: RMC/2022/3672 dated 26.04.2022)

Amarjeet Mehta Dr. Manish St

Dr. Manish Sharma Organizing Secretary

orzing Chairperson

Dr. Dhiren Gupta President, PICC

Dr. Arun Bansal Secretary, PICC (

Dr. Rajiv Uttam Chairman Sclentific Committee

Dr. Sheikh Minhaj Ahmed Scientific Convenor















Organized by Department of Paediatric Surgery MS, Sanaras Lindu University, Varanas

## HOLFOLL OH PARTICUPATION

This is to certify that

### Dr. Aukur Mandelia

has attended/participated in the 17th Paediatric Endoscopic Surgeons of India as Speaker in CME held on 8-10 April 2022.

He/She has presented

Surgical Heuristics: Handling on-table exigencies TITLED:

//dg reference number; 2489/2027 on 21/3/2022

Clarent !

Utter Pradesh Medical Council Credit Hour: 06

18X

DR VAIEHAV PANDEY ORGANISING SECRETARY

DR M SRINIVASA RAO SECRETARY PESI

PROF. A.N. GANGOPADHYAY ORGANISING CHAIRMAN

CHAIRMAN PESI

DR S RAMESH

Deccan Chapter of IAPS

6" to 8" May 2022

UTORDA BEACH, GOA. Planet Hollywood Beach Resort

PAEDIATRIC UROLOGY 4th DECCAN COURSE IN

Biennial course in Paediatric Urology with world renowned faculty Indian Association of Paediatric Surgeons Organised by the Deccan Chapter of

This is to certify that Dr.

has participated as a Delegate in the 4th Deccan Course in Paediatric Urology

held from 6th to 8th May at Planet Hollywood Beach Resort, UTORDA BEACH, GOA.

Deccan Chapter of IAPS Dr. Sanjeev Kaddu Chairman

Dr. Sudhakar Jadhav Organising Chairman

Organising Chairman Dr. Sanjay Khope

Organising secretary Dr. Santosh Patil

Organising secretary Dr. Kant Shah



### INDIAN RADIOLOGICAL & IMAGING ASSOCIATION

LUCKNOW CITY CHAPTER

### CERTIFICATE

202		VIIIVE TO	
39 88 W	Prof./Dr ATHAR SH	AMIM AV-1	Participated in the
This is to certify that	Prot./Dr	17 178	
0.0		70 81	
	cknow City Chapter, organi	ized by Mindray Med	ical India Pvt. Ltd.
			111-2
	Faculty/, Delegate/ Present	19 / 2 <sup>nd</sup> / 2 <sup>nd</sup> ]	Prize
on 17th April, 2022 as	Faculty/ Delegate/ Present	er & won-1 / 2 / 3	
THE PARTY OF THE			
			5 7 7 mm a
	0000000		
-> Mules	D. G. bas Cashi Sarkar	Prof. Neera Kohli	Dr. Sheo Kumar
Prof. S Bhadury Patron In Chief	Dr. Sabya Sachi Sarkar Padma Shri Awardee	President	Secretary 1RIA, Lucknow
IRIA, Lucknow	Patron IRIA, Lucknow	IRIA, Lucknow	material state and secretary

Scanned by CamScanner

# INDIAN RADIOLOGICAL & IMAGING ASSOCIATION

TECHNICACIENT CHAPTER

## CERTIFICATE

Participated in the This is to certify that Prof./Dr. RODIN. CME Program of Lucknow City Chapter, organized by Mindray Medical India Pvt. Ltd.

on 17th April, 2022 as Faculty/ Delegate/ Presenter & won 1\*t/2\*\*

Parron In Chief HIA LUCKNOW

Jatron 101A, Lucknow Padıma Shrl Awardee

rof. Neera Koh HILL, Lucknow President

Dr. Sheo Kumar

IRIA, Luckmow



### 79th Annual Conference All India Ophthalmological Society 24th -27th June 2021

Certificate o

### Awarded to

DR. VIKAS KANAUJIA

for evaluating the INSTRUCTION COURSE

abstracts on Neuro Ophthalmology

for the 79th Virtual Annual Conference of AIOC, 2021

Prof. Mahipal S. Sachdev

President - AIOS

Prof. Namrata Sharma Hony, General Secretary

Validity unknown

Digitally signed by DR PABTA BISWAS Date: 2021.06.27 20:33.02 +05:30 Reason: Chairman - Scientific Committee, AIOS

Dr. Partha Biswas

Chairman Scientific Committee





### 79th Annual Conference All India Ophthalmological Society 24th -27th June 2021

Certificate of Participation

This is to certify that

DR. VIKAS KANAUJIA

was the Chairperson & Judge at the "Neuro Ophthalmology"

POSTER PODIUM PRESENTATION SESSION

on 25.06.2021

79th Virtual Annual Conference of AIOC, 2021

Prof. Mahipal S. Sachdev

President - AIOS

Prof. Namrata Sharma Hony. General Secretary

Validity unknown

Digitally signed by DR PAD 1 A BISWAS Date: 2021.06.27 20:28:10 +05:30 Reason: Chairman - Scientific Committee, AIOS

Dr. Partha Biswas

Chairman Scientific Committee





### **MONSOON SUMMIT 2021**

INTERNATIONAL NEUROLOGY UPDATE



Certificate

This is to certify that

### Dr. VINITA ELIZABETH

has actively participated as Delegate in the MONSOON SUMMIT 2021 - International Neurology Update Virtual Conference, from 9th to 11th July, 2021

Ulway

Dr. P.C. Gilvaz Chairman Monsoon Summit 2021 mo

Dr. K.P. Vinayan Secretary Monacon Summit 2021 SylapaPN

Dr. P.N. Sylaja Chairman, Scientific Committee Monsoon Summit 2021 Dr. Mohanan N

Or. Mohanan N
President
KAN

Dr. Suresh Chandran C J

KAN

Balon











**Virtual Conference** 

### **UP-UK NEUROCON 2021**

27th Annual Conference of UP-UK Neuroscience Society

Theme: 'Breaking the Barriers'

7th - 8th August, 2021, Jhansi (U.P.)

Organized by :
Bundelkhand Neurology Foundation and MLB Medical College Jhansi



This is to certify that

### DR. VINITA ELIZABETH

has participated as **Delegate** in the "UP-UK NEUROCON 2021" from 7th to 8th August, 2021


Dr. Sanjay Beharl

Rai

Or Rajesh Verma Secretary UP UK Need actience seconds Aried Kankan

Dr Arvind Kankane Organizacy worefur, UP UK neuroom 2023

braken



Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS,Lucknow



25"-26" September 2021





2" Annual Conference of the Central Zone & UP Necon Theme: Concern and Care Quoluty newform

Grand-5 Resort, Meerut, Uttar Pradesh

Organised by; NNF India NNF UP & IAP Meerut Branch



This is to Certify that Dr. ABALTEET

a paper on whose a dustra

presented

Br. Albik Bhardwai UP NNF Secretary P NNF President Or Ashok Rai

> Dinesh Temar NIVE Secretary

Best Paper Award 2nd Runne

Organizing President Dr. Rajoey Prakash

Organizmo Secretary Dr. Amir Lipadhyay

Organizing Chairperson Dr. Manish Agarwal

Ranian K Pejaver **NNF President** 

00

# CZ-UP NE®CON

25"-26" September 2021

2021



Amnual Conference of the Central Zone & UP Neocon Theme: Concern and Care anduty newform conc...

Grand-5 Resort, Meerut, Uttar Pradesh

Organised by; NNF India NNF UP & IAP Meerut Branch

Certificate

that Dr.

paper on A

presented

and declared

Free Paper 1st Runner up

Or. Dinesh Tomar HILF Secretary

JP NNF President Dr. Ashok Rai

Or Alok Bhardwaj UP NNF Secretary

Dr. Rajeev Prakash Organizing President

Organizing Secretary Dr. Amit Upadhyay

Organizing Chairperson Or. Manish Agarwal

139





This is to certify that Dr ANANT MEHROTRA

has participated as Faculty/Delegate in the NEUROVASCON 2021 organized by Department of Neurosurgery, PG1MER, Chandigarh.

Accredited 8 Credit Hours from Punjab Medical Council, Mohā.، vide Letter No. PMC/CME/2021/3841/Dt. 13.9.2021

Dr. N.K. Vekataramana President, CVSI

Dr. Paritosh Pandey Pentis Pandey Secretary, CVSI

Dr. Navneet Singla Organizing serrer

Punjab Medical Council Dr. Manoj Sobti

Col Varun Bajpai Ventra Cubta Dr. S. K. Cupta Dr. S. K. Cupta President







### Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow 226 014

FAX: 91-522-2668017, 2668129 Email: registrar@sqpgi.ac.in

Ref. No.: PGI/ER/ACAD/ CF-07/4176/2021

Phones 91 (522) 2494820

Dated: 20/10/2021.

### OFFICE ORDER

Dr. Anant Mehrotra, Additional Professor, Department of Neurosurgery has been permitted to attend the "NEUROVASCON-2021"scheduled to be held from 24th to 26" September, 2021 at PGIMER Chandigarh" with financial support from the Institute under the following terms & conditions:-

- 1. Permission to attend above National Conference with financial support from the
- 2. T.A./D.A & Registration fee Rs. 14000 ·GST@18% on production of original receipt as per rules.
- 3. 03 days duty leave from 23<sup>rd</sup> to 25<sup>th</sup> September, 2021.
- 4. He will leave on 23<sup>rd</sup> September 2021 & return on 26<sup>th</sup> September, 2021.
- 5. He will submit participation certificate and a report within a period of 15 days of
- 6. HOD of the concerned department will ensure that departmental and patient care work should not suffer during the above leave of Di. Mehroti in the department.
- 7. He will submit his department report when proceeding for attending the aforesaid events and also submit arrival report after return when resuming duty mentioned date & time.
- 8. This will be his First National Conference with financial support of the Institute in the financial year 2021-22.

This issues with the approval of Director.

(PROF. AFZAL AZIM) **EXECUTIVE REGISTRAR** 

Copy to:

- 1. Dr. Anant Mehrotra, Additional Professor, Department of Neurosurgery, SGPGIMS.
- 2. HOD, Neurosurgery, SGPGIMS.
- 3. Finance Officer, SGPGIMS.

4. Concerned file.

(PROF. AFZAL AZIM) **EXECUTIVE REGISTRAR** 

अस्मना नमी जिल

FAX: 91-522-2668017, 2668129 Email: registrar@sgpgi.ac.in

Ref. No.: PGI/ER/ACAD/CF-09/4052/2020

Phones: 91 (522) 2494820

### OFFICE ORDER

Dr. Sanjay Kumar, Additional Professor, Department of Anaesthesiology has been permitted to attend the '43rd Annual Conference of Indian Society of Anaesthesiologists-UP State (UPISACON 2021)"scheduled to be held from 01.10.2021 to 03.10.2021 at Varanasi (UP) alongwith 05 days duty leave from 30<sup>th</sup> September, 2021 to 4<sup>th</sup> October, 2021 with financial support from the Institute under the following terms & conditions:-

- 1. Permission to attend above National Conference with financial support from the Institute in financial year 2021-2022.
- 2. TA/DA & Registration fee Rs. 5500+GST@18% on production of original receipt as per rules.
- 3. 05 days duty leave from 30.09.2021 to 04.10.2021.
- 4. He will submit participation certificate and a report within a period of 15 days of return.
- 5. HOD of the concerned department will ensure that departmental and patient care work should not suffer during the above leave of Dr. Sanjay Kumar in the department.
- 6. He will submit his departure report when proceeding for attending the aforesaid conference and also submit arrival report after return when resuming duty mentioning date & time.
- 7. This will be his First National Conference v th financial support of the Institute in the financial year 2021-22.

This issues with the approval of Director.

(PROF. AFZAL AZIM) EXECUTIVE REGISTRAR

Copy to:

1. Dr. Sanjay Kumar, Additional Professor, Department of Anaesthesiology.

2. HOD, Anaesthesioogy, SGPGIMS.

3. Finance Officer, SGPGIMS.

4. Concerned file.

(PROF. AFZAL AZIM) EXECUTIVE REGISTRAR

8/10/21

















### 31st Annual Conference of the Indian Society of Organ Transplantation

7th - 10th October 2021, Hybrid Conference, Kochi

Dr. Shubhi Kamthan This is to certify that ......

has been awarded Second Prize in Mini Oral - Basic Science in the 31st Annual Conference of the Indian Society of Organ Transplantation held at Kochi in association with Association of Cochin Nephrologists from 7th - 10th October 2021.

> Topic : Urinary Soluble CD163 and CD163+ M2 Macrophage Tissue Infiltration in Antibody-Mediated Renal Allograft Rejection

Dr. Jai Prakash ISOT President

Hierland Dr. Vivek Balkrishna Kute

Dr. Abi Abraham M ISOT Secretary ISOT 2021 Org. Chairman

ah bel

Dr. Rajesh R Nair

ISOT 2021 Org. Secretary

Organised by



GEORGE'S MEDICAL UNIVERSITY, LUCKNOW DEPARTMENT OF RADIODIAGNOSIS,

Certificate of Participal

This is to Certify that Dr. Tanya Dikshit participated in CME on "Advances in MR Imaging" & won 1st Prize in Quiz Competition on 23.10.2021



Dr. Anit Parihar Organising Secretaries

Dr. Neera Kohii

Organising Chairpersons

Lt Col Varun Baipai VS





1

### Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebarell Road, Lucknow 226 014

FAX 91-522-2868017 2868129 Email reportar groups at in

Phones: 91 (522) 2494009

2494011

Ref: PGLER/ACAD/CF-86/ /7/ File RSD No.: 3129 19

/2021

Dated: /0/0//2021

OFFICE ORDER

Dr. Neha Nigam, Assistant Professor, Department of Pathology has been permitted to CYTOCON 2021 (Virtual Conference) to be held from 19.11.2021 to 21.11.2021 with financial support from the Institute on the following terms and conditions:

- 1. Permission to attend CYTOCON 2021 (Virtual Conference) to be held from 19.11.2021
- Registration fee of Rs. 1500 on production of original receipt.
- 3. Dr. Neha Nigam will submit her participation certificate and a report on the above event
- Head of department concerned will ensure that departmental work ill not suffer.
- 5. This will be her 1st National Conference with financial support nom the Institute in the

This issue, with the approval of the Director.

Dr. Afzal Azim Executive Registrar

### Copy to:

- i. Dr. Neha Nigam, Assistant Professor, Department of Pathology. ii. Concerned HOD.
- iii. Finance Officer.
- iv. Concerned File.

Dr. Afzal Azim Executive Registrar

Lt Col Varun Bajpai VSM **Executive Registrar** 

SGPGIMS, Lucknow



## ALL INDIA INSTITUTE OF MEDICAL SCIENCES PATNA **ASPICON 2021**

3rd National Conference on Antimicrobial Stewardship Practices in India

3rd - 4th December, 2021

Dr. Chinmoy Sahu. has participated as Gaest Farmer This is to Certify that.....

ChairpersonJudge/Member of Organising Committee in the "3" National Correction on American S

Practices" ASPICON 2021 held from 3rd – 4th December, 2021 in AIIMS Parna. Bilian India

Dr. Shahjanand Pd. Singh

gistrar, Bihar Council of Medical Registration

Dr. Prathyusha K. 3 Prothymen

Organizing Secretary

Co-Organizing Seeretary Dr. Asim Sarfraz grayers, most

J. Care

Dr. Prasan Kumar Panda General Secretary, \$45P1

Dr. Austral Shaffe Proster Sist

Dr. Bhaskar Thakuria

Director, AHMS, Patma Dr. P K Singh

- 2.31

Dr. Umesh Bhadani Dean, AHMS, Patna

(selephini)

is conference is accredited with 8 conference credit hours as per letter no. 2627 +2.2012 states [1112] by 8 har Conserved in Means Season

Dr. Binod Kumar Pati Co- Organizing Chairman



### Sanjay Gandhi Postgraduate Institute of Medical Sciences Raebareli Road, Lucknow 226 014

109

FAX: 91-522-2668017, 2668129 Email: registrar@sgpgi.ac.in

Phones: 91 (522) 2494009

Dated: 17 17 - /2021

Ref: PGI/ER/ACAD/CF-49/ 4941 /2021 File RSD No.: 1430/17

### OFFICE ORDER

Dr. Chinmoy Sahu, Associate Professor, Department of Microbiology has been permitted to attend the National Conference ASPICON 2021 from 03.12.2021 to 04.12.2021 at AIIMS, Patna with financial support from the Institute on the following terms and conditions:

- 1. Permission to attend the conference ASPICON 2021 from 03.12.2021 to 04.12.2021 at AIIMS, Patna.
- 2. Duty Leave for 04 days from 02.12.2021 to 05.12.2021.

3. TA, DA as per rules.

4. Registration fee of Rs. 3000 on the production of original receipt.

5. Dr. Chinmoy Sahu will submit his participation certificate and a report on the above event

6. HOD will ensure the availability of 50% faculty members on duty during the entire period

of absence of the respective faculty member. 7. This will be his 1<sup>st</sup> National Conference with financial support from the Institute in FY 2021-2022.

This issues with the approval of the Director.

Dr. ...izal Azim **Executive Registrar** 

Copy to:

Dr. Chinmoy Sahu, Associate Professor, Department of Microbiology

- i. Concerned HOD.
- ii. Finance Officer.
- iii. Concerned File. iv.

Dr. Afzal Azim **Executive Registrar** 

Lt Col Varun Bajpai VSM **Executive Registrar** SGPGIMS, Lucknow



### Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow 226 014



FAX: 91-522-2668017, 2668129 Email: registrar@sgpgi.ac.in

Phones: 91 (522) 2494009

2494011

Ref: PGI/ER/ACAD/CF-07/ 5020 /2021

File RSD No.: 11001/14

Dated: 21/12/12021

### OFFICE ORDER

Dr. Anant Mehrotra, Additional Professor, Department of Nuerosurgery has been permitted to attend NSICON 2021 (Virtual Conference) from 10.12.2021 to 12.12.2021 with financial support from the Institute on the following terms and conditions:-

Permission to attend NSICON 2021 (Virtual Conference) from 10.12.2021 to 12.12,2021.

Registration fee of Rs. 1180 on the production of original receipt. 2.

Dr. Anant Mehrotra will submit his participation certificate and a report within a 3. period of 15 days on return.

Head of department concerned will ensure that departmental work will not suffer. 4.

This will be his 2<sup>nd</sup> National Conference with financial support from the Institute in 5. the FY 2021-2022.

This issues with the approval of the Director.

Dr. Afzal Azim **Executive Registrar** 

Copy to:

1/Dr. Anant Mehrotra, Additional Professor, Department of Nuerosurgery.

- 2. Concerned HOD.
- 3. Finance Officer.
- 4. Concerned File.

Dr. Afzal Azim **Executive Registrar** 

Dr. Apant Mehrotra M.S., M.Ch.

Additional Professor Deptt. of Neurosurgery SGPGIMS, Lucknow

> Dr. Anant Me motra M.S., M.Ch. Additional Professor

Deptt. of Neurosurgery SGPOIMS, Lucknow



### Sanjay Gandhi Postgraduate Institute of Medical Sciences Raebareli Road, Lucknow 226 014

522-2668017, 2668129 Email: registrar@sgpgi.ac.in

Ref: PGI/ER/ACAD/CF-89/

168 /2021

File RSD No.: 4249/19

Phones: 91 (522) 2494009

Dated: /0/01/2021

### OFFICE ORDER

Dr. Alka Verma, Assistant Professor, Department of Emergency Medicine has been permitted to attend Virtual World Academic Congress of Emergency Medicine to be held from 10.12.2021 to 19.12.2021 with financial support from the Institute on the following terms and conditions:

- 1. Permission to attend Virtual World Academic Congress of Emergency Medicine.
- 2. Registration fee of Rs. 8850 on production of original receipt.
- 3. Dr. Alka Verma will submit her participation certificate and a report on the above event within a period of 15 days on return.
- 4. Head of department concerned will ensure that departmental work will not suffer.
- 5. This will be her 1<sup>st</sup> National nference with financial support from the Institute in the

This issues with the approval of the Director.

Dr. Afzal Azim **Executive Registrar** 

### Copy to:

- Dr. Alka Verma, Assistant Professor, Department of Emergency Medicine.
- ii. Concerned HOD.
- iii. Finance Officer.
- iv. Concerned File.

Dr. Afzal Azim **Executive Registrar** 

Çoh Varun Bajpai VSM



### Sanjay Gandhi Postgraduate Institute of Medical Sciences

Raebareli Road, Lucknow 226 014

FAX: 91-522-2668017, 2668129 Email: registrar@sgpgi.ac.in

Ref: PGI/ER/ACAD/CF-66/ 4886 /2021

File RSD No.: 6690/17

Phones: 91 (522) 2494009

2494011

Dated: 13/12/2021

### OFFICE ORDER

Dr. Divya Srivastava, Associate Professor, Department of Anesthesiology has been permitted to attend the National Conference ICACON 2021 from 17.12.2021 to 19.12.2021 at Lady Hardinge Medical College, New Delhi with financial support from the Institute on the following terms and conditions:

- 1. Permission to attend ICACON 2021 from 17.12.2021 to 19.12.2021 at Lady Hardinge Medical College, New Delhi.
- 2. 03 days of Duty Leave.
- 3. TA, DA as per rules.
- 4. Registration fee of Rs. 6500 on the production of original receipt.
- 5. Dr. Divya Srivastava will submit her participation certificate and a report the above event within a period of 15 days on return.
- 6. HOD will ensure the availability of 50% faculty members on duty during the entire period of absence of the respective faculty member.
- 7. This will be her 3<sup>rd</sup> National Conference with financial support from the Institute in the FY 2021-2022.

This issues with the approval of the Director.

Jr. Afzal Azim **Executive Registrar** 

Copy to:

- Dr. Divya Srivastava, Associate Professor, Department of Anesthesiology. i.
- Concerned HOD. ii.
- Finance Officer. iii.
- Concerned File. iv.

Dr. Afzal Azim **Executive Registrar** 

Lt Col Varun Bajpai VSM **Executive Registrar** 

SGPGIMS, Lucknow

## 



### CERTIFICATE

This is to certify that

Dr. Ulday Pratap Singh

31st Annual Conference of North Zone Urological Society of India, New Delhi has participated as Faculty in the

17" - 19" December 2021

Organizing Secremy Dr P P Singfi

Prof (Dr) Rajeer Sood Organizing Chairman

Dr. Sudhir Ranual

President, NZUSI

Dr. Annep Kumar Secretary, NZUSI









Indian Association of Gastrointestinal Endo-Surgeons &

Max Institute of Minimal Access, Bariatric & Robotic Surgery FIRST FALLS FELLOWSHIP COURSE IN ROBO

December 17 - 19, 2021 | The Leela Ambience, Convention Hotel, New Delhi

# CERTIFICATE OF PARTICIPATION

This is to certify that

## Dr. BASANT KUMAR

has Actively Participated as DELEGATE during

FIRST FALS FELLOWSHIP COURSE IN ROBOTIC SURGERY held on 17 - 19 December 2021

Prof Sunil Popat President, IAGES

**Dr. Ramesh Aggarwala** IAGES FALS Board Chairman Kowo U Agran Us

Organising Chairman Dr Vivek Bindal

### **CME/CPD Certificate**

This is to certify that

### Ruchika Tandon DM (Neurology)

participated in the

### XXV World Congress of Neurology

October 3-7, 2021

and received 35 credits

Prof William Carroll
WFN President

Prof Christopher Kennard WCN 2021 Scientific Program Chair

European Accreditation Council for Continuing Medical Education (UEMS/EACCME)

The XXV World Congress of Neurology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net.

The XXV World Congress of Neurology is designated for a maximum of, or up to, 35 European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

American Medical Association (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of *AMA PRA Category 1 Credits*™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/cme/uemseaccme-credit-recognition.

Royal College of Physicians and Surgeons of Canada

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca/rcsite/cpd/providers/international-accreditation/agreements-e.









**Virtual Conference** 


### **UP-UK NEUROCON 2021**

27th Annual Conference of UP-UK Neuroscience Society

Theme: 'Breaking the Barriers'

7th - 8th August, 2021, Jhansi (U.P.)

Organized by : Bundelkhand Neurology Foundation and MLB Medical College Jhansi



Dr. Pawan Kumar Verma

2nd Prize Winner for Presenting a Award Paper

"Topic: Deep Brain Stimulation (DBS) for Parkinson's Disease: Protocol, Case Selection, and Our Initial Experience"

in the UP-UK NEUROCON 2021 from 7th to 8th August, 2021

Stories Bahari Dri


B4"

Or Rojech Verma


Aried Kankane


Dr Arvind Kankane

Sapon



Balon





braken

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS,Lucknow



# WFNS YOUNG NEUROSURGEON AWARD

XVII WFNS World Congress in Bogota, Colombia, March 2022 This is to certify that the scientific work presented at the

"Quantitative Assessment of Brainstem Distortion in Vestibular Schwannoma and Its Implication in Occurrence of Hydrocephalus."

## By Ashutosh Kumar

Santov Beran Jaresh Sardhara, Prabhaker Mishra, Vivek Singh, Vandan Raiyani, Kamlesh Singh Bhaisora, Arun Kumar Srivastava

Has been recognized as one of the best five contributions from the Young Neurosurgeons.


Nelson M. Oyesiku

President, WFNS

Neurosurgeons Award Committee Chairman, WFNS Young Paulo Pereira

> March 13 18, 2022 Rogota, Colombia

Conference: 8th to 10th April 2022 Workshops: 6" & 7" April 2022



Jerthing of Participation

This is to certify that

lies participated as a Faculty in

CHITICARE 2022 Conference held on 8" to 10". April 2022

Gujarat Medical Council has granted Nine Credit Points



Dr Deepok Govif Organizing Chairman

Dr Dhruve Chaudhry

Dr Rajesh Chandra Mishra Chorman Scientific Committee

Harry Colomby March

Dr Arindam I

### INDIA NON JUDICIAL

### Government of National Capital Territory of Delhi

### e-Stamp

Certificate No.

IN-DL38375245953045U

Certificate Issued Date

27-May-2022 03:53 PM

Account Reference

IMPACC (IV)/ di988103/ DELHI/ DL-DLH

Unique Doc. Reference

SUBIN-DLDL98810361924436253681U

Purchased by

JSS MEDICAL RESEARCH ASIA PACIFIC PVT LTD

Description of Document

Article 5 General Agreement

Property Description

Not Applicable

Consideration Price (Rs.)

(Zero)

First Party

JSS MEDICAL RESEARCH ASIA PACIFIC PVT LTD

Second Party

Not Applicable

Stamp Duty Paid By

JSS MEDICAL RESEARCH ASIA PACIFIC PVT LTD

Stamp Duty Amount(Rs.)

(One Hundred only)



Please write or type below this line

### CLINICAL REGISTRY AGREEMENT

This Tri-Partite Agreement ("the Agreement") is made on this 26th Day of Jul, 2022 ("Effective Date") at New Delhi.

Protocol Title: SHOCK/TL/R-2021-01: A Prospective, Observational, Single Arm, Multicenter Registry to evaluate clinical outcomes of the Shockwave Coronary Intravascular Lithotripsy (IVL) followed by stent implantation in Calcified Coronary Arteries in Real World Indian Patient Population.

Statutory Alert:

The authenticity of this Stamp certificate should be underlying the design come of using e-Stamp Mobile App of Stock Holding Grant Design Come of Stock Hold

The onus of checking the legitimacy is on the user of the bertiff

3. In case of any discrepancy please inform the Competent Authority

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

PACIFIC PUT LTD JSS MEDICAL RESEARCH ASIA PACIFIC PUT LTD JSS MEDICAL RESEARCH ASIA PACIFIC PUT LTD JSS MEDICAL RESEARCH ASIA PACIFIC I

PVT UTD JSS MEDICAL RESEARCH ASIA PACIF



### BY AND BETWEEN

Translumina Therapeutics LLP, having its Registered Office at, Ground Floor, Metro Tower, Local Shopping Complex, MOR Land, New Rajinder Nagar, New Delhi – 110060, India, Phone: 91-11-2874 (hereinafter referred to as "Sponsor") have delegated the above mentioned registry to CRO viz. JSS Medical Research Asia Pacific Pvt. Ltd.

Sponsor has contracted JSS Medical Research Asia Pacific Private Limited, having its registered office at corporate Head Office at Tower 2,1st South wing Floor, L & T Business Park, 6th Floor, Vatika Mindscapes, (Tower B), Plot 12/4, Sector 27D, Delhi Mathura Road, Near Saraj Khwaja Metro Station, Faridabad-121003, as CRO (Hereinafter referred to as "CRO") to coordinate and/or perform activities on behalf of the Sponsor, required for the conduct of the Registry and for the purposes of this Agreement of the FirstPart

### AND

Sanjay Gandhi Post Gradute Institute of Medical Sciences, New PMSSY Rd, Raibareli Rd, Lucknow, Uttar Pradesh 226014 (hereinafter referred to as "Institution or site"), which expression shall, unless repugnant to the context or meaning thereof shall be deemed to mean and include its affiliates and permitted assigns), of the Second Part

### AND

<u>Dr. Aditya Kapoor, DM (Cardiology)</u> working as a Professor & Head (Cardiology) at <u>Sanjay Gandhi</u>
Post Gradute Institute of Medical Sciences, New PMSSY Rd, Raibareli Rd, Lucknow, Uttar Pradesh
226014 (hereinafter referred to as "<u>Site Investigator"</u>) which expression shall, unless repugnant to
context or meaning thereof shall be deemed to mean and include its successors and assigns of the
Third Part

The CRO, Institution and Site Investigator are henceforth referred to individually as and collectively as "Parties".

AND WHEREAS, the Institution represents and warrants that it is equipped to undertake the Registry along with the Purpose as envisaged in this Agreement and accordingly has the requisite experience and expertise for the above said.

Now, therefore, in consideration of the premises and the mutual promises and covenants expressed herein, Sponsor represented through its Lead Principal Investigator and/or CRO, the Site and/or the Site Investigator, hereby agrees to conduct the Registry on the following terms and conditions.

### 1. RULES FOR INTERPRETING THIS AGREEMENT

Headings are for convenience only, and do not affect interpretation. The following rules also apply in interpreting this Agreement, except where the context makes it clear that a rule is not intended to apply.

(a) reference to any statute, regulation, proclamation, ordinance, by-law, or guideline includes all statutes, regulations, proclamations, ordinances, by-laws or guidelines varying, consolidating or replacing them and a reference to a statute includes all regulations, proclamations, ordinances, by-laws or guidelines issued under that statute.

(b) Words importing the singular include the plural and vice versa and reference to one gender

includes all genders.

IN WITNESS WHEREOF the parties hereto have accepted and executed this Agreement as of the day and year first set above. This Agreement has been executed in Triplicate; each party having received one original.

### ACCEPTED AND AGREED:

SITE INVESTIGATOR:

Name: Dr. Aditya Kapoor

Title: Professor & Head

Date: 3 Aug 2012

INSTITUTION:

Name:

Prof. R.K. DHIMAN

Director

Sanjay Gandhi Post Graduate

Title: -

Institute of Medical Sciences LUCKNOW-226 014, INDIA Date: 01. 09.2022

CRO

Name: Mr. Kishor Kumar

Title: Chief Financial Officer

Faridabad Political Control of the C

Date: 26th' July'2022







**3** 2021 **3** 

BH 103139



NOVARTIS HEALTHCARE PRIVATE LIMITED (First Part)

AND

gr. Sanjeev (Second Part)

AND

Sanjay Gandhi Post Graduate Institute of Medical Sciences (Third Part)

V. Mingintally

Sapon



### CLINICAL TRIAL AGREEMENT

This Clinical Trial Agreement ("Agreement") is entered into as of [	the provisions of
AND	

### AND

Sanjay Gandhi Post Graduate Institute of Medical Sciences, located at Lucknow ("Institution") registered under state legislature Act, 1983 and having its address at Raebareli road, Lucknow 226014 which expression shall mean and include its successors and assigns of the SECOND PART;

### AND

Dr. Sanjeev, assistant professor, Department of Haematology as clinical practitioner in the field of Haematology acting in the role of principal investigator ("Principal Investigator") which expression shall mean and include his/her heirs, executors, administrators and assigns of the THIRD PART;

Novartis, Institution and Principal Investigator are hereinafter individually referred to as the "Party" and jointly as the "Parties". For the purposes of this Agreement, "Affiliate(s)" shall mean any entity which directly or indirectly controls, is controlled by or is under common control of Novartis.

### RECITALS:

WHEREAS, Novartis is to perform a clinical trial (hereinafter the "Trial) to evaluate the following drug: Crizanlizumab, SEG101 (hereafter the "Trial Drug") in accordance with a protocol entitled "An Indian Multi-centric Phase IV study to assess the safety of Crizanlizumab with or without hydroxyurea therapy in sickle cell disease patients with vaso-occlusive crises', Protocol No-CSEG101A2403" and its potential subsequent amendments (hereinafter collectively the "Protocol").

WHEREAS, the Institution and the Principal Investigator having each reviewed the Protocol for the Trial and sufficient information regarding the Trial Drug to evaluate their interest in participating in the Trial, wish to conduct in the Trial and assure that they have sufficient authority, competence and experience in clinical trials, along with the necessary infrastructure and technical means to perform the

WHEREAS the Principal Investigator is an employee of the Institution,

The Institution and Principal Investigator shall carry out the Trial in accord

WHEREAS, the Parties wish to set forth certain legal and commercial terms and conditions under /hich the Trial shall be conducted;

NOW THEREFORE, the Parties, in consideration of the above and the mutual promises set forth elow, agree as follows:

CONFORMANCE WITH LAW AND ACCEPTED PRACTICE

Lt Col Varun Bajpai VSM

**Executive Registrar** SGPGIMS, Lucknow



NESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed their duly authorised representatives.

NOVARTIS HEALTHCARE Pvt Ltd.	Sanjay Gandhi Post Graduate Institute of Medical Sciences	
By: Mingarothy	Maran	
Name:	By:	
Murugananthan K.	Name:	
Country Monitoring Head	Title:	
Date:	Date: "\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
O .	o/c	
	Sarricas	
	PRINCIPAL INVESTIGATOR OF SANJEEV	
	Associate Professor Department of Hematology S.C.P.C.I.M.S., Eucknow U.P226014	
	Name: Dr. Sanjeev	
	Title: Principal Investigator	
2	Date: 17/02/2022	

braken





### INDIA NON JUDICIAL





### **Government of National Capital Territory of Delhi**

### 

### Certificate No.

Certificate Issued Date

Account Reference

Unique Doc. Reference

Purchased by

Description of Document

**Property Description** 

Consideration Price (Rs.)

First Party

Second Party

Stamp Duty Paid By

Stamp Duty Amount(Rs.)

IN-DL05054049809906U

16-Mar-2022 01:32 PM

IMPACC (IV)/d/700603/ DELHI/ DL-DLH

UBIN-DLDL70060398783511234109U

TMEDIPHODUCTS

T/MEDIPRODUCTS PVT LTD

DIRECTOR SANJAY GANDHI POST GRADUATE INSTITUTE OF MEDICAL SCIENCES AND PROF GYAN CHAND SGPGIMS

T MEDIPBODUCTS PVT LTD

(One Hundred only)

सत्यमेव जयते





Please write or type below this line IN-DL05054049809906U

This non-judicial stamp paper forms an integral part of clinical trial agreement (CTA) executed between Datt Mediproducts Pvt. Ltd., Director (SGPGIMS) & Prof. Gyan Chand, Dept. of Endocrine Surgery, SGPGIMS Lucknow

(Principal Investigator)

(Institute/Hospital)

Clinical Trial Agreement

Siddharthland

Statutory Alert:

1. The authenticity of this Stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App of Stock Holding Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.

2. The onus of checking the legitimacy is on the users of the certificate.

3. In case of any discrepancy please inform the Competent Authority.





This Clinical Trial Agreement ("Agreement" is made between DATT MEDIPRODUCTS PRIVATE LIMITED, (hereinafter referred to as "SPONSOR") a company incorporated under the COMPANIES ACT 1956, having registered office at Gajraj Chambers, 2B, second floor, 86 B/2, Topsia Road (South), Kolkata 700046 and corporate office at 56, Community Center, East of Kailash, New Delhi – 110065, on the First Party.

### AND

Director, SGPGIMS (hereinafter referred to as "Investigation Site"), which is located at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raibareli Road, Lucknow- 226014, Uttar Pradesh, India., on the Second Party.

AND

Prof. Gyan Chand, whose designation is "Professor" at Department of Endocrine Surgery, Sanjay Gandhi Post Graduate Institute of Medical Sciences, (herein after referred to as "Principal Investigator" (PI), which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include his/her heirs, executers, administrators and successors) of the Third Party;

Sponsor, Principal Investigator (PI) and Institution shall individually be referred as "Party" and collectively as "Parties".

### **RECITALS:**

### WHEREAS,

- A. SPONSOR, is inter-alia, engaged in the business of manufacturing and marketing of medical device along with research, product development & clinical research,
- B. The INVESTIGATOR is engaged in the treatment of subjects with potential exposure to the indication intended for treatment, at an Institution/hospital;
- C. The INSTITUTION is the facility where the clinical trials and study will be conducted ethically and as per the approved Clinical Investigation Plan/protocol;
- D. SPONSOR is willing to engage the Principal Investigator and Institution to conduct the clinical trial and the study on non-exclusive basis and Institution and Principal INVESTIGATOR are willing to carry out the study on the terms set out in this Agreement.
- E. The purpose of this AGREEMENT is to agree on terms and conditions, as well as procedures, according to which the clinical trials and the study will be conducted, and on the division of duties and responsibilities between the parties conducting the said trials/study.
- F. The SPONSOR is desirous of conducting the study as per IEC approved protocol.

(Principal Investigator)

(Institute/Hospital)

Clinical Trial Agreement

Page 2 of 19
Page 2 of 19
Page 2 of 19
Page 17 1 No. 00





### CLINICAL TRIAL AGREEMENT

Clinical Investigation Plan/Protocol Title:	A randomized, open label, single centre Post Market Surveillance Study to evaluate the efficacy and safety of a new antimicrobial wound dressing (VELVERT) compared to standard dressing (SD) in the treatment of Diabetic foot ulcer.	
Clinical Investigation Plan/Protocol Number:	Protocol No.: DMPL/CIP-02-2020/CT/VV; Version No.: 1.0, Date: 03-Sep-2020	
Date of Agreement:	17-Mar-2022	
SPONSOR		
Name:	Datt Mediproducts Pvt. Ltd.	
Address:	Registered office: Gazraj Chambers, 2B, Second Floor, 86 B/2, Topsia Road (South), Kolkata, 700046. Corporate office: 56, Community Center, East of Kailash, D Block, New Delhi, Delhi 110065.	
PRINCIPAL INVESTIGATOR		
Name:	Prof. Dr. Gyan Chand	
Address:	Department of Endocrine Surgery, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli road, Lucknow,226014, Uttar Pradesh.	
INSTITUTION		
Name:	Prof. R K Dhiman	
Address:	Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raibareli Road, Lucknow- 226014, Uttar Pradesh, India.	

(Principal Investigator)

(Institute/Hospital)

Clinical Trial Agreement

(Sponsor) MED



- 15.5 The invalidity or unenforceability of any provision of this Agreement shall not in any way affect, impair or render unenforceable this Agreement or any other provision contained herein, which shall remain in full force and effect.
- No amendment to this agreement shall be valid unless mutually agreed in writing and executed by the parties.
- 15.7 This Agreement represents the entire engagement between parties and supersedes all prior negotiations, understanding the agreements, written or oral, relating to the subject matter herein.

relating to the subj	ect matter herein.	
In Witness, whereof, the Date.	Parties herby sign and execute th	is Agreement as of Effective
FOR SPONSOR:		
Signature: Siddhe	orth Pandey	
Name: Dr Siddharth Pande	ey	
Title: Vice president & RN	ND Head	
Address: Datt Mediproduc – 110065, India	ets Pvt. Ltd., 56, Community Center	r, East of Kailash, New Delhi
FOR SANJAY GAND SCIENCES: Signature:	HI POST GRADUATE INS	TITUTE OF MEDICAL
Title: Director Sanj	Prof. R.K. DHIMAN Director ay Gandhi Post Graduate rute of Medical Sciences Socreta date has fitute of Medical radesh, India.	مال Sciences, Raibareli Road,
FOR PRINCIPAL INVESTIGATION OF SIGNATURE:  Name: Dr. Gyan Chand  Title: Professor	Dr. Gyan Chan Professo Dept. of Endocrine Surge S.G.P.G.I. M.S., Luckno	or eon
Address: Department of E Medical Sciences,	Indocrine Surgery, Sanjay Gandh	i Post Graduate Institute of
		Sidolhar + h Pandey
(Principal Investigator)	(Institute/Hospital)	(Sponsor) MEDIO
Clinical Trial Agreement		Page 18 of 19



महाराष्ट्र MAHARASHTRA

**①** 2021 **①** 

BG 124182

Novartis Healthcare Private Limited (FIRST PART)



AND

2 9 JUN 2022

कल्खापा

Sanjay Gandhi Post Graduate Institute of Medical Sciences (SECOND PART)

AND

Dr. Jayantee Kalita (THIRD PART)

TILL

V. W

Sont

Sapon



# **CLINICAL TRIAL AGREEMENT**

This Clinical Trial Agreement ("Agreement") is entered into as of [22 Nov 2024] ("Effective Date") between Novartis Healthcare Private Limited, a company incorporated under the provisions of the Companies Act, 1956, and having its registered office at Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra, India (hereinafter referred to as "Novartis" which expression shall unless repugnant to meaning or context mean and include its successors and assigns) of the FIRST PART;

### AND

Sanjay Gandhi Post Graduate Institute of Medical Sciences, located at Uttar Pradesh ("Institution") registered under the provision of the State Legislature Act and having its address at Raebareli road, lucknow-226014, Uttar Pradesh, India which expression shall mean and include its successors and assigns of the SECOND PART;

## AND

*Dr. Jayantee Kalita* as clinical practitioner in the field of *Neurology* acting in the role of principal investigator ("Principal Investigator") which expression shall mean and include his/her heirs, executors, administrators and assigns of the THIRD PART;

Novartis, Institution and Principal Investigator are hereinafter individually referred to as the "Party" and jointly as the "Parties". For the purposes of this Agreement, "Affiliate(s)" shall mean any entity which directly or indirectly controls, is controlled by or is under common control of Novartis.

## **RECITALS:**

WHEREAS, Novartis is to perform a clinical trial (hereinafter the "Trial) to evaluate the following drug LOU064/remibrutinib (hereafter the "Trial Drug") in accordance with a protocol entitled "A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.", CLOU064C12301" and its potential subsequent amendments (hereinafter collectively the "Protocol").

WHEREAS, the Institution and the Principal Investigator having each reviewed the Protocol for the Trial and sufficient information regarding the Trial Drug to evaluate their interest in participating in the Trial, wish to conduct in the Trial and assure that they have sufficient authority, competence and experience in clinical trials, along with the necessary infrastructure and technical means to perform the Trial.

WHEREAS the Principal Investigator is an employee of the Institution,

WHEREAS, the Parties wish to set forth certain legal and commercial terms and conditions under which the Trial shall be conducted:

NOW THEREFORE, the Parties, in consideration of the above and the mutual promises set forth below, agree as follows:

## 1. CONFORMANCE WITH LAW AND ACCEPTED PRACTICE

The Institution and Principal Investigator shall carry out the Trial in accordance with:

- (a) the Protocol;
- (b) Good Clinical Practice (GCP) including the International Conference for Harmonization (ICH) GCP;
- (c) the Declaration of Helsinki of the World Medical Association, "Ethical Principles for Medical Research Involving Human Subjects";

Sapon



IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorised representatives.

Novartis HEALTHCARE Pvt Ltd.  By: Mame: Murugananthan K.  Country Monitoring Head  Title: Date: 22 Nov 2022	Sanjay Gandhi Post Graduate Institute of Medical Science  By:  Name: Prof R.K Diman Prof. R.K. DHIMAN Director  Title: Director Sanjay Gandhi Post Graduate Institute of Medical Sciences LUCKNOW-226 014, INDIA
ii E	PRINCIPAL INVESTIGATOR  By:
	Name: Dr. Jayantee Kalita  Title: Professor

Balon

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS,Lucknow



# INDIA NON JUDICIAL

# Government of Uttar Pradesh

Certificate No.

Certificate Issued Date

Account Reference

Unique Doc. Reference

Purchased by

Description of Document,

Property Description.

Consideration Price (Rs!)

First Party

Second Party

Stamp Duty Paid By

Stamp Duty Amount(Rs.)

IN-UP01247166819988V

14-Dec-2023 04:40 PM

NEWIMPACC (SV)/ up14733204/ LUCKNOW SADAR/ UP-LKN

SUBIN-UPUP1473320498270532973189V - ..

ANSHIKA SRIVASTAVA

Article 5 Agreement or Memorandum of an agreement

Not Applicable

ANSHIKA SRIVASTA

Not Applicable

ANSHIKA SRIVASTAVA

(One Hundred only)





Please write or type below this line

# MEMORANDUM OF AGREEMENT

This MEMORANDUM OF AGREEMENT is made on this Fourteen December day of Two thousand and Twenty Three BY AND BETWEEN President of India, acting through Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, hereinafter referred to as the 'DBT' (which expression' unless excluded by or repugnant to the subject shall mean and include its successor-inoffice and assigns) of the ONE PART;

- AND

Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Lucknow-226014, UP, India, a society under the Societies Registration Act -

The nicky of this Stamp cartificate should be verified at 'www.shcilestamp.com' or using a Stamp Mobile App of Stock Holding Bajpai VSM, company in the details on this Cartificate and as available on the website / Mobile App renders it invalid.

Executive Registrar SGPGIMS, Lucknow

1860, having its registered office in/at Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Lucknow-226014, UP, India. hereinafter referred to as SGPGIMS (which expression shall where the context so admits include its successors and permitted assigns) of the OTHER PART;

WHEREAS DBT being desirous of Human genetics and cardiomyopathies decided to support a project submitted by Dr. Anshika Srivastava, Assistant Professor, Department of Medical Genetics, SGPGIMS, Lucknow, India for the attainment of the objectives, hereinafter described in the Annexure I annexed hereto:

This Memorandum of Agreement (MoA) defines the role and responsibilities of the participating agencies, monitoring and other matters related to the "Harnessing Genome sequencing and engineering (CRISPR/Cas9) technologies for identification of shared genetic and molecular etiology in pediatric and adult Cardiomyopathies."

# NOW THE PARTIES HERETO AGREE AS FOLLOWS:-

1.0. ROLE OF DEPARTMENT OF BIOTECHNOLOGY, NEW DELHI

To provide funds to the extent of Rs. 86,60,988.00 (Rupees Eighty Six Lakhs Sixty Thousand Nine Hundred and Eighty Eight Only) over a period of Three (03) years from the date of sanction of the project Sanction Letter No.-(BT/PR38372/GET/119/329/2020) dated 06.01.2022, from 06.01.2022 to 05.01.2025 (Dr. Anshika Srivastava, SGPGIMS, Lucknow for undertaking activities as detailed in decreased in the second Annexure 1. Details of the funds to be provided are given in Annexure II.

- 2.0. ROLE OF Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Lucknow-226014, UP, India
- 2.1. To provide their contribution of (NIL) for (duration in years) years from date of sanction of the project as detailed in Annexure - II. (Provide the cost in place of NIL if a jointly supported project).
- 2.2. To provide existing facilities as mentioned in the project document.
- 2.3. To be responsible for accomplishing objectives identified and activities listed:
- 2.4. To allow the Scientists authorized by DBT to work with the Research & Development team of the center in all stages of process development and production.
- 2.5. To recruit all scientific and non-scientific staff as sanctioned by DBT.
- 2.6. To prepare and submit all periodical reports and other documents that would be required by DBT.
- 2.7. To maintain a separate audit head of account for the grants received from DBT for the project.

To submit an annual audited statement of expenditure incurred under the project.

To ensure effective utilization of the grant given by DBT for the grant given given grant given by DBT for the grant given given given grant given given

- 2.10. The manpower, both scientific and non-scientific, recruited shall be purely on contractual terms & conditions such that the contract for engagement of the manpower shall run concurrently with the said project period only.
- 3.0 DURATION OF PROJECT
- 3.1 Duration of project shall be Three (03) years from the date the Project has been sanctioned by DBT.
- 4.0 RIGHTS OF OWNERSHIP/TECHNOLOGY TRANSFER AND UTILIZATION
- 4.1 The know-how generated from the project by SGPGIMS, Lucknow will be the joint property of SGPGIMS, Lucknow and DBT, Government of India. It shall be the responsibility of Sanjay Gandhi Postgraduate Institute of Medical Sciences(SGPGIMS), Raebareli Road, Lucknow-226014, UP, India to take necessary action for protection of the intellectual property arising out of the PROJECT through proper instruments, such as, patents, copy rights, etc.
- 4.2 The know-how developed may be transferred to other entrepreneurs on a non-exclusive basis on such terms and conditions as may be determined by DBT.
- 4.3 All the assets including the equipment and produce acquired will be the property of DBT and shall not be utilized for purposes other than those for which the grant has been sanctioned. The rights of SGPGIMS, Lucknow under this MoA shall not be transferred to any other party without prior approval in writing of DBT.
- 4.4 It shall be the responsibility of the project investigator (s) and SGPGIMS,

  Lucknow to ensure that support of DBT is suitably acknowledged in the in

  scientific publication/ patents/ technology transfer documents etc. arising out of
  the PROJECT. It shall also be the responsibility of the project investigators and
  institute to ensure the inclusion of reference/ grant number and duration of the
  financial support while making the acknowledgement of the financial support
  received from DBT.

Dr. Anshika Srivastava
Assistant Professor

Dept. of Medical Genetics Sanjay Gandhi Post Graduate Institute of Medical Sciences, LUCKNOW-226014, INDIA

Bayen

# 5. SECRECY

It is hereby agreed that the participating agencies shall keep information and data collected completely secret provided that the right to transfer the technology shall rest with the DBT.

# 6. MONITORING

- 6.1 The progress of implementation of the project and proper utilization of grant shall be reviewed by the DBT and by the Monitoring Committee set up by DBT.
- 6.2 The periodic progress of physical achievements and the utilization of funds, statement of expenditure shall be evaluated by the Monitoring Committee.
- 6.3 The Comptroller and Auditor General of India, at his discretion shall have the right of access to the books and accounts of SGPGIMS, Lucknow for the grants received from DBT for this project.
- 6.4 The DBT may terminate the grant at any stage if it is convinced that the grant has not been properly utilized or appropriate progress has not been made. In the event, DBT terminates the grant, SGPGIMS, Lucknow shall hand over all documents including technical details and equipment purchased related to the project.

# 7.0 DURATION OF MEMORANDUM OF AGREEMENT

This MoA will remain inforce for the duration of the project and until all claims are settled between DBT and SGPGIMS, Lucknow.

# 8.0 ARBITRATION

In the event of any question, dispute or difference whatsoever arising between the parties to this Agreement out of or relating to the construction, meaning, scope, operation or effect of this Agreement or the validity of the breach thereof shall be referred to an Arbitrator to be appointed by mutual consent of both the parties herein. If the parties cannot agree on the appointment of the Arbitrator within a period of one month from the notification by one party to the other of existence of such dispute, then the Arbitrator shall be nominated by the Secretary, Department of Legal Affairs, Ministry of Law & Justice, Government of India. The provisions of the Arbitration and Conciliation Act, 1996 will be applicable and the award made there under shall be final and binding upon the parties hereto, subject to legal remedies available under the law. Such differences shall be deemed to be a submission to arbitration under the Indian Arbitration and Conciliation Act, 1996, or of any modifications or reenactments thereof.

Anastrilia



### 9.0. **GOVERNING LAW**

This Contract shall be governed by the Law of India for the time being in force.

IN WITNESS WHEREOF the parties hereto have signed, sealed and delivered this Agreement on the day, month and year first above written in presence of:

	Signed by
	(Designation) For and on behalf of The President of India
Signatures of two witnesses (from DBT):	

i.

ii.

Prof. R.K. DHIMAN Director Sanjay Gandhi Post Graduate Signed and stamped by: Institute of Medical Sciences (Director, SGPGIMS, LuckHangW-226 014, INDIA

For and on behalf of SGPGIMS, Lucknow

Name, Signature and stamp of Two Witnesses (from Institute/ University/

Organization)):

i.

Lepti Saxena Dr. Deepti Saxena

Associate Professor

Associate Professor

Dept. of Medical Genetic Dept. of Medical Genetics

Dr. Somya Srivasta ii. Department of Medical Genetics Sanjay Candhi Post Graduate Medical Sciences II ATTERED I MEDICAL DELETICES INDIA

Lt Col Varun Bajpai VSM **Executive Registrar** SGPGIMS, Lucknow

(28

# सारतीय गर न्यायिक एक सो रुपये Rs. 100 NE ONE HUNDRED RUPEES

COLOR TO THE TINDIA SOLOR TO THE TOTAL TOT

उत्तर प्रैंदेश UTTAR PRADESH

FY 346730

2.2 MAR

# MEMORANDUM OF AGREEMENT

This MEMORANDUM OF AGREEMENT is made on this 11 of January of Two Thousand Twenty One and Director, SGPGIMS Lucknow BY AND BETWEEN President of India, acting through Director, Department of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, hereinafter referred to as the 'DBT' (which expression unless excluded by or repugnant to the subject shall mean and include its successor-in-office and assigns) of the ONE PART;

## AND

Sanjay Gandhi Postgraduate of Institute of Medical Science, Lucknow (SGPGI, hereafter), a society under the Societies Registration Act – 1860, having its registered office in/at <u>Lucknow</u>, hereinafter referred to as <u>SGPGIMS</u> (which expression shall where the context so admits include its successors and permitted assigns) of the OTHER PART;

WHEREAS DBT being desirous of <u>Basic Science Research</u> decided to support a project submitted by <u>Dr. Alok Kumar</u>, <u>Associate Professor</u>, <u>Department of</u>

Von

de la



Molecular Medicine & Biotechnology and Dr. Shantanu Pande, Department of Cardiovascular and Thoracic Surgery, SGPGIMS, Lucknow for the attainment of the objectives, hereinafter described in the Annexure I annexed hereto;

This Memorandum of Agreement (MoA) defines the role and responsibilities of the participating agencies, monitoring and other matters related to the "Determination and establishment of key molecular therapeutic approach for remodelling of pericardial heart valve of Tetralogy of Fallot"

# NOW THE PARTIES HERETO AGREE AS FOLLOWS:-

# 1.0. ROLE OF DEPARTMENT OF BIOTECHNOLOGY, NEW DELHI

To provide funds to the extent of Rs.66,50,240/- (Rupees Sixty Six Lakhs Fifty Thousand Two Hundred and Forty Only) over a period of Three years from the date of sanction of the project, to Dr. Alok Kumar, Associate Professor, Department of Molecular Medicine & Biotechnology and Dr. Shantanu Pande, Department of Cardiovascular and Thoracic Surgery, SGPGIMS, Lucknow for undertaking activities as detailed in Annexure 1. Details of the funds to be provided are given in Annexure II.

# 2.0. ROLE OF SANJAY GANDHI POSTGRADUATE OF INSTITUTE OF MEDICAL SCIENCE, LUCKNOW (Institute)

- 2.1. To provide their contribution of <u>nil</u> for <u>3</u> years from date of sanction of the project as detailed in Annexure II. (if a jointly supported project)
- 2.2. To provide existing facilities as mentioned in the project document.
- 2.3. To be responsible for accomplishing objectives identified and activities listed.
- 2.4. To allow the Scientists authorized by DBT to work with the Research & Development team of the center in all stages of process development and production.
- 2.5. To recruit all scientific and non-scientific staff as sanctioned by DBT.
- 2.6. To prepare and submit all periodical reports and other documents that would be required by DBT.
- 2.7. To maintain a separate audit head of account for the grants received from DBT for the project.

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

Nh



- 2.8. To submit an annual audited statement of expenditure incurred under the project.
- 2.9. To ensure effective utilization of the grant given by DBT for the purpose for which it was granted and to ensure timely progress of project work.
- 2.10. The manpower, both scientific and non-scientific, recruited shall be purely on contractual terms & conditions such that the contract for engagement of the manpower shall run concurrently with the said project period only.

# 3.0 DURATION OF PROJECT

3.1 Duration of project shall be 3 years from the date the Project has been sanctioned by DBT.

# 4.0 RIGHTS OF OWNERSHIP/TECHNOLOGY TRANSFER AND UTILIZATION

- 4.1 The know-how generated from the project by <u>SGPGIMS</u> will be the joint property of <u>SGPGIMS</u> and DBT, Government of India. It shall be the responsibility of <u>SGPGIMS</u> to take necessary action for protection of the intellectual property arising out of the PROJECT through proper instruments, such as, patents, copy rights, etc.
- 4.2 The know-how developed may be transferred to other entrepreneurs on a non-exclusive basis on such terms and conditions as may be determined by DBT.
- 4.3 All the assets including the equipment and produce acquired will be the property of DBT and shall not be utilized for purposes other than those for which the grant has been sanctioned. The rights of <u>SGPGIMS</u> under this MoA shall not be transferred to any other party without prior approval in writing of DBT.
- 4.4 It shall be the responsibility of <u>SGPGIMS</u> to ensure that support of DBT is suitably acknowledged in the publications (papers, reports, etc.) arising out of the PROJECT.

1

Sapon



# 5. SECRECY

It is hereby agreed that the participating agencies shall keep information and data collected completely secret provided that the right to transfer the technology shall rest with the DBT.

# 6. MONITORING

- 6.1 The progress of implementation of the project and proper utilization of grant shall be reviewed by the DBT and by the Monitoring Committee set up by DBT.
- 6.2 The periodic progress of physical achievements and the utilization of funds, statement of expenditure shall be evaluated by the Monitoring Committee.
- 6.3 The Comptroller and Auditor General of India, at his discretion shall have the right of access to the books and accounts of this research project at SGPGIMS for the grants received from DBT for this project.
- 6.4 The DBT may terminate the grant at any stage if it is convinced that the grant has not been properly utilized or appropriate progress has not been made. In the event, DBT terminates the grant, <u>SGPGIMS</u> shall hand over all documents including technical details and equipment purchased related to the project.

# 7.0 DURATION OF MEMORANDUM OF AGREEMENT

This MoA will remain in force for the duration of the project and until all claims are settled between DBT and <u>SGPGIMS</u>.

# 8.0 ARBITRATION

In the event of any question, dispute or difference whatsoever arising between the parties to this Agreement out of or relating to the construction, meaning, scope, operation or effect of this Agreement or the validity of the breach thereof shall be referred to an Arbitrator to be appointed by mutual consent of both the parties herein. If the parties cannot agree on the appointment of the Arbitrator within a period of one month from the notification by one party to the other of existence of such dispute, then the Arbitrator shall be nominated by the Secretary, Department of Legal Affairs, Ministry of Law & Justice, Government of India. The provisions of the Arbitration and Conciliation Act, 1996 will be applicable and the award made there under shall be final

4

**Y** 

Lt Col Varun Bajpai VSM Executive Registrar



Signed by -

and binding upon the parties hereto, subject to legal remedies available under the law. Such differences shall be deemed to be a submission to arbitration under the Indian Arbitration and Conciliation Act, 1996, or of any modifications or reenactments thereof.

# 9.0. GOVERNING LAW

(Dr. Surendra Kumar Agarwal)

(Dr. Vikas Agarwal)

Witnesses:

This Contract shall be governed by the Law of India for the time being in force.

IN WITNESS WHEREOF the parties hereto have signed, sealed and delivered this Agreement on the day, month and year first above written in presence of:

1. *	(Designation)
2.	For and on behalf of The President of India
Witnesses:	Signed by
1.————————————————————————————————————	(Designation) DIRECTOR
2.————————————————————————————————————	Prof. R. K. DHIMAN Director Sanjay Gandhi Post Graduate Institute of Medical Sciences LUCKNOW-226 014, INDIA



# INDIA NON JUDICIAL Government of Uttar Pradesh

# e-Stamp



Certificate No.

Certificate Issued Date

Account Reference

Unique Doc. Reference

Purchased by

Description of Document

Property Description

Consideration Price (Rs.)

First Party

Second Party

Stamp Duty Paid By

Stamp Duty Amount(Rs.)

: IN-UP48166778929699T

31-Aug-2021 11:26 AM

NEWIMPACC (SV)/ up14267604/ LUCKNOW SADAR/ UP-LKN

SUBIN-UPUP1426760485102997461551T

SGPGIMS LUCKNOW

Article 5 Agreement or Memorandum of an agreement

Not Applicable

:

SGPGIMS LUCKNOW

DBT NEW DELHI

SGPGIMS LUCKNOW

100

(One Hundred only)



-Please write or type below this line-----

# MEMORANDUM OF AGREEMENT

This MEMORANDUM OF AGREEMENT is made on this \_\_\_\_\_\_ day of Two thousand and Nineteen BY AND BETWEEN President of India, acting through \_\_\_\_\_ Department of Biotechnology. Ministry of Science and Technology, Government of India, New Delhi, hereinafter referred to as the 'DBT' (which expression unless excluded by or repugnant to the subject shall mean and include its successor-in-office and assigns) of the ONE PART;

AND

Lt Col Varun Bajpai VSM

Janjay Gandhi postgraduate Institute of Medical Sciences, Raiberali Road, Lucknow. UP Act No 30 of 1983(2906(2)/XVII---I-1(Ka)-29-82) dated Oct 13, 1983 having its registered office at Lucknow hereinafter referred to as 'SGPGIMS' (which expression shall where the context so admits include its successors and permitted assigns) of the OTHER PART;

WHEREAS DBT being desirous of (Centres of Excellence (COE) on Translational Research on Bio-inspired Nanomaterials and Drugs from endophytes), decided to support a project submitted by *Dr Sanjay Gambhir* (*Project Co-Investigator*) and *Dr Manish Dixit* (*Project Co-Investigator*) for the attainment of the objectives, hereinafter described in the Annexure I annexed hereto:

This Memorandum of Agreement (MoA) defines the role and responsibilities of the participating agencies, monitoring and other matters related to the "Centres of Excellence (COE) on Translational Research on Bio-inspired Nanomaterials and Drugs from endophytes (sanction Order No. 102/IFD/SAN/295/2018-19)".

# NOW THE PARTIES HERE TO AGREE AS FOLLOWS:

# 1.0 ROLE OF DEPARTMENT OF BIOTECHNOLOGY, NEW DELHI

To provide funds to the extent of 43,75,000.00 (Forty Three Lakh seventy five Thousand rupees only) over a period of five years from the date of sanction of the project, to SGPGIMS for undertaking activities as detailed in Annexure-I. Details of the funds to be provided are given in Annexure-II.

# 2.0 ROLE OF Sanjay Gandhi postgraduate Institute of Medical Sciences, Raiberali Road, Lucknow.

- 2.1\* To provide their contribution of NIL for 05 years from date of sanction of the project as detailed in Annexure II. (if a jointly supported Project).
- 2.2 To provide existing facilities as mentioned in the project document.
- 2.3 To be responsible for accomplishing objectives identified and activities listed.
- 2.4 To allow the Scientists authorized by DBT to work with the Research & Development team of the center in all stages of process development and production.
- 2.5 To recruit all scientific and non-scientific staff as sanctioned by DBT.
- 2.6 To prepare and submit all periodical reports and other documents that would be required by DBT.

report of the work done by him on the project and the money spent till the date of his/her release and shall also arrange to refund the unspent balance, if any.

The organization should maintain subsidiary accounts of the Govt. of India grant and furnish it 22. to the Audit Officer as and when the recurring and non-recurring expenditure exceeds the limits of Rs. 5.00 lakhs.

Signature of Co-Investigator

Date:

Signature of Executive Authority of Institute/ University with seal

Sanjay Gandhi Posi Graduale Institute of Medical Sciences LUCKNOW-226 014, INC/A

Date:



# INDIA NON JUDICIAL

# **Government of Uttar Pradesh**



# e-Stamp

Certificate No.

IN-UP67093582423558U

Certificate Issued Date

16-Apr-2022 01:58 PM

Account Reference

NEWIMPACC (SV)/ up14238304/ MOHANLALGANJ/ UP-LKN

Unique Doc. Reference

SUBIN-UPUP1423830425406120737386U

Purchased by

DR AMITA MOIRANGTHEM

Description of Document

Article 5 Agreement or Memorandum of an agreement

Property Description

Not Applicable

Consideration Price (Rs.)

First Party

DR AMITA MOIRANGTHEM

Second Party

Not Applicable

Stamp Duty Paid By

DR AMITA MOIRANGTHEM

Stamp Duty Amount(Rs.)

(One Hundred only)





Please write or type below this line



Worth & Verific MEMORANDUM OF AGREEMENT is made on this 30<sup>th</sup> March day of Two thousand and twenty two BY AND BETWEEN President of India The Whousand and twenty two BY AND BETWEEN President of India, acting through

Biotechnology, Ministry of Science and Technology, Government of India, New

Delhi, hereinafter referred to as the 'DBT' (which expression unless excluded by

repugnant to the subject shall mean and include its successor-in-office and assigns) of the ONE PART;

# AND

Sanjay Gandhi Postgraduate Institute of Medical Sciences, a society under the Societies Registration Act – 1860, having its registered office in/at Raebareli Road, Lucknow, Pin 226014, Uttar Pradesh, hereinafter referred to as SGPGIMS (which expression shall where the context so admits include its successors and permitted assigns) of the OTHER PART;

WHEREAS DBT being desirous of <u>Clinical research Project</u> decided to support a project submitted by <u>Dr Amita Moirangthem</u>, <u>Sanjay Gandhi Postgraduate Institute of Medical Sciences</u>, <u>Lucknow</u> for the attainment of the objectives, hereinafter described in the Annexure I annexed hereto;

This Memorandum of Agreement (MoA) defines the role and responsibilities of the participating agencies, monitoring and other matters related to the Mission Project on Pediatric Rare Genetic Disorders.

# NOW THE PARTIES HERETO AGREE AS FOLLOWS:-

1.0. ROLE OF DEPARTMENT OF BIO	<b>TECHNOLO</b>	GY, NEW DELHI
To provide funds to the extent of		
five years from the date of sanction of	the project, to	Dr Amita Moirangthem,
SGPGIMS for undertaking activities as of		
to be provided are given in Annexure II.		



ROLE OF SGPGIMS..... (Institute/NGO)

To provide their contribution of \_\_\_\_\_(NIL) \_\_\_\_ for five years from date of sanction of the project as detailed in Annexure – II. (provide the cost in place of NIL if a jointly supported project).

To provide existing facilities as mentioned in the project document.

- 2.3. To be responsible for accomplishing objectives identified and activities listed.
- 2.4. To allow the Scientists authorized by DBT to work with the Research & Development team of the center in all stages of process development and production.
- 2.5. To recruit all scientific and non-scientific staff as sanctioned by DBT.
- 2.6. To prepare and submit all periodical reports and other documents that would be required by DBT.
- 2.7. To maintain a separate audit head of account for the grants received from DB' for the project.

- 18. The human resources that may be engaged for the project by the Institute are not to be treated as employees of the Govt. of India and the deployment of such human resource at the time of completion or termination of project, will not be the concern/responsibility of the Govt. of India. The Organisation may make reservations for Scheduled Castes, Schedule Tribes etc. in the human resource to be engaged for the project in accordance with the instruction issued by the Govt. of India from time to time.
- 19. The Deptt. of Biotechnology reserves the right to terminate the grant at any stage and also to recover the amounts already paid if it is convinced that the grant has not been properly utilized or the work on the project has been suspended for any unduly long period or appropriate progress is not being made.
- 20. The project will become operative with effect from the date of release of the first installment for the project.
- 21. If the Investigator to whom a grant for a project has been sanctioned leaves the institution where the project is being implemented, he shall submit five copies of complete and detailed report of the work done by him on the project and the money spent till the date of his/her release and shall also arrange to refund the unspent balance, if any.
- 22. The Memorandum Agreement, to be sent to Department of Biotechnology should be on Non-Judicial stamp paper of Rs. 100/-.
- 23. The organisation should maintain subsidiary accounts of the Goyt, of India grant and furnish it to the Audit Officer as and when the recurring and nonrecurring expenditure exceeds the limits of Rs. 5.00 lakhs.

& it ary

fature of Executive Authority of Institute/ University

Date:

Signature and seal of Project Coordinator (If applicable)

Date:

Signature and seal of all Principal Investigator(s)/ Co-PI(s):

ADVOCATE & NOTARY

Tahsii Mohanlakan, Lucknow

Department of Medical Genet Sanjay Gandhi Post Grac 3 Institute of Medical Scien

Signature and seal of all Co-Investigator (s)

Date:

arun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

Gandhi Post Graduate

identified the deponent/execusing surety the has Signed/put T.L before me,



महाराष्ट्र MAHARASHTRA

**3** 2022 **3** 

= 2 IIIN 2022

- 2 JUN 2022

07AA 701210



CLINICAL TRIAL AGREEMENT ("Agreement")

between

Covance India Pharmaceutical Services Pvt. Ltd., Building No. 1, Unit No. 601, Raheja Mindspace, Plot Nos. Gen/2/1/D, Gen/2/1/E & Gen2/1/F at MIDC, Trans Thane Creek Industrial

Area, Shiravane, Nerul, Navi Mumbai, Maharashtra 400706, India and its affiliates, including but not limited to Covance Inc., 206 Carnegie Center, Princeton, New Jersey, 08540, USA (hereinafter collectively referred to as "Covance" or "CRO")

and

Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, UP – 226014, India

GST R No: 09AAAJS3913N2ZN "("Institution")

CTA\_BI\_Core Version\_1.3\_12\_Jul\_2019

Page 1 of 42

Duke CRI\_8450449\_India CTA Template updated by Covance version 1, including FA, 27 Nov 2020

Protocol Ref: 1245-0202 BillCode: 8450449 Site No.: IND23

Investigator Name: Dr. Sudeep Kumar

Master Financial Appendix Template: Version 9, 26 Feb 2019
Boehringer Ingelheim/Study Approved Template: Version 1, 27 Nov 2020

Sponsor CONFIDENTIAL

and

Dr. Sudeep Kumar, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, UP – 226014, India ("Investigator")

# RECITALS

WHEREAS, Duke Clinical Research Institute ("Duke") has engaged Covance, in its capacity as a contract research organization as defined in ICH-GCP 1.20 to act as an independent contractor of Duke to coordinate the Trial (as defined below), sponsored by Boehringer Ingelheim, pharmaceutical company with its legal address at "Binger str., 173, 55216 Ingelheim, Germany ("Sponsor") to assist Sponsor in conducting the Trial;

WHEREAS, Sponsor, a research-driven pharmaceutical company, is sponsoring and conducting a clinical trial of Jardiance®, empagliflozin (the "Investigational Product") according to the Clinical Trial Protocol for BI Trial No. 1245-0202 including all documents attached thereto and referenced therein (the "Protocol") entitled "EMPACT-MI: A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction" as amended (the "Trial"), incorporated herein by reference and provided to Institution and/or Investigator by the Sponsor or its designee under separate cover in the regulatory document package; and

WHEREAS, Sponsor and CRO seek to engage the services of Institution and Investigator to carry out the Trial in accordance with the Protocol; and

WHEREAS, Institution operates a facility engaged in research activities and services including the creation, implementation and documentation of clinical research, testing and trials and desires to participate as a site for the conduct of the Trial, as contemplated by this Agreement; and

WHEREAS, Investigator is engaged in medical research on behalf of Institution and desires to participate in and serve as the principal Investigator on behalf of Institution and to conduct clinical investigations as part of the Trial, as contemplated by this Agreement.

NOW, THEREFORE, the Parties hereto agree as follows:

# 1. OBLIGATIONS OF INSTITUTION AND INVESTIGATOR

# 1.1 Conduct of the Trial.

1.1.1 Protocol. Investigator will conduct the Trial at Institution's facility/-ies located at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, UP – 226014, India in accordance with the Protocol.

CTA\_BI\_Core Version\_1.3\_12\_Jul\_2019

Page 2 of 42

Duke CRI\_8450449\_India CTA Template updated by Covance version 1, including FA, 27 Nov 2020



DocuSign Envelope ID: C6CB5FB4-2C4A-4E03-87C8-0727E0D5B094

Protocol Ref: 1245-0202 BillCode: 8450449 Site No.: IND23

Investigator Name: Dr. Sudeep Kumar

DocuSigned by:

Master Financial Appendix Template: Version 9, 26 Feb 2019
Boehringer Ingelheim/Study Approved Template: Version 1, 27 Nov 2020

# Sponsor CONFIDENTIAL

IN WITNESS WHEREOF, the Parties have executed this Agreement in 3 originals by their duly authorized representatives.

Covance India Pharmaceutical Services Pvt. Ltd.

By: Or. Shethar Dawkhar
Name: Dr. Shekhar S Dawkhar
Title: Senior Director 6/21/2022
Date:
INSTITUTION
R.K. DHIMAN
By:    Prof. R.K. DHIMAN
Name: Prof. R.K. Dhiman Gandhi sical Scientific
Title: Director
Date: 11/7/ Institute of 1286
1 1001
INVESTIGATOR:
· Oan
Ву:
Name: Dr. Sudeep Kumar
Date: 27 june 2020
1

CTA\_BI\_Core Version\_1.3\_12\_Jul\_2019

Page 30 of 42

Duke CRI\_8450449\_India CTA Template updated by Covance version 1, including FA, 27 Nov 2020





পশ্চিমবঙ্গ पश्चिम बंगाल WEST BENGAL

AG 794091

# CLINICAL STUDY AGREEMENT

This Clinical Study Agreement ("Agreement") is made as of	(the	"Effective Dat	e") b	<b>v</b> and
amongg				

Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow-226014, hereafter referred to as Institution.

And

.

2. Dr.Ujjala Ghoshal, Professor and HOD, Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow- 226014, India, hereafter referred to as Principal Investigator (PI)

And

Medclin Research Pvt. 1.td. Having its registered office at Acropolis, unit 10/5, 10th floor 1858/1, Rajdanga Main Road, Kol-107, hereafter referred to as Clinical Research Organization (CRO)

Confidential

Page **1** of **13** 

# WHEREAS,

Sponsor (Alkem Laboratories, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400013) based on the representation and warranties given by the CRO, desires to engage CRO on non-exclusive basis to initiate study of "In vitro susceptibility of Ceftriaxone or Ceftriaxone combination with Sulbactam & Tazobactam in community acquired and nosocomial infections against gram-negative and gram -positive bacteria." (Hereinafter referred to as the "Study")

- a. The CRO has approached the Institution and Principal Investigator to perform the study in accordance with the corresponding Protocol, and all applicable rules and regulations. The Institution and PI agree to conduct the study in accordance with the same.
- b. The Institution is equipped to undertake the Study and the Institution, CRO and Principal Investigator have agreed to perform the Study according to the terms and conditions hereinafter set forth.

# 1. REPRESENTATIONS AND WARRANTEES:

- a. Each party represents and warrants to and covenants with the other that:
  - It has been duly incorporated or created and is validly subsisting and in good standing under the applicable laws of its incorporation mentioned elsewhere in this agreement; wherever applicable,
  - ii. It has the corporate power and authority to enter into and perform its obligations under this Agreement, whenever applicable,
- iii. This Agreement has been duly authorized, executed and delivered by it and constitutes a valid and binding obligation enforceable against it in accordance with its terms;
- iv. Neither the execution and delivery of this Agreement by either party, nor the performance by such party of its obligations here under nor compliance by such party with the provisions hereof will violate, adversely effect, contravene or breach or create a default or accelerate any obligation under any indenture, mortgage, lease, agreement, instrument, Memorandum or Articles of Association or charter or by-law provision, statute, regulation, judgment, ordinance, decree, writ, injunction or law applicable to such party;

# b. Institution represents that

- i. It is entitled to procure the services of Principal investigator and shall ensure the performance of the obligations of the Principal Investigator set out in this agreement.
- ii. The Institution shall notify Medclin if the Principal Investigator ceases to be employed by or associated with the Institution and shall use its best endeavors to find a replacement acceptable to both The Sponsor and CRO. In order to ensure high standard of clinical trials, if no mutually acceptable replacement can be found, The CRO may terminate this agreement pursuant to clause 19(c).

# c. Principal Investigator represents:

i. A competent person to sign this agreement on behalf of his sub-investigators and research staff. The terms "Investigator" or "Investigators" as used in this Agreement refers, as applicable, to the Principal Investigator and his sub investigators and research staff and the Institution.

Confidential

	EXHIBIT A	A		
Site Name	Sanjay Gandhi	Sanjay Gandhi Postgraduate Institute of Medical Sciences,		
	Lucknow			
Study Title	combination wi	eptibility of Ceftriax ith Sulbactam & Tazol losocomial infections a tive bacteria	pactam in community gainst gram-negative	
Sponsor	Alkem Laborat	ories Wo	Mily as Description	
Principal Investigator	Dr. Ujjala Ghos	shal		
CRO Name	Medclin Resear	Medclin Research Pvt Ltd, Kolkata		
Total Number of Subjects	60			
=	Unit price	No. Of unit	Total	
Research Grant	1500	60	90000	
CRC fees	500	60	30000	
IOH (25%)			22500	

- a) The Principal Investigator hereby confirms that she has read and understood the clinical trial protocol entitled "In vitro susceptibility of Ceftriaxone or Ceftriaxone combination with Sulbactam & Tazobactam in community acquired and nosocomial infections against gram-negative and gram -positive bacteria"
- b) The investigator agrees to the protocol of this trial and will perform the study in accordance with ICMR Good Clinical Practice, and applicable laws, rules and regulations.
- c) Payment will be processed as per invoice raised by site.

Felt parabel

Page 13 of 13
Lt Col Varun Bajpai VSM
Executive Registrar

SGPGIMS, Lucknow

Confidential



# INDIA NON JUDICIAL

# **Government of Karnataka**

		e-Stamp
	RALIN PAR WE OF RAJIV PARAFE OF RAJIV	PARAKH DR RAJIV PARAKH DR RAJIV PARAKH DR RA
e Se auv	MAKH DE COMPANAKH DR RAJE PARAKE	PARAKH DR RAJIV PARAKH DR RAJIV PAR
	Certificate No. Promity PARAKII OR BE CA	IN-KA97508375867238T
R	Certificate Issued DatePARAKH	07-Apr-2021 12:45 PM ARAKH DR RAJIV PARAKH DR RA
	Account Reference KH DR R. :	NONAGC (FL) kaksfc108/ HALASURIJ/KALBARAKH DR RAJIV PARA
G g	Unique Doc. Reference DF.	SUBIN-KAKAKSEGL0866551773276660TIV PARAKH DR RAJIV PARA
Ž.	es ille manetil into A . Menet	ではずりまつから、100mm (100mm) 100mm
	Purchased by, PARAKH :	BIOQUEST SOLUTIONS PVT LTD. V PARAKH DR RAJIV PARAK
	Description of Document :	Article 12 Bond TAN DR RAJIV PARAKH DR RA
	Description BRAIN:	AGREEMENT PARAKH DR RAJIV PARAKH DR RA
	Consideration Price (Rs.) :	O PARAKH DR RAJIV PARA
	SHELL WILLIAM FILM WESTER OF	(Zero)
	Control of the Contro	2 APARAKH DR RAJIV PARA
	First Party :	DB-RAJIV PARAKH DR RA
	Second Party :	BIOQUEST SOLUTIONS PVT LTD
	Stamp Duty Paid BykH :	BIQUEST SOLUTIONS PVT LTD
: 1	ALTO CATARI OR DAILY P.	OF PANIANDASU OF PA
- 17	Stamp Duty Amount(As.) :	100 EL AND PARA
	·	(One Hundred only).
20	TAKE DR R.	RAJEGIRAKH OBRARI PARA
0.7	THE NE DR RAINV	ARAKH PERRAMANAK EDR RAJA BARAK EDR RAJA BARAK EDR PARA
	* CLASS PARAGES NO.	AJIV PARAKH DR THE CONTROL OF RAJ
Š.	1 FORACH DE RANV PARANT	PARAKH DE KAJIV PARAKH DE KAJIV PARA
nS	THE THE THE THE PARAMETER OF REJIVE	
		DR RAJIV MARAKH DR RAJIV PARALIS DR RAJIV PARAKH DR RAJIV PARAS
10	HARLES TO BE THE STATE OF THE S	PARAKH DR RAJIV PARAKH DR RAJIV PARAKH DR RAJIV SOLUTION OF RAJ
1	AUTO PARAKH DE LA	RAKH DE B 0 5150837586
	AKH AKH DR RAJIÝ	RAJIV PA
	- 'IV PARAKH D	RS. 100
	ASH H OR RAJIV	R RAJIV PA \9
663 50	AJIV CVITA OKO V PARAKH DI A NO RA NO DINAMA	DR RAJIV PARAKH DR RAJIV PARAKH DP TO JIV PARA
5	NAV PREASE DR RAJIV PARAKIT DR RAJIV 2	ARAKH DE RAJIV PARAKH DE RAJIV ETELEN DE DA IN
¥)	AT FE SEL PARKET OR KEINV PARAKH	LINICAL REGISTRY AGREEMENTAKH DE KAJIV PARAKH DE RAJIV PARAK
		And the state of t

THIS AGREEMENT IS MADE ON THE 07 Apr 2021 AT Bangalore.

# BY AND BETWEEN

Dr. Rajiv Parakh, Chairman having his office at Division of Peripheral Vascular & Endovascular Sciences, Medanta- The Medicity, Sec-38, Gurgaon, Haryana - 122001, India (hereinafter referred to as "NATIONAL INVESTIGATOR", which term shall also include his heirs, representatives, successors, permitted assigns) of the One Part;

MS.

Chalman, Division of Periph Vescular à Endovescular Surgieri

✓ Jodania - The Medicity 88, Gurugram Hanyana, India

Statutory Alert: 10 . ( ) The authenticity of this Stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.

Principal Investigator

Head of Institution

Lt Col Varun Bajpai VS of Stock Holding Registrar SGPGIMS, Lucknow

# AND

BIOQUEST SOLUTIONS PRIVATE LIMITED, a company registered under the Companies Act, 1956, having its registered office at #24, wellington street, Richmond town, Bangalore - 560 025 (hereinafter referred to as "BIOQUEST", which term shall also include its successors or permitted assigns) of the Second Part

## AND

Dr. Raghunandan Prasad, Associate Professor, Department of Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, New PMSSY Rd, Raibareli Rd, Lucknow, Uttar Pradesh 226014, India. (hereinafter referred to as the 'Principal Investigator' which expression shall wherever the context so requires mean and include his legal heirs, administrators, executors, representatives, successors and permitted assigns) of the Third Part

# AND

Sanjay Gandhi Postgraduate Institute of Medical Sciences, New PMSSY Rd, Raibareli Rd, Lucknow, Uttar Pradesh 226014, India. (hereinafter referred to as 'Participating Institution' which expression shall wherever the context so requires mean and include its doctors, their respective legal heirs, administrators, executors, representatives, successors and permitted assigns) of the Third Part

National Investigator, BioQuest, Participating Institution and Principal Investigator are referred to individually as a "Party" and collectively as the "Parties".

- 1. The National Investigator has engaged BioQuest for conducting observational registry titled "A Prospective, Multicentric, Non-Interventional, Real-World, Data Collection Registry to Evaluate the Effectiveness, Safety and Durability of SUPERA Stent for the Treatment of De Novo or Restenotic Superficial Femoral Artery or Complex Femoropopliteal Artery Lesions in Indian patients" through its separate agreement dated 13th Feb 2020 between National Investigator and BioQuest.
- 2. The Participating Institution and Principal Investigator have the qualified personnel and the facilities equipped according to Good Clinical Practices (GCP) to undertake the registry (defined herein below);
- 3. NOW THEREFORE, it is agreed as follows between the Parties hereto:
- 1 **DEFINITIONS** In this agreement, unless the context otherwise requires, the following words shall have the meanings ascribed to them in this Clause.
- 1.1 "Agreement" means this Agreement, including its appendix, if any and all amendments and modifications thereto made in accordance with the provisions hereof or which are incorporated herein expressly by reference.
- "Force Majeure" means labour disturbances, riots, war, unexpected weather 1.2 conditions for the time and location of the Services, or any other cause beyond the reasonable control of the affected Party which by exercise of reasonable diligence could not have been prevented or provided against, except financial distress.
- Site/Registry Site means the participating institutions that take part in the registry. 1.3
- In this Agreement, unless the context otherwise requires, the singular includes the 1.4 plural and vice versa, references to persons includes corporations, words importing the

National Investigator

Chabrinan, Muldon of Peripheral Vasculas d Endownersias Surgery Medania - The Madichy mark i drawma i como fo the state of the s

BjoQuest Solution Bangalore Principal Investigator

Head of Institution

- Changes to the Protocol. If at a future date changes in the Protocol appear desirable, such changes may be made through prior written agreement between National Investigator and Participating Institution and the Principal Investigator. If such changes affect the cost of the Registry, PI/ Participating Institution will submit to National Investigator a written estimate for approval. If in the course of performing this Agreement, however, generally accepted standards of clinical research and medical practice relating to the safety of Subjects require a deviation from the Protocol, such standards will be followed. In such case, the Party aware of the need for a deviation will immediately inform the other of the facts causing such deviation as soon as the facts are known to the Party.
- 25 Safety and Reporting. The recording of adverse events (AEs) is an important aspect of the Registry documentation. It is the Principal Investigator's responsibility to document all AEs according to the guidelines of the Protocol.

By signing this Agreement, each Party confirms that it has read this Agreement and agrees to all responsibilities and requirements described by each document.

# 1. National Investigator

Name	Title	Signature	Date
ajiv Parakh N	ational Investigator	Dan	13-082021-011AKH, N
	5		Challanea, Deplemen of Re-

# 2. BioQuest Solutions Pvt. Ltd

Name	Title	Signature	Date
Haumanthy Reddy	Goup Head-BRS	CH Redd	07 (A) 23 die

# 3. Principal Investigator

Name	Title	Signature	Date
Dr. Raghunandan Prasad	Principal Investigator	Pa	

# 4. Participating Institution

Name	Title	Signature	Date

National Investigator

ASSESS A ENGLISHBOARD BURGARY

will be the blockery

BioQuest Solutions

Principal Investigator

Head of Institution

Andreia - The Medialy

Prof. R. KUSHIMAN
Director

Director
Saviay Gandhi Post Graduate
Institute of Medical Sciences
LUCKNOWWAR 6014a1NSIA

Executive Registrar SGPGIMS, Lucknow

# Annexure A: BUDGET AND PAYMENTS SCHEDULE

For each completed patient, PI will receive any amount of Rs. 10000. This amount will be paid as per the schedule detailed below. The fee is inclusive of Institutional overheads, if any.

Set forth milestones will be considered for payment at the submission of an invoices on a quarterly basis to BioQuest and it will be processed after review and approval from National Investigator.

# Milestone payments:

Milestone	Value (inclusive of TDS, if any)	
Upon enrolment of a patient(s)	50%	
Upon Completion of final FU visit	50%	

All payment in the above Milestone Table shall be inclusive of Institutional overheads, if any and any applicable taxes will be deducted as per applicable local tax laws. Whereas GST, 18% will be in additional to the above-mentioned investigator fees.

Any Fee charged by Ethics committee will be paid directly by BioQuest on behalf of National investigator.

<u>Payment Recipient and Mailing Address.</u> All cheque shall be made payable to the entity / person mentioned here.

The mailing address for cheque shall be:

Address:

The further details for the payments should be provided as:

Describbers (American approx	Director, SGPGIMS,	
Payee Name (Account name)	Research Account	
Account Number	10095237491	
Bank Name	State Bank of India	
Branch Name	SGPGIMS, Lucknow	
Branch Code	007789	
IFSC Code	SBIN0007789	
PAN Number*	AAAJS3913N	

The Amount paid under this Agreement shall be subject to statutory deduction of tax at source.

National Investigator

ij samgar, Panden di Pender

for one a companied comme

life bettys. The MacKety

oouest Solution

Principal Investigator

Head of Institution

Director
Sanjay Gandhi Post Graduate
Institute of Medical Sciences
VUCKNOW-226 014, INDIA



उत्तर प्रदेश UTTAR PRADESH

FY 279513.

1 4 JAN 2022

MEMORANDUM OF AGREEMENT - HYPORT ADJUVANT

AND

Dr Sanjoy Chatterjee, Senior Consultant, Tata Medical Center, Kolkata, hereinafter referred to as 'TMC'.

The institution Tata Medical Center, situated at 14,MAR, Rajarhat, New Town, Kolkata-700160, hereinafter referred to as 'TMC'.

This Memorandum of Agreement (MoA) defines the role and responsibilities of the participating agencies, monitoring and other matters related to the HYPORT Clinical Trial

Pemiertet

KOLKATA Z

HE PARTIES HERE TO AGREE AS FOLLOWS: -

ROLE OF TATA MEDICAL CENTER, KOLKATA

To provide funds to the extent of Rs 10,000 per month from St. Morda 7022

Over a period of 2 years or might be less from the date of signature of MOU to SGPGIMS towards clinical trial coordinator fee and others for the HYPORT Adjuvant Clinical Trial. This will be bank transfer in the Institution bank account after TMC receive a request for transfer every 3 months, along with Utilization Certificate of previous 3 months.

Duration of project shall be 2 years from the date the MOU has been sanctioned. The duration of 2. DURATION OF PROJECT project could be increased in case the recruitment has not been completed.

3. ROLE OF SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES,

To utilize the funding received from TMC towards the clinical coordinator fees and others to support the HYPORT Adjuvant Trial and submit the utilization report signed by authorized signatory and Finance Head of the institution.

IN WITNESS WHEREOF the parties here to have signed, sealed and delivered this Agreement on the day, month and year first above written in presence of:

Witnesses:

Signed by Dr Punita Lal, Professor, Radiotherapy Principal Investigator, SGPGIMS, Lucknow

Signed by Dr. RK Dhiman, Gardhi Post Sciences
Director, SGPGIMS Luchold Sciences Director, SGPGIMS, Luckiion of 1975 614, INDIV

Witnesses:

Signed by Dr. Sanjoy Chatterjee Senior Consultant, Radiation Oncology

Tata Medical Center, Kolkata

Signed by Mr.Sanjeev Kumar

Chief Financial Officer

Tata Medical Center, Kolkata

Tammen Chandy Signed by Dr.

Director, Tata Medical Center, Kolkata



महाराष्ट्र MAHARASHTRA

**3** 2021 **3** 

23 SEP BE 356557



27/1/2021

Salon

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow



# **CLINICAL TRIAL AGREEMENT**

This Clinical Trial Agreement ("Agreement") is entered into as of [27 SEPT 202]("Effective Date") between Novartis Healthcare Private Limited, a company incorporated under the provisions of the Companies Act, 1956, and having its registered office at Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai — 400 051, Maharashtra, India (hereinafter referred to as "Novartis/Sponsor" which expression shall unless repugnant to meaning or context mean and include its successors and assigns) of the FIRST PART;

AND

Sanjay Gandhi Post Graduate Institute of Medical Sciences, located at Lucknow ("Institution") registered under State Legislature Act, 1983 and having its address at Raebareli road, lucknow-226014, Uttar Pradesh, India which expression shall mean and include its successors and assigns of the SECOND PART;

AND

*Dr. Anshul Gupta, Asscolate Professor I Block, Dept of Haematology* as clinical practitioner in the field of *Hematology and Haemato Oncology* acting in the role of principal investigator ("Principal Investigator") which expression shall mean and include his/her heirs, executors, administrators and assigns of the THIRD PART;

Novartis, Institution and Principal Investigator are hereinafter individually referred to as the "Party" and jointly as the "Parties". For the purposes of this Agreement, "Affiliate(s)" shall mean any entity which directly or indirectly controls, is controlled by or is under common control of Novartis.

# **RECITALS:**

WHEREAS, Novartis is to perform a clinical trial (hereinafter the "Trial) to evaluate the following drug: MBG453 (hereafter the "Trial Drug") in accordance with a protocol entitled "A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2), CMBG453B12301" and its potential subsequent amendments (hereinafter collectively the "Protocol").

WHEREAS, the Institution and the Principal Investigator having each reviewed the Protocol for the Trial and sufficient information regarding the Trial Drug to evaluate their interest in participating in the Trial, wish to conduct in the Trial and assure that they have sufficient authority, competence and experience in clinical trials, along with the necessary infrastructure and technical means to perform the Trial,

WHEREAS the Principal Investigator is an employee of the Institution.

WHEREAS, the Parties wish to set forth certain legal and commercial terms and conditions under which the Trial shall be conducted:

NOW THEREFORE, the Parties, in consideration of the above and the mutual promises set forth below, agree as follows:

# CONFORMANCE WITH LAW AND ACCEPTED PRACTICE

The Institution and Principal Investigator shall carry out the Trial in accordance with:

- (a) the Protocol;
- (b) Good Clinical Practice (GCP) including the International Conference for Harmonization (ICH) GCP;

(c) the Declaration of Helsinki of the World Medical Association, "Ethical Principles for Medical Research Involving Human Subjects";

Sapon



IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorised representatives.

NOVARTIS HEALTHCARE Pvt Ltd.

Title: Country Trial Operations Lead
Date: 8th oct 2021

Name: Saumya Mathew

SANJAY GANDHI POST GRADUATE INSTITUTE OF MEDICAL SCIENCES
By:
Name: Seniar Gandhi Post Graduate
Title: Institute of Medical Sciences
Date:
ulle
-0
PRINCIPAL INVESTIGATOR
Ву:
Name: Dr. Anshul Gupta
Title:Associate Professor, Department of Hematology
Date:

braken

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow



# INDIA NON JUDICIAL

# **Government of Karnataka**

Rs. 100

## e-Stamp

IQVIA RDS INDIA PRIVATE LIMITED IQVIA RDS INDIA POP YATE LIMITED IQVIA RDS INDIA PRIVATE LIMITES TELIMITED IQVIA ROS INDIA PRIVATE LIMITED CONTINUE NORIVATE LIMITED IQVIA SOS INDIA PRIVATE LIMITED IQ VIA ROS INC IN-KA02327940902535T ATE LIMITED IOVIA RDS INDIA PRIVAT ED IQVIA ROS INDIA PRIVATE LIMITED юу Certificate Issued Dateмитео и 15-Apr-2021:05:23 PM-NONACC (FI)/kacrsfl08/ PADMANABHANAGAR SUBIN-KAKACRSFL087542068409931 LT RDS INDIA PRIVATE LIMITED VATURIQUE DOW Reference 1/4 OVIA RDS INDIA PRIVATE LIM VATE LIMITED IQ VIA ROS INC IQUIA ROS INDIA PRIVATE LIMITED Description of Document Article 12 Bond DS INDIA PRIVATE LIMITED CLINICAL TRIAL AGREEMENT ICVIDESCRIPTION PRIVATE I TE LIMITED IQVIA ROS INC TE LIMITED TO YIL RDS INC (Zero) VATE LIMITED IQVIA RDS I DS INDIA PRIVATE LIMITED IQVIA ROS INDIA PRIVATE LIMITED TELIMITED IQVIS BUS INC IQVIEITS Party A PRIVATE I SANUAY GANDHI POST GRADUATE INSTITUTE IN THE LIGHTED IN THE LIGHTE Stamb Duty Paid By INC IQVIA RDS INDIA PRIVATE LIMITED Stamp Duty Amount (Rs. (One Hundred only). QVIA ROS INGIA PRIVATE LIMITE VATE LIMITED IQVIA RDS INDIA PI सत्यमव जयत IOVIA ROS INDIA PRIVATE LIMITED À VATE LIMITED IQVIA ADS INDIA PRIVA IQVIA RDS INDIA PRIVATE LIMITED IQVIAN VATE LIMITED IQVIA RDS INDIA PRIVATE LIMINA IQVIA RDS INDIA PRIVATE LIMITED IOVIA RDS INDIATA AZO IQVIA ROS INDIA PRIVATE LIM ATE LIMITED TOVIA ROS INDIA PRIVATE LIMITED TOVIA ROS INDIA PRIVATE LIMITED ATE LIMITED IQVIA RDS INDIA PR TA PRIVATE LIMO MOIA PRIVATE ON A RD 645 ta RDS india private limited iqvia RDS india private limi? IOVIA ROS A PRIVAT RS. 100 IOVIA RDS ALTED IQVIA RDS INDIA PRIVATE LIMITED IQVIA RDS INDIA PRIVATE LIMITED IQVIA RDS INDIA PIÈVATE LIMIT

ATE LIMITED IOVIA RDS INDIA PRIVATE LIMITED IOVIA RDS INDIA PRIVATE LIMITED IOVIA RDS INDIA PRIVATE LIMITED



The authenticity of this Stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App of State ChildWarun Bajpai VS Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.

| Propositive P

. The onus of checking the legitimacy is on the users of the certificate.

Executive Registrar SGPGIMS, Lucknow

Blood draw, phlebotomy, routine venipuncture for collection of specimen(s), simple for centra laboratory (teriflunomide levels if applicable; serum pregnancy if applicable; tuberculosis test; ferritin and transferrin saturation; HIV, HBV and HCV testing; Evobrutinib concentration; Biochemistry; Hematology; Supplemental LFT; Hepatic Panel; Coagulation; Immunoglobulin levels; Novel liver function protein/genomic biomarkes); PD substudy samples if applicable: Includes preparation of specimen; Blood Sampling	1,337
Lab handling and/or shipping of specimen(s) to central laboratory, simple -	677
Urine pregnancy, gonadotropin chorionic (hCG) (BetahCG); qualitative (local lab) -	1,133
Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension (T-SPOT)(local lab)	2,144
Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis B virus (local lab); HCV RNA, quantification (local lab)	4,129
Magnetic resonance imaging, brain including brain stem (MRI); with contrast material(s) (eg, proton)	49,099
Interpretation and Report; Magnetic resonance imaging, brain including brain stem (MRI); with contrast material(s) (eg, proton) -	8,291
Magnetic resonance imaging, brain including brain stem (MRI); without contrast material (eg, proton) - healthy volunteer dummy run	39,628
Copies of Diagnostic Films, Complex - Per Copy - for sharing MRI scans with central reviewer	2,053
Urine collection for local (urinalysis and urine pregnancy if applicable) and central laboratory (microscopis exam if applicable)	342
Lab handling and/or shipping of urine specimen(s) to central laboratory, simple -	455
Single 12-lead ECG: Includes tracing, interpretation and report -	1,901
Health resource utilization -	692
Columbia Suicide Severity Rating Scale, physician administered	1,982
Electronic Extended Disability Status Scale (EDSS); rater-administered -	6,252

MerckAlliance/Protocol Number: MS200527\_0082 Protocol Amendment 2.0/India\_March21 Amendment # 1\_ Site 447\_ Dr. Jayantee Kalita\_22Apr2021 Ho

Page 5 of 7

## AMENDMENT NUMBER ONE TO CLINICAL TRIAL AGREEMENT

This Amendment One (this "Amendment #1") to the Clinical Trial Agreement (the "Agreement"), dated 07Apr2021 by and between Sanjay Gandhi Post Graduate Institute of Medical Sciences, with business address located at Raebareli Road, Lucknow-226014, Uttar Pradesh, India. ("Institution"), and IQVIA RDS (India) Private Limited, having a place of business at Omega Embassy Tech Square Marathahalli- Sarjapur Outer Ring Road, Kadubeesanahalli Bangalore- KA- 560103, India ("IQVIA") and Dr. Jayantee Kalita, with business address at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow- 226014, Uttar Pradesh, India. ("Investigator"), and is effective as of the date last signed below ("Effective Date"). All capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Agreement.

WHEREAS, IQVIA, and Institution and Investigator entered into the Agreement, pursuant to which the Parties agreed that Institution would conduct the following clinical trial sponsored by Merck Healthcare KGaA for the conduct of the study with details below:

**Protocol Number** 

MS200527 0082

Principal Investigator:

Dr. Jayantee Kalita; and

**Protocol Title** 

: "A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in

Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety"

WHEREAS, the parties wish to amend the Agreement due to the Protocol Amendment dated 09 December 2020 / Version 2.0 and effect the required budget changes;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Section D, as found in Attachment A is hereby amended by deleting it in its entirety and replaced with the section below.

# DOUBLE BLIND PERIOD

Visit	Cost/Unit (including Overhead) INR
Screening Visit	41414.75
Baseline Visit	47446.75
Week 2	18131.1
Week 4	22293.7
Week 6	18131.1
Week 8	18131.1
Week 10	18131.1
Week 12	35934.6
Week 14	18131.1
Week 16	18131.1
Week 18	18131.1

MerckAlliance/Protocol Number: MS200527 0082 Protocol Amendment 2.0/India\_March21 Amendment # 1\_ Site 447\_ Dr. Jayantee Kalita\_22Apr2021

Lt Col Varun Bajpai VSM **Executive Registrar** SGPGIMS, Lucknow

**IN WITNESS WHEREOF**, the parties hereto have caused this Amendment #1 to be executed by their duly authorized representatives as of the effective date first set forth above.

# AKNOWLEDGED AND AGREED BY THE PARTIES BELOW

IQVIA RDS (INDIA) PRIVATE LIMITED	SANJAY GANDHI POST GRADUATE INSTITUTE OF MEDICAL SCIENCES
Signature: Cadhad	Signature: TFISI21
Name (Print): Shweta Pradhan	Name (Print): Prof. R K Dhiman
Title: Director & Head, Site Management	Title: Director, SGPGIMS R. K. Orodo Gradua
Date: 28   Apr   2021	Date: Prom Omini Pour Sound
P	Name (Print): Prof. R K Dhiman, AND Print Or Standard Prof. R J. P
INVESTIGATOR O	UlGul
Signature: <u>Dr. Jayantee Kalita</u>	
Name (Print): Principal Investigator	vo g <sup>eg</sup>
Title: Professor	De 12
071 may 10021	



महाराष्ट्र MAHARASHTRA

O 2022 O

54AA 348725



# Amendment #2 \Clinical Study Agreement

This amendment dated 30 March 2023 to the Clinical Study Agreement (the "Amendment") is entered into by and between Sanjay Gandhi Postgraduate Institute of Medical Sciences, a clinical research site with its principal office and place of business at Raibareily Road, Lucknow - 226014, Uttar Pradesh, India ("Institution"), Dr. Jayantee Kalita, having an address at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raibareily Road, Lucknow - 226014, Uttar Pradesh, India ("Principal Investigator") and Medpace Clinical Research LLC, located at 5375, Medpace Way, Cincinnati, Ohio 45227 ("Medpace"), collectively, (the "Parties").

VIB0551.P3.S1 Dr Jayantee Kalita Site #4103

Page 1 of 3

Lt Col Varun Bajpai vsM

Cot Varun Bajpai VSM
Executive Registrar
SGPGIMS,Lucknow



## WITNESSETH:

WHEREAS, the Parties entered into a Clinical Study Agreement as of 28 January 2021 (the "Agreement") pursuant to which Institution is conducting a Study based on Protocol No. VIB0551.P3.S1, entitled "A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study With Open-Label Period To Evaluate The Efficacy And Safety Of Inebilizumab In Adults With Myasthenia Gravis", (the "Protocol"); and

WHEREAS, the Parties desire to amend the Agreement to amend the budget in Schedule A of the Agreement contained therein.

NOW THEREFORE, the Parties hereby agree as follows:

- 1. Schedule A of the Agreement shall be deleted in its entirety and replaced with the Schedule A appended to this Amendment.
- 2. All other provisions of the Agreement shall remain unchanged and in effect.

[SIGNATURE PAGE TO FOLLOW]

VIB0551.P3.S1 Dr Jayantee Kalita Site #4105

Page 2 of 3

Bapon



IN WITNESS WHEREOF, the Parties hereto have executed this Amendment by proper persons thereunto duly authorized

FOR MEDPACE, ON ITS OWN BEHALF	
AND AS PAYMENT AGENT OF SPONSOR	INSTITUTION
Ву:	By:
Name: Taher Sadriwala	Name:
Title: Sr. Associate Director – Clinical Trial Management	Prof. R.K. DHIMAN  Director  Candhi Post Graduate
Date: 01/Jun 12023	Title: Sanjay Gandhi Post Glados Sanjay Gandhi Post Glados Institute of Medical Sciences Institute of Medical Sciences I UCKNOW-226 014, INDIA
	Read and Acknowledged by:
	Principal Investigator
	Ву:
	Name: Prof. Jayoutes Kalite
	Date: 16/ Jun 2023

VIB0551.P3.S1 Dr Jayantee Kalita Site #4105

Page 3 of 3

Balon

Lt Cof Varun Bajpai VSM
Executive Registrar
SGPGIMS,Lucknow



# MUTUAL CONFIDENTIALITY AGREEMENT – Protocol no.: 64407564MMY3009 dated 28 April 2023 ("Effective date")

# By and Between

- Johnson & Johnson Private Limited, a company with CIN U33110MH1957PTC010928through its pharmaceutical division Janssen, having its corporate office at Arena Space, Behind Majas Bus Depot, Off J.V. Link Road, Jogeshwari (E) Mumbai 400060 ("J&J"), and
- Dr. Sanjeev ("Investigator"), adult Indian, with professional registration no DLH20160000110KTK residing at Lucknow and presently engaged by Sanjay Gandhi Post Graduate Institute of Medical Sciences, 226014, as a Associate Professor, and
- 3. Sanjay Gandhi Post Graduate Institute of Medical Sciences("Institution"), a registered trust/foundation, operating from SGPGIMS, Raebareli Road Lucknow-226014, India

Referred to jointly as "Parties" and separately as "Party".

Background - Each Party wishes to disclose to the other Parties, Confidential Information in relation to the Study to explore and evaluate the possibility and scope of collaboration and engagement in context of the Study ("Study Purposes"), but ensure that the other Parties maintains the confidentiality of its Confidential Information.

Now, therefore, in consideration of the premises and the mutual promises and covenants expressed herein, each Party agree as follows:

- 1. (a) Confidential Information shall mean all information (however recorded, preserved or disclosed) disclosed by a Party (hereinafter referred to as "Disclosing Party") or its employees, officers, affiliates, representatives or advisers (together, its "Representatives") to the other Party or Parties (hereinafter individually referred to as "Receiving Party" and jointly referred to as "Receiving Parties") and such Receiving Party's Representatives in relation to the Study in any manner. Confidential Information shall include, but not be limited to, scientific, commercial, business, financial, technical data including, drawings, films, documents, analyses, compilations, studies, medical information related to medicinal products, dossiers, product know-how and the like, either orally or in written or electronic format or by demonstration or computer readable media otherwise, irrespective of it being marked or otherwise designated to show expressly or by necessary implication that it is proprietary to the Disclosing Party or that it is prepared by the Disclosing Party or that it belongs to the Disclosing Party, and such confidential information shall include developed intellectual property results and specifications and contents relating to the Study as received by the Receiving Parties and their Representatives.
- 1. (b) "Study" means a clinical trial with respect to Protocol no.:64407564MMY3009 with Protocol Titled: "A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (TalPom), Talquetamab in Combination with Teclistamab (TalTec), and Elotuzumab (IV), Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib (SC), and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received at Least 1 Prior Line of Therapy"

J&J India Tripartite CDA (Mutual) 10 June 2020 GCO India Protocol no.: 64407564MMY3009 customized date 19 Apr 2023

Page 1 of 4

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow



- 2. <u>Duty of Receiving Party</u>. Each Receiving Party here by agrees to keep the Confidential Information received by it in confidence and strictly not to disclose it to any third party or use it for any purpose other than for Study Purposes. However, nothing herein shall prevent a Receiving Party from disclosing the Confidential Information to its Representatives, if such persons need to know such information for Study Purposes, provided that the Receiving Party shall ensure that such Representatives are subject to a confidentiality obligations with respect to such Confidential Information of at least the same level as envisaged under this Agreement. Each Receiving Party agrees that it will be fully responsible, for any breach by its Representatives of their confidentiality obligations with respect to such Confidential Information under this Agreement.
- 3. <u>Structure Information</u>. Unless otherwise mutually agreed in writing between the Parties, the Investigator or Institution shall not identify the chemical structure or molecular composition of J&J's proprietary compound(s) or molecular entity/entities or any data from which J&J's proprietary compound's or molecular entity's chemical structure or molecular composition may be readily determined or elucidated, except if authorized by J&J and shall be disclosed only to those Representatives of Receiving Party who are identified and authorized in writing by J&J to receive such structure, composition or data. For the avoidance of doubt, such structure, composition or data that might be disclosed directly by Principal Investigator to J&J shall not be considered "Confidential Information" of Investigator or Institution or both for any purpose hereunder.
- 4. <u>Exceptions</u>. Each Receiving Party shall not be obligated to maintain in confidence or to refrain from disclosing or using the Confidential Information if such information:
- a) was known to the Receiving Party prior to being received from the disclosing party or its Representatives as evidenced by the Receiving Party's written records; or
- b) is or without the fault of the Receiving Party (or any of its Representatives) becomes part of the public domain; or
- is received by the Receiving Party from a third party having to the knowledge of the recipient no obligation of confidence to the other parties hereto; or
- d) is independently developed by or on behalf of the Receiving Party without reliance on the information received hereunder as evidenced by the Receiving Party's written records or other competent evidence.
- 5. <u>Non-Disclosure/Publicity.</u> No Party will disclose, and each Party will direct its Representatives, who are aware of the contemplated discussions, not to disclose, publish or disseminate, at any time to any person the identity of the other Parties and the fact that Confidential Information has been made available or that discussions are taking place for Study Purposes or any of the terms, conditions or other facts with respect to Study or Study Purposes, including the status thereof.
- 6. <u>Business Acknowledgement</u>. The Investigator and Institution hereby acknowledge that J&J or its group companies or affiliates may presently have internal development programs relating to the Study, or without recourse to the Confidential Information disclosed hereunder may undertake such development programs, or may receive information on the same or related subject matter from third parties, and may develop and commercialize products and/or services relating to such subject matter independently or in cooperation with such third parties.
- 7. <u>Compelled Disclosures</u>. In the event a Receiving Party or Receiving Parties (or any person to whom it has transmitted the Confidential Information received hereunder) is required by law or legal process to disclose any of such Confidential Information, then the concerned Receiving Party(ies)will (i) provide the Disclosing Party with prompt notice of such event so that the Disclosing Party may intervene to protect the confidentiality of the

J&J India Tripartite CDA (Mutual) 10 June 2020 GCO India Protocol no.: 64407564MMY3009 customized date 19 Apr 2023

Page 2 of 4



Confidential Information and (ii) at the Disclosing Party's request and expense, use reasonable efforts to obtain assurance that confidential treatment will be accorded to the Confidential Information to be disclosed.

- 8. <u>Return of Confidential Information</u>. All written and electronic documents containing Confidential Information and other confidential material in tangible form including copies thereof in any form irrespective of storage or presentation medium, received by a Receiving Party under this Agreement shall remain the property of the Disclosing Party. Upon request of the Disclosing Party and solely at the expense of the concerned Receiving Party, all such documents (together with any copies or excerpts thereof) and such other material received hereunder shall promptly be either returned to the Disclosing Party or destroyed and the destruction confirmed to the Disclosing Party in writing. Notwithstanding the return or destruction of the documents and materials, each Receiving Party will continue to be bound by its obligations under this Agreement.
- 9. <u>No Right or License</u>. No right or license to use any Confidential Information disclosed hereunder, either express or implied, is granted to the Receiving Parties.
- 10. <u>Accuracy of Confidential Information</u>. Each Receiving Party understands that although the Disclosing Party and its Representatives have endeavored to include in the Confidential Information, information that it believes to be relevant for the purpose of the recipient's evaluation, neither the Disclosing Party nor any of its Representatives have made or make any representation or warranty as to the accuracy or completeness of the Confidential Information.
- 11. <u>No Obligation to Pursue Proposed Transaction</u>. Unless and until a definitive agreement between the parties with respect to Study Purposes has been executed and delivered, no Party will be under any legal obligation of any kind whatsoever with respect to such a transaction by virtue of this or any written or oral expression by any of its representatives, except for the matters specifically agreed to herein.
- 12. <u>Survival</u>. The obligations of Section 2 shall continue for forty-eight months from the Effective Date of this Agreement and for Section 3 shall be in perpetuity or as long as permitted by law.
- 13. <u>Governing Law.</u> Any disputes that may arise from this Agreement or in relation thereto shall be governed under Indian laws and the parties hereby agree to submit themselves to the exclusive jurisdiction of the competent courts in Lucknow. This clause shall survive the expiration or termination of the Agreement
- 14. Entire Agreement & Modifications; Severability; Construction. This Agreement contains the entire agreement between the parties and supersedes all pre-existing agreements, whether oral or written, between the parties respecting its subject matter. Modifications or waivers of this Agreement shall only be effective if made in writing and signed by all the parties hereto. The invalidity of any provision of this Agreement will not affect the enforceability of any other provision hereof. The Parties have jointly negotiated and drafted this Agreement and this Agreement shall be interpreted without presumption favoring or disfavoring any Party by virtue of authorship of any provision of this Agreement. This Agreement shall not be assignable, in whole or in part, by any Party without the prior written consent of the other Parties, and any such assignment without prior written consent shall be considered void.

[SIGNATURE PAGE FOLLOWS]

J&J India Tripartite CDA (Mutual) 10 June 2020

GCO India Protocol no.: 64407564MMY3009 customized date 19 Apr 2023

Page 3 of 4

Lt Co1 Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow



This Agreement is executed in three counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

For Johnson & Johnson Private Limited

By: Manik Prabhu

Nanna

Print Name: Dr. Manik Prabhu Nanna Print Title: Manager-Global Clinical Operation, India

Date:

For Institution

Print Name: Dr. R K Bain and Gandhi Post Graduate

Print Title: Director Institute of Medical Sciences
Sanian Co. 114. INDIA Print Title: Director Institute of Medical Sciences,
Sanjay Gandhi Post Graduate Institute of Medical Sciences,

Lucknow

Date:

Institution Seal:

**Principal Investigator** 

By:

Print Name: Dr. Sanjeev

Print Title: Associate Professor

Date: 03/05/2023

Physician Seal:

Dr. SANJEEV Associate Professor Department of Hematology S.G.P.G.I.M.S., Lucknow U.P.-226014

J&J India Tripartite CDA (Mutual) 10 June 2020 GCO India Protocol no.: 64407564MMY3009 customized date 19 Apr 2023

Page 4 of 4

Lt Col Varun Bajpai VSM **Executive Registrar** SGPGIMS, Lucknow



महाराष्ट्र MAHARASHTRA

**O** 2022 **O** 

BW 522341

500

13.22

17.5

æ



उप क्रीपानार **अधिकारी** कल्याण

NOVARTIS HEALTHCARE PRIVATE LIMITED (FIRST PART) 0 NOV 2023

AND

Sanjay Gandhi Post Graduate Institute of Medical Sciences (SECOND PART)

ÄND

Dr. Dharmendra Bhadauria (THIRD PART)

- TO

HEAVEN ON A CCT LINET

LA my garatho

) Vsi

Lt Col Varun Bajpai VSM
Executive Registrar

SGPGIMS, Lucknow

# FIRST AMENDMENT TO CLINICAL TRIAL AGREEMENT

This first Amendment is made at Mumbai and entered into on 20 day of 20 by and between;

NOVARTIS HEALTHCARE PRIVATE LIMITED, a company incorporated under the Indian Companies Act, 1956 and having its registered office at Inspire BKC, 7<sup>th</sup> Floor, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra, India (hereinafter referred to as "Novartis", which expression shall, unless repugnant to the context or meaning thereof be deemed to mean and include its successors and assigns) of the First Part;

AND

Sanjay Gandhi Post Graduate Institute of Medical Sciences, located at Uttar Pradesh ("Institution") registered under the provision of the State Legislature Act and having its address at Raebareli road, lucknow-226014, Uttar Pradesh, India which expression shall mean and include its successors and assigns of the SECOND PART;

AND

*Dr. Dharmendra Bhadauria* as clinical practitioner in the field of *Nephrology* acting in the role of principal investigator ("Principal Investigator") which expression shall mean and include his/her heirs, executors, administrators and assigns of the THIRD PART;

(Novartis, Principal Investigator, and Institution may hereinafter be individually referred to as 'Party' and are collectively referred as 'Parties').

### **WHEREAS**

A. By a Clinical Trial Agreement dated 25 Feb 2022 entered into between the Parties hereto ("Agreement"), the Principal Investigator and the Institution have agreed to provide certain Clinical Trial related services to Novartis on the terms and conditions contained in the Agreement.

B. Now by this first Amendment, the Parties are desirous of modifying and restating the subclause on 'Use of Trial Drug', and 'PUBLICATION' and 'TRANSPARENCY/DISCLOSURE, Modifying Annex-1 (Update in Payment Schedule for Corrected cost) 'clause to amend the Agreement on the terms and conditions herein after appearing.

NOW THIS AMENDMENT WITNESSETH AND IT IS HERE BY AGREED BY AND BETWEEN THE PARTIES AS FOLLOWS:

lause 5.2 (Use of Trial Drug) of the Agreement is modified, and the revised clause 5.2 is

Lt Col Varun Bajpai VSM
Executive Registrar
SGPGIMS,Lucknow

Sanjay Gandhi Post Graduate Institute of

IN WITNESS WHEREOF, the Parties to this Amendment have caused their duly authorized representatives to enter into and execute this Amendment.

**Novartis Healthcare Private Limited** 

Name:

Title: Date: Murugahanthan K.

SSO Country Head

26 Dec 2023

	Medical Sciences
	By: ANN
2	Name: Prof. R K Dhiman Acting Director Sanjay Gandhi Post Graduate
•	Title: Director Institute of Medical Sciences Lucknow - 226014, INDIA
	Date:
	- hatafaidi
	PRINCIPALINVESTIGATOR
	Ву:
	Name: Dr. Dharmendra Singh Bhadauria
	Title: Professor, Department of Nephrology
	Date:

Salon

Lt Col Varun Bajpai VSM Executive Registrar SGPGIMS, Lucknow

### FILE NO. CRG/2021/002331-C

### SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(A statutory body of the Department of Science & Technology, Government of India)

Science and Engineering Research Board 3rd & 4th Floor, Block II Technology Bhavan, New Mehrauli Road New Delhi - 110016

Dated: 12 January, 2022 🎤

### ORDER

Subject Research project entitled Understanding the human endogenous retrovirus-mediated regulation of CD5 isoform expression and its functional characterization, under the guidance of Dr. Ambak Kumar Rai, Biotechnology, Motilal Nehru National Institute of Technology, Mnnit allahabad campus, teliarganj, allahabad, Allahabad, Utiar pradesh-211004 and by Dr. Sameer Srivastava, Assistant Professor, Biotechnology, Motilal Nehru National Institute Of Technology and by Dr. Chandra Prakash Chaturvedi, Associate Professor & Wellcome Trust DBT India Alliance Fellow, Stem Cell Research Center, Dept Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences and by Dr. Kulwant Singh, Assistant Professor, Stem Cell Research Center Department Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences.

- I. In continuation of SERB's sanction order No. CRG/2021/002331 dated 12 January, 2022, sanction of the competent authority is hereby accorded to the payment of a sum of Rs.1324600/- under 'Grants-in-aid Capital' to Motilal Nehru National Institute Of Technolgy, Mnnit Allahabad Campus, Teliarganj, Allahabad, Allahabad, Uttar Pradesh-211004 being the grant for the financial year 2021-2022 for implementation of the above said project,
- 2. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at the website (www.serb.gov.in) and as mentioned in the sanction order of even number dated 12 January, 2022.
- 3. As this is the first grant being released under 'Grants-in-aid Capital' for the project, no previous U/C is required,
- 4. The expenditure involved is debitable to Fund for Science & Engineering Research (FSER) This release is being made under Core Research (rant (Interdisciplinary Biological Sciences) (Capital).
- 5. The Sanction has been issued with the approval of the competent authority on 06 January, 2022 and vide Diary No. SERB/F/7127/2021-2022 dated 11 January, 2022.
- 6. The release amount of Rs. 1324600/- (Rupees Thirteen Lakh Twenty Four Thousand Six Hundred only) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

PFMS Unique Code	NIT02	1
Account Name	PROJECT ACCOUNT MNNIT	4
Account Number	77660100016031	. 7
Bank Name & Branch	BANK OF BARODA BRANCH NAME: MNNIT BRANCH; ADDRESS: MNNIT ALLAHABAD, PRAYAGRAJ-211004, UTTAR PRADESH INDIA	
IFSC/RTGS Code	BARBOVJMNRE	1
Email id of A/C Holder	deanrc@mnnit.ac.in	
Email id of PI	ambakrai@mnnit.ac.in	

(Dr. Thangaradjou T) Scientist F msls@serb.gov.in

To, Under Secretary SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C R Building, IIIrd Floor I.P. Estate, Delhi-110002	
2.	Sanction Folder, SERB , New Delhi.	
3.	File Copy	

braken

# FILE NO. CRG/2021/002331 SCIENCE & ENGINEERING RESEARCH BOARD

Science and Engineering Research Board 3rd & 4th Floor, Block II Technology Bhavan, New Mehrauli Road New Delhi - 110016

Dated: 12-Jan-2022

### ORDER

Subject: Financial Sanction of the research project titled "Understanding the human endogenous retrovirus-mediated regulation of CD5 isoform expression and its functional characterization." under the guidance of Dr. Ambak Kumar Rai, Biotechnology, Motilal Nehru National Institute of Technology, Mnnit allahabad campus, teliargani, allahabad, Allahabad, Uttar pradesh-211004 and by Dr. Sameer Srivastava, Assistant Professor, Biotechnology, Motilal Nehru National Institute Of Technology and by Dr. Chandra Prakash Chaturvedi, Associate Professor & Wellcome Trust DBT India Alliance Fellow, Stem Cell Research Center, Dept Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences and by Dr. Kulwant Singh, Assistant Professor, Stem Cell Research Center Department Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences - Release of 1st grant.

Sanction of Science and Engineering Research Board (SERB) is hereby accorded to the above mentioned project at a total cost of Rs. 5098324/-(Rs. Rupees Fifty Lakh Ninety Eight Thousand Three Hundred and Twenty Four only Only) with break-up of Rs. 1324600/- under Capital (Non-recurring) head and Rs.3773724/- under General (Recurring) head for a duration of 36 months. The items of expenditure for which the total allocation of Rs. 5098324/- has been approved are given below:

The following budget may be considered for Motilal Nehru National Institute Of Technology, MNNIT Allahabad Campus, Teliarganj, Allahabad

S. No	Head	Total (în Rs.)
A	Non-recurring	
proof	Equipment -> Microvolume spectrophotometer -> Cooling microcentrifuge machine -> Computational Work station -> Gel Doc Imaging System	1324600
A'	Total (Non-Recurring)	1324600
В	Recurring Items	
1	Recurring - I : (Manpower) Recurring - II : (Consumables, Travel, Contingencies) Recurring - III : Scientific Social Responsibility	1350240 1050000 60000
2	Recurring - IV (Overhead Charges)	378484
$B^{-}$	Total (Recurring)	2838724
С	Total cost of the project (A' + B')	4163324

The following budget may be considered for Sanjay Gandhi Postgraduate Institute Of Medical Sciences, Raebareli Road Lucknow India

S. No	Head	Total (in Rs.)
A	Non-recurring	
ì	Equipment	0
A'	Total (Non-Recurring)	0
В	Recurring Items	
4	Recurring - I : (Manpower) Recurring - II : (Consumables, Travel, Contingencies) Recurring - III : Scientific Social Responsibility	0 850000 0
2	Recurring - IV (Overhead Charges)	85000
B'	Total (Recurring)	935000
С	Total cost of the project (A' + B')	935000

- 2. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at website ( www.serb.gov.in).
- 3. Overhead expenses are meant for the host Institute towards the cost for providing infrastructural facilities and general administrative support etc. including benefits to the staff employed in the project.
- 4. While providing operational flexibility among various subheads under head Recurring-A, it should be ensured that not more than Rs. 1.6 lakh each should be spent for travel and contingency.

Varyen .

### FILE NO. CRG/2021/002331

### SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(A statutory body of the Department of Science & Technology, Government of India)

Science and Engineering Re**searc**h Board 3rd & 4th Floor, Block II Technology Bhavan, New Mehrauli Road New Delhi - 110016

Dated 12 January, 2022

### ORDER

Subject: Financial Sanction of the research project titled Understanding the human endogenous retrovirus-mediated regulation of CD5 isoform expression and its functional characterization, under the guidance of Dr. Ambak Kumar Rai, Biotechnology, Motilal Nehru National Institute of Technology, Mnnit allahabad campus, teliarganj, allahabad, Allahabad, Uttar pradesh-211004 and by Dr. Sameer Srivastava, Assistant Professor, Biotechnology, Motilal Nehru National Institute Of Technology and by Dr. Chandra Prakash Chaturvedi, Associate Professor & Wellcome Trust DBT India Alliance Fellow, Stem Cell Research Center, Dept Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences and by Dr. Kulwant Singh, Assistant Professor, Stem Cell Research Center Department Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences - Release of 1st grant.

Sanction of Science and Engineering Research Board (SERB) is hereby accorded to the above mentioned project at a total cost of Rs. 4163324/- (Rs. Forty One Lakh Sixty Three Thousand Three Hundred and Twenty Four Only) with break-up of Rs. 1324600/- under Capital (Non-recurring) head and Rs. 2838724/- under General (Recurring) head for a duration of 36 months. The items of expenditure for which the total allocation of Rs. 4163324/- has been approved are given below:

The following budget may be considered for Motilal Nehru National Institute Of Technolgy, MNNIT Allahabad Campus, Teliarganj, Allahabad

S. No	Head	Total (in Rs.)
A	Non-recurring	
	Equipment -> Microvolume spectrophotometer -> Cooling microcentrifuge machine -> Computational Work station -> Gel Doc Imaging System	1324600
A'	Total (Non-Recurring)	1324600
В	Recurring Items	
ferro	Becurring - 1: (Manpower) Recurring - II: (Consumables, Travel, Contingencies) Recurring - III: Scientific Social Responsibility	1350240 1050000 60000
2	Recurring - IV : (Overhead Charges)	378484
B'	Total (Recurring)	2838724
С	Total cost of the project (A' + B')	4163324

- 2. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at website ( www.serb.gov.in).
- 3. Overhead expenses are meant for the host Institute towards the cost for providing infrastructural facilities and general administrative support etc. including benefits to the staff employed in the project.
- 4. While providing operational flexibility among various subheads under head Recurring-II, it should be ensured that not more than Rs. 1.5 lakh each should be spent for travel and contingency.
- 5. Budget sanctioned under Scientific Social Responsibility (SSR) is meant only for activites enlisted under SSR norms and under no circumstances it can be reappropriated.
- 6. As per rule 211 of GFR, the accounts of project shall be open to inspection by sanctioning authority/audit whenever the institute is called upon to do so.
- 7. The sanctioned equipment would be procured as per GFR and its disposal of the same would be done with prior approval of SERB.
- 8.The institute will furnish to the SERB, separate Utilization certificate(UCs) financial year wise to the SERB for Recurring (Grants-in-aid General) & Non-Recurring (Grants for creation of capital assets) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.
- 9. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.
- 10. The manpower sanctioned in the project, if any is co-terminus with the duration of the project and SERB will have no liability to meet the fellowship and salary of supporting staff if any, beyond the duration of the project
- 11. The institute may refund any unspent balance to SERB by means of a Demand Draft favoring "FUND FOR SCIENCE AND ENGINEERING RESEARCH" payable at New Delhi.

Boyles

# FILE NO. CRG/2021/002331-G

## SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(A statutory body of the Department of Science & Technology, Government of India)

Science and Engineering Research Board 3rd & 4th Floor, Block II Technology Bhavan, New Mehrauli Road New Delhi - 110016

Dated: 12 January, 2022

#### ORDER

Subject, Research project entitled Understanding the human endogenous retrovirus-mediated regulation of CD5 isoform expression and its functional characterization, under the guidance of Dr. Ambak Kumar Rai, Biotechnology, Motifal Nehru National Institute of Technology, Munit allahabad campus, teliarganj, allahabad, Allahabad, Uttar pradesh-211004 and by Dr. Sameer Srivastava, Assistant Professor, Biotechnology, Motifal Nehru National Institute Of Technology and by Dr. Chandre Prakash Chaturvedi, Associate Professor & Wellcome Trust DBT India Alliance Fellow, Stem Cell Research Center, Dept Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences and by Dr. Kulwant Singh, Assistant Professor, Stem Cell Research Center Department Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences.

- 1. In continuation of SERB's sanction order No. CRG/2021/002331 dated 12 January, 2022, sanction of the competent authority is hereby accorded to the payment of a sum of Rs.967600/- under 'Grants-in-aid General' to Motifal Nehru National Institute Of Technology, Mnnit Allahabad Campus, Teliarganj, Allahabad, Allahabad, Uttar Pradesh-211004 being the grant for the financial year 2021-2022 for implementation of the above said project.
- 2. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at the website (www.serb.gov.in) and as mentioned in the sanction order of even number dated 12 January, 2022.
- 3. As this is the first grant being released under 'Grants-in-aid General' for the project, no previous U/C is required.
- 4. The expenditure involved is debitable to Fund for Science & Engineering Research (FSER) This release is being made under Core Research Grant (Interdisciplinary Biological Sciences) (General).
- 5. The Sanction has been issued with the approval of the competent authority on 06 January, 2022 and vide Diary No. SERB/F/7128/2021-2022 dated 11 January, 2022...
- 6. The release amount of Rs. 967600/- (Rupecs Nine Lakh Sixty Seven Thousand Six Hundred only) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below:

PFMS Unique Code	NIT02	1
Account Name	PROJECT ACCOUNT MNNIT	1
Account Number	77660130016031	
Bank Name & Branch	BANK OF BARODA BRANCH NAME: MNNIT BRANCH; ADDRESS: MNNIT ALLAHABAD, PRAYAGRAJ-211004, UTTAR PRADESH INDIA	
IFSC/RTGS Code	BARBOVJMNRE .	<
Email id of A/C Holder	deanrc@mnnit.ac.in	
Email id of PI	ambakrai@munit.ac.in	

(Dr. Thangaradjou T)
Scientist F
msls@serb.gov.in

To,

Under Secretary SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C.R.Building, IIIrd Floor I.P. Estate, Delhi-110002
2.	Sanction Folder, SERB , New Delhi.
3.	File Copy

Valor Valor

# FILE NO. CRG/2021/002331

### SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(A statutory body of the Department of Science & Technology, Government of India)

Science and Engineering Research Board 3rd & 4th Floor, Block II Technology Bhavan, New Mehrauli Road New Delhi - 110016

Dated 12 January, 2022

### ORDER

Subject: Financial Sanction of the research project titled "Understanding the human endogenous retrovirus-mediated regulation of CD5 isoform expression and its functional characterization." under the guidance of Dr. Chandra Prakash Chaturvedi, Stem Cell Research Center, Dept of Hematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road Lucknow India and by Dr. Sameer Srivastava, Assistant Professor, Biotechnology, Motifal Nehru National Institute of Technology and by Dr. Chandra Prakash Chaturvedi, Associate Professor & Wellcome Trust DBT India Alliance Fellow, Stem Cell Research Center, Dept Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences and by Dr. Kulwant Singh, Assistant Professor, Stem Cell Research Center Department Of Hematology, Sanjay Gandhi Postgraduate Institute Of Medical Sciences - Release of 1st grant.

Sanction of Science and Engineering Research Board (SERB) is hereby accorded to the above mentioned project at a total cost of Rs. 935000/- (Rs. Nine Lakh Thirty Five Thousand. Only) with break-up of Rs. 0/- under Capital (Non-recurring) head and Rs. 935000/- under General (Recurring) head for a duration of 36 months. The items of expanditure for which the total allocation of Rs. 935000/- has been approved are given below. The following budget may be considered for Sanjay Gandhí Postgraduate Institute Of Medical Sciences, Raebareli Road Lucknow India

S. No	Head	Total (in Rs.)
A	Non-recurring	
1	Equipment	U
A'	Total (Non-Recurring)	0
В	Recurring Items	
1	Recurring - I. (Manpower) Recurring - II. (Consumables, Travel, Contingencies) Recurring - III. (Scientific Social Responsibility	85000C 0
2	Recurring - IV : (Overhead Charges)	85000
B'	Total (Recurring)	935000
С	Total cost of the project (A' + B')	935000

- 2. Sanction of the SERB is also accorded to the payment of Rs. 378300/- (Rupees Three Lakh Seventy Eight Thousand Three Hundred only) under 'Grants-in-aid General' to DIRECTOR, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road Lucknow India being the first installment of the grant for the year 2021-2022 for implementation of the said research project.
- 3. The expenditure involved is debitable to Fund for Science & Engineering Research (FSER) This release is being made under Core Research Grant. (Interdisciplinary Biological Sciences)
- 4. The Sanction has been issued to Sanjay Gandhi Postgraduate Institute Of Medical Sciences, Raebareli Road Lucknow India with the approval of the competent authority under delegated powers on 06 January, 2022 and vide Diary No. SERB/F/7129/2021-2022 dated 11 January, 2022
- 5. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at website ( www.setb.gov.in).
- 6. Overhead expenses are meant for the host institute towards the cost for providing infrastructural facilities and general administrative support etc. including benefits to the staff employed in the project.
- 7. While providing operational flexibility among various subheads under head Recurring-II, it should be ensured that not more than Rs. 1.5 lakh each should be spent for travel and contingency.
- 8. Budget sanctioned under Scientific Social Responsibility (SSR) is meant only for activites enlisted under SSR norms and under no circumstances it can be reappropriated.
- 9. As per rule 211 of GFR, the accounts of project shall be open to inspection by sanctioning authority/audit whenever the institute is called upon to do so.
- 10. The sanctioned equipment would be procured as per GFR and its disposal of the same would be done with prior approval of SERB.
- II. The release amount of Rs. 378300/ (Rupees Three Lakh Seventy Eight Thousand Three Hundred only) will be drawn by the Under Secretary of the SERB and will be disbursed by means of RTGS transaction as per their Bank details given below

PFMS Unique Code	SGPGIMS	4
Account Name	DIRECTOR, SGPGIMS, RESEARCH A/C	
Account Number	10095237491	
Bank Name & Branch	STATE BANK OF INDIA BRANCH NAME: SGPGIMS, ADDRESS: SGPGIMS, RAEBAREILY ROAD, LUCKNOW	
IFSC/RTGS Code	SBIN0007789	
Email id of A/C Holder	sro@sgpgi ac in	
Email id of PI	ambakraj@mnnit.sc.in	

Bupn